

2011

# The Role of Inflammatory Molecules in Hypertension

Jeffrey Paul Cardinale

*Louisiana State University and Agricultural and Mechanical College, jcardi2@tigers.lsu.edu*

Follow this and additional works at: [https://digitalcommons.lsu.edu/gradschool\\_dissertations](https://digitalcommons.lsu.edu/gradschool_dissertations)



Part of the [Veterinary Medicine Commons](#)

---

## Recommended Citation

Cardinale, Jeffrey Paul, "The Role of Inflammatory Molecules in Hypertension" (2011). *LSU Doctoral Dissertations*. 3610.  
[https://digitalcommons.lsu.edu/gradschool\\_dissertations/3610](https://digitalcommons.lsu.edu/gradschool_dissertations/3610)

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please contact [gradetd@lsu.edu](mailto:gradetd@lsu.edu).

**THE ROLE OF INFLAMMATORY MOLECULES IN HYPERTENSION**

**A Dissertation**

**Submitted to the Graduate Faculty of the  
Louisiana State University and  
Agricultural and Mechanical College  
in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy**

**In**

**The Interdepartmental Program in  
Veterinary Medical Sciences through the  
Department of Comparative Biomedical Sciences**

**By  
Jeffrey Paul Cardinale  
B.S., Louisiana State University, 2006  
August 2011**

## ACKNOWLEDGEMENTS

*“Don't worry. As long as you hit that wire with the connecting hook at precisely 88mph the instant the lightning strikes the tower... everything will be fine.”*

- Dr. Emmett Brown; Back to the Future

On occasion in life, a series of highly unlikely events conspire to bring you to a moment entirely unseen, but a moment, in this case, that brings great joy. Several months ago, much less 6 years ago, I could not have envisioned that I would be typing an acknowledgements section for a Dissertation manuscript comprising only portions of my research to date, and for that, I have many people to thank.

First and foremost, I would like to express my sincerest gratitude to my major professor, Dr. Joseph Francis. Thank you first for providing me with this opportunity, and then, for the guidance, expertise and advice during all stages of this research work thereafter. Also, your understanding during this time of personal growth and change is greatly appreciated. As you well know, I have come a long way since those first few months. Your patience and support have helped me to overcome many trying situations, and for this I will be forever grateful.

I would also like to thank my committee members for their hard work and guidance. Dr. Susan Eades for everything you have done for me since my undergraduate years: in leading me towards an appreciation of the basic sciences and a life of research, for introducing me to Dr. Francis, as well as for support throughout these graduate school years. I am eternally grateful. Dr. Romain Pariaut, you are a consummate professional and a trusted friend whose advice I have often sought. Your love and enjoyment of the heart is infectious, and I hope that at some point in the future, we have the opportunity to again work together. Dr. Daniel Kapusta, thank you for allowing me to pick your brain, question the deeper aspects of basic research, and also for your

support during these past several years. Finally, my gratitude to Dr. Masami Yoshimura for your hard work, dedication and concern. I am extremely thankful that I had such a dedicated and supportive group of clinicians and researchers to lead me towards this ultimate goal.

I would also like to thank Dr. Nithya Mariappan and Dr. Masudul Haque for their help and expertise in molecular and experimental techniques, and Mrs. Julie Millard and Mrs. Sherry Ring, for their assistance in immunohistochemistry, tissue sectioning and staining. I am also especially appreciative of the other faculty members and staff in the Department of Comparative Biomedical Sciences, especially my administrative ladies in the office (who always provided entertaining respites from the daily grind), my graduate advisor Dr. George Strain and my department head Dr. Gary Wise, for your example and encouragement. Finally, I want to thank the countless others from the School of Veterinary Medicine and LSU, especially the following: Dr. Arthur Penn and Dr. Inder Sehgal for their sage advice, Dr. Rhett Stout and Ms. Cecilia Koon and the entire DLAM staff for caring for my experimental animals, Dr. Ashley Stokes for her friendship and mentorship and Dr. Carley Saelinger for “keeping it real.”

I sincerely appreciate the friendship and support provided by my lab mates: Dr. Deepmala Agarwal, Dr. Rahul Dange, Dr. Carrie Elks, Mr. Anand Nair, Miss Lindsey Pelych and Dr. Jorge Vila. A very special thanks goes to Dr. Anuradha Guggilam and Dr. Srinivas Sriramula. These two individuals taught me a great deal (about science, life and India) and have become very close friends in the process, thank you both for everything. Within the department, I would also like to thank my colleagues and friends: Mrs. Maria Cochran, Dr. Denada Dibra, Dr. Jeffry Cutrera (a good friend who should definitely add an ‘e’ into his name) and Dr. Danielle Tatum (a close friend, gracious host and future neighbor). These individuals all played instrumental roles in every aspect of my time here.

A very special thanks goes to my dear friends in Baton Rouge, Mr. B.J. Brooks and Mr. Aaron Rolling, for keeping me from falling into a mundane existence. Also, Miss Tayler Schulte and Mr. Justin Landry (though I can't imagine it will be this way for much longer), these two individuals were not only a close and strong support for me, but they are incredible friends who opened their home to me without hesitation and allowed me to be their "Dupree" for the final months of my time here in Baton Rouge.

Finally, I thank my family, Jerry, Yvette and Jessica Cardinale, for everything you have done over the years. I love you all. Mrs. Leslie van Duyvendijk and Miss Mollie Mesman, thank you both and I love you. For my wife, Lauren, enough cannot be said regarding my love, admiration, respect and gratitude towards you. You are everything a graduate student husband (and a husband in general) could ask. These years have been long, but without you, they would have been impossible. I love you!

In conclusion, science, and much like the quote, is a journey, and the people who have supported and helped me to this point, are a series of seemingly unlikely events that came together and produced amazing, if not an improbable result. I feel that the product written herein, as well as the product that is myself, is proof of this very concept. My hypothesis from the first day in lab is correct, I have and will succeed.

## TABLE OF CONTENTS

<b>ACKNOWLEDGEMENTS.....</b>	<b>ii</b>
<b>LIST OF ABBREVIATIONS.....</b>	<b>vii</b>
<b>ABSTRACT.....</b>	<b>xiii</b>
<b>CHAPTER 1. INTRODUCTION AND REVIEW OF LITERATURE.....</b>	<b>1</b>
<b>HYPERTENSION.....</b>	<b>2</b>
<b>THE FUNCTION OF THE RENIN-ANGIOTENSIN SYSTEM IN</b>	
<b>HYPERTENSION.....</b>	<b>3</b>
<b>INFLAMMATION, NUCLEAR FACTOR-<math>\kappa</math>B IN HYPERTENSION.....</b>	<b>8</b>
<b>REACTIVE OXYGEN SPECIES IN HYPERTENSION.....</b>	<b>10</b>
<b>THE BRAIN IN HYPERTENSION.....</b>	<b>17</b>
<b>STATEMENT OF THE PROBLEM AND SPECIFIC AIMS.....</b>	<b>22</b>
<b>REFERENCES.....</b>	<b>24</b>
<b>CHAPTER 2. TUMOR NECROSIS FACTOR – INDUCED OXIDATIVE STRESS</b>	
<b>REGULATES COMPONENTS OF THE RENIN-ANGIOTENSIN</b>	
<b>SYSTEM.....</b>	<b>32</b>
<b>INTRODUCTION.....</b>	<b>33</b>
<b>MATERIALS AND METHODS.....</b>	<b>36</b>
<b>RESULTS.....</b>	<b>41</b>
<b>DISCUSSION.....</b>	<b>47</b>
<b>REFERENCES.....</b>	<b>53</b>
<b>CHAPTER 3. HDAC INHIBITION ATTENUATES INFLAMMATORY,</b>	
<b>HYPERTROPHIC AND HYPERTENSIVE RESPONSES IN</b>	
<b>SPONTANEOUSLY HYPERTENSIVE RATS.....</b>	<b>58</b>
<b>INTRODUCTION.....</b>	<b>59</b>
<b>MATERIALS AND METHODS.....</b>	<b>61</b>
<b>RESULTS.....</b>	<b>65</b>
<b>DISCUSSION.....</b>	<b>72</b>
<b>PERSPECTIVES.....</b>	<b>79</b>
<b>REFERENCES.....</b>	<b>80</b>
<b>CHAPTER 4. CENTRAL TUMOR NECROSIS FACTOR-<math>\alpha</math> BLOCKADE REVERSES</b>	
<b>ANGIOTENSIN II – INDUCED ALTERATIONS IN RENIN-</b>	
<b>ANGIOTENSIN SYSTEM COMPONENTS AND ATTENUATES</b>	
<b>HYPERTENSION.....</b>	<b>84</b>
<b>INTRODUCTION.....</b>	<b>85</b>
<b>MATERIALS AND METHODS.....</b>	<b>86</b>
<b>RESULTS.....</b>	<b>89</b>

DISCUSSION.....	94
REFERENCES.....	100
<b>CHAPTER 5. NUCLEAR FACTOR-<i>kappa</i>B BLOCKADE IN THE PARAVENTRICULAR NUCLEUS MODULATES RENIN- ANGIOTENSIN SYSTEM COMPONENTS AND ATTENUATES HYPERTENSION.....</b>	<b>103</b>
INTRODUCTION.....	104
MATERIALS AND METHODS.....	105
RESULTS.....	112
DISCUSSION.....	119
PERSPECTIVES.....	126
REFERENCES.....	126
<b>CHAPTER 6. CONCLUDING REMARKS.....</b>	<b>131</b>
OVERALL SUMMARY OF FINDINGS.....	132
SIGNIFICANCE OF RESEARCH AND FUTURE DIRECTIONS.....	136
REFERENCES.....	140
<b>APPENDIX: LETTER OF PERMISSION.....</b>	<b>142</b>
<b>VITA.....</b>	<b>144</b>

## LIST OF ABBREVIATIONS

%FS	% fractional shortening
$\cdot\text{ClO}^-$	hypochlorite
$\text{H}_2\text{O}_2$	hydrogen peroxide
$\cdot\text{O}_2^-$	superoxide
$\cdot\text{OH}$	hydroxyl moiety
$\cdot\text{OH}^-$	hydroxyl radical
$\text{ONOO}\cdot$	peroxynitrite
i.m.	intramuscular
i.p.	intraperitoneal
p.o.	orally
s.c.	subcutaneously
ACE2	angiotensin converting enzyme 2
aCSF	artificial cerebrospinal fluid
Ad	adenovirus/adenoviral vector
AdEmpty	adenoviral vector with an empty cassette region (control virus)
ADH	anti-diuretic hormone/vasopressin
AdIkB	adenoviral vector containing an inhibitory- <i>kappa</i> B cassette insert
AHA	American Heart Association
Ang (1-7)	angiotensin (1-7)
Ang (1-9)	angiotensin (1-9)
Ang I	angiotensin I
Ang II	angiotensin II



Ang III	angiotensin III
Ang IV	angiotensin IV
ANOVA	analysis of variance
ANP	atrial natriuretic peptide
AP	area postrema
ARB(s)	angiotensin receptor blocker(s)
AT <sub>1</sub> R	angiotensin II type-1 receptor
AT <sub>2</sub> R	angiotensin II type-2 receptor
AT <sub>4</sub> R	angiotensin II type-4 receptor
BBB	blood brain barrier
BH <sub>4</sub>	tetrahydrobiopterin
BW	body weight
CDC	Centers for Disease Control
cDNA	complementary DNA
CMH	1-hydroxyl-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine
CNS	central nervous system
CRP	C-reactive protein
Cu/Zn-SOD	copper/zinc SOD
CVD(s)	cardiovascular disease(s)
CVO(s)	circumventricular organ(s)
DHBA	dihydrobetulinic acid
DNA	deoxyribonucleic acid
DOCA	deoxycorticosterone acetate

EDTA	ethylenediaminetetra acetic acid
ELISA	enzyme-linked immunosorbent assay
EMSA	electrophoretic mobility shift assay
eNOS	endothelial NOS
EPI	epinephrine
EPR	electron paramagnetic spin resonance
ERK1/2	extracellular signal-related kinase 1/2
ESR	electron paramagnetic spin resonance
ETN	etanercept
GABA	<i>gamma</i> -amminobutyric acid
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
HAT	histone acetyltransferase
HDAC	histone deacetylase
HDACi	HDAC inhibitor(s)/inhibition
HIF	hypoxia inducible factor
HPLC	high performance liquid chromatography
HR	heart rate
HW	heart weight
HW/BW	heart weight/body weight
HYD	hydralazine
IACUC	Institutional Animal Care and Use Committee
ICV	intracerebroventricular
IL	interleukin

iNOS	inducible NOS
IVSTd	interventricular septal thickness in diastole
IVSTs	interventricular septal thickness in systole
I $\kappa$ B	inhibitory- <i>kappa</i> B
KHB	Kreb's HEPES buffer
LV	left ventricle
LVIDd	left ventricular internal diameter in diastole
LVIDs	left ventricular internal diameter in systole
LVPWTd	left ventricular posterior wall thickness in diastole
LVPWTs	left ventricular posterior wall thickness in systole
LW	lung weight
LW/BW	lung weight/body weight
MAP	mean arterial pressure
MAPK	mitogen-activated protein kinase
MasR	<i>Mas</i> receptor
MCP-1	monocyte chemotactant protein-1
MEF2	myocyte enhancer factor-2
MHC	myosin heavy chain
MHz	megahertz
mRNA	messenger RNA
NADPH	nicotinamide adenine dinucleotide phosphate
NE	norepinephrine
NEP	neutral endopeptidase

NFκB	nuclear factor- <i>kappa</i> B
NIH	National Institutes of Health
nNOS	neuronal NOS
NO	nitric oxide
NOS	nitric oxide synthase
Nox1	NADPH oxidase with gp91 <i>phox</i> homologue
Nox2	NADPH oxidase with gp91 <i>phox</i>
Nox4	NADPH oxidase with gp91 <i>phox</i> homologue
NTS	nucleus tractus solitarius
OVLT	organum vasculosum lamina terminalis
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PDTC	pyrrolidine dithiocarbamate
PEG-SOD	polyethylene glyco-conjugated SOD
PIC(s)	proinflammatory cytokine(s)
PVN	paraventricular nucleus
RAAS	renin-angiotensin-aldosterone system
RAS	renin-angiotensin system
RNA	ribonucleic acid
ROS	reactive oxygen species
RT-PCR	reverse transcriptase PCR
RVLM	rostral ventrolateral medulla
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis

SEM	standard error of the mean
SFO	subfornical organ
SHR	spontaneously hypertensive
SHRSP	SHR stroke-prone
siRNA	small interfering RNA
SNS	sympathetic nervous system
SOD	superoxide dismutase
SON	supraoptic nucleus
Tei	(isovolumic contraction time + isovolumic relaxation time)/ejection time
Temp	Tempol
TNF	tumor necrosis factor- <i>alpha</i>
TNFR1	TNF receptor type-1
TNFR2	TNF receptor type-2
VLM	ventrolateral medulla
VPA	valproic acid
WHO	World Health Organization
WKY	wistar-kyoto

## ABSTRACT

Hypertension is a serious condition with high morbidity and mortality rates, as well as a major predisposing factor for multiple cardiovascular and renal diseases. Angiotensin II (Ang II) of the renin-angiotensin system (RAS) plays a pivotal role in propagating the hypertensive response. Moreover, hypertension is considered a chronic low-grade inflammatory condition that intimately involves the actions of proinflammatory cytokines (PICs) such as tumor necrosis factor-*alpha* (TNF). Recent evidence highlights the role that inflammation, specifically TNF, plays in hypertension and in regulating the RAS, but the understanding as to how inflammation is regulated following Ang II or TNF activation, as well as the resultant consequences, is currently unclear. Based upon the literature and work from our laboratory, we hypothesize that inflammatory regulation in local tissues alters the systemic hypertensive response, possibly through an inflammatory-driven reactive oxygen species (ROS) mechanism. Therefore, we examined the role of inflammatory mediators in the heart and brain in regulating the hypertensive response through the modulation of ROS, the transcription factor Nuclear Factor-*kappa*B (NF $\kappa$ B) and the dysregulation of components of the RAS. To examine this interaction, we conducted a series of *in vivo* experiments designed to better understand these mechanisms. First, we evaluated the effects of TNF infusion on blood pressure response and RAS component expression in the heart. We further explored these inflammatory mechanisms in spontaneously hypertensive rats through the actions of histone deacetylases in maintaining the hypertensive state through inflammatory modulation. Next, we examined the interaction of TNF in the brain in regulating the RAS in the Ang II-induced hypertensive drive. Finally, we examined how NF $\kappa$ B in the hypothalamic paraventricular nucleus contributed to the dysregulation of the RAS and adverse pressure responses in Ang II-induced hypertension. Combined, these studies demonstrate

a functional and signaling dependence between PICs and the RAS in hypertension, potentially through a ROS-mediated mechanism. These findings provide insight into the important signaling pathways involved in hypertension, as well as outline potential future therapeutic targets for the continued fight against this debilitating disease.

## **CHAPTER 1**

### **INTRODUCTION AND REVIEW OF LITERATURE**



## **HYPERTENSION**

The World Health Organization (WHO) lists hypertension as one of the world's great public health problems and the leading cause of death worldwide (2002). Within the United States, the Centers for Disease Control (CDC) and the American Heart Association (AHA) conclude that more than 74 million American adults, or 1 in 3 ages 20 and over, have high blood pressure (Lloyd-Jones, Adams et al. 2010). Less than 78% of these people know that they suffer from hypertension, and of those that are aware, less than 68% are currently being treated.

Hypertension is not only a serious condition with its own high morbidity and mortality rates, it is also a major risk factor for multiple cardiovascular diseases (CVDs), including myocardial infarction, stroke, heart failure, atrial fibrillation, aortic dissection and peripheral arterial disease. Moreover, with the rise in extraneous causes for increased blood pressure, including obesity, salt intake, poor lifestyle choices and a growing population of aging individuals, the incidence of hypertension is rising (Lloyd-Jones, Adams et al. 2010). While physicians do not know the cause for more than 90-95% of their hypertensive patients, the condition is easily detectable. However, and even more disturbing, is that of these individuals, more than half do not have their hypertension under control. In 2006 alone, greater than 56,000 people died in the United States from this debilitating condition.

Hypertension is classified as a systolic/diastolic blood pressure of 140/90 mmHg or higher. However, with epidemiological data suggesting significant increases in CVDs developing at lower pressures, the current definition remains contentious. As a result, physicians are becoming increasingly wary of pre-hypertensive conditions and initiating therapeutics more proactively. Hypertension can be further broken down into primary (essential) or secondary (identifiable) hypertension. In primary hypertension, a single reversible cause for the elevated

blood pressure cannot be identified, roughly accounting for the 90-95% of hypertensive cases observed. For the remaining 5-10% of clinical cases, a more distinct cause can be detected, falling under the moniker secondary hypertensive.

Current therapeutics for primary hypertension are multiple and varied, exploiting the many endogenous controlling mechanisms of normal pressure response as well as the pathophysiological hypertensive contributors. Briefly, these therapies can include lifestyle modifications and/or a bevy of pharmacological therapeutics. Lifestyle modifications can include weight reduction, sodium reduction, diet modification, increased physical activity and moderation of alcohol and tobacco consumption, amongst others. Common pharmacological interventions can include any number of drugs alone or in combination, including, but not limited to, diuretics,  $\beta$ -blockers,  $\alpha$ -blockers,  $\text{Ca}^{2+}$  channel blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) (Izzo, Sica et al. 2008). However, many current therapeutics fail to have a beneficial effect on over 50% of treated individuals, prompting the need for novel therapeutic approaches and a greater understanding of the mechanistic pathways involved in the pathogenesis and maintenance of hypertension.


## **THE FUNCTION OF THE RENIN-ANGIOTENSIN SYSTEM IN HYPERTENSION**

**The Renin-Angiotensin System in Normal Physiology.** There are many controlling factors for normal blood pressure regulation, including local autoregulation, baroreceptor signaling and the renin-angiotensin-aldosterone system (RAAS, herein referred to as RAS for renin-angiotensin system) (Guyton and Hall 2006). In its classically understood pathway, following a decrease in blood pressure, the RAS becomes activated. A reduced blood pressure decreases glomerular filtration rate, therefore increasing the time that the filtrate can undergo reabsorption, leading to an increased reabsorption of sodium and chloride ions from the proximal tubules. The increased

chloride concentration is detected by the macula densa of the kidneys and causes the release of renin from the juxtaglomerular cells of the afferent artery. Circulating renin cleaves circulating angiotensinogen (produced and released by the liver) into the decapeptide angiotensin I (Ang I), which is subsequently converted by ACE (abundantly synthesized and located within the vasculature of the lungs) into the biologically active octapeptide angiotensin II (Ang II). Ang II is the primary effector peptide of the RAS, eliciting its actions through either Ang II type-1 or type-2 receptors (AT<sub>1</sub>R and AT<sub>2</sub>R, respectively) (Allen, Zhuo et al. 2000; Lavoie and Sigmund 2003). The AT<sub>1</sub>R is the main receptor through which Ang II acts, inducing vasoconstriction, aldosterone secretion, increased sympathetic activation and sodium retention, amongst its many other actions, all intended to raise blood pressure to its homeostatic levels (Allen, Zhuo et al. 2000). Once normalized, these same factors negatively signal back upon themselves to shut off these arterial pressure raising functions. The AT<sub>2</sub>R, the less common of the two receptors, is thought to be cardioprotective and display actions opposing those of the AT<sub>1</sub>R, but this concept remains poorly understood. Though the following depicts the classical RAS (also see Figure 1.1), recent research has shown that a majority of the tissues within the body have their own local RAS, including the heart, vasculature and brain, and that these tissue systems are capable of producing all the associated components of the classical RAS (Lavoie and Sigmund 2003).

Further complicating the original understanding of the RAS was the identification of a separate RAS axis that exhibited cardioprotective properties and seemed to be a counterbalance to the actions of Ang II. Following its initial discovery in 2000, ACE2 was shown to cleave Ang I into Ang (1-9), which is subsequently converted to Ang (1-7) by ACE (Donoghue, Hsieh et al. 2000; Tipnis, Hooper et al. 2000; Xu, Sriramula et al. 2011). Ang II can also be converted by ACE2 to Ang (1-7) (Vickers, Hales et al. 2002). By acting through the Mas receptor (MasR),

Ang (1-7) has actions that oppose those of Ang II, including vasodilatation and anti-hypertrophic properties (Santos, Simoes e Silva et al. 2003). Additional pathways by which the components of the RAS can act are increasingly coming under investigation. The AT<sub>4</sub>R subtype, the roles of Ang III and Ang IV, the chymase activation pathway and a non-AT<sub>1</sub>/non-AT<sub>2</sub>R are a few of the various novel mechanisms currently being studied (Xu, Sriramula et al. 2011). Regardless, these diverse systems highlight the major difference from our traditional understanding of the RAS to this multifaceted system that is only recently becoming more elucidated.




**Figure 1.1. The components of the renin-angiotensin system.** The balance between the vasoconstrictor/pro-hypertensive and vasodilator/anti-hypertensive axes are critical to the maintenance of blood pressure control and the perpetuation of hypertension. Ang, Angiotensin; ACE, Ang converting enzyme; NEP, Neutral endopeptidase; AT<sub>1</sub> and AT<sub>2</sub>R, Ang II Type-1 and Type-2 receptor, respectively.

**The RAS in Hypertension.** Under typical blood pressure homeostasis, the RAS and its various components function without producing a pathological condition. However, following any of the many triggers that can induce the commencement of a hypertensive response, the RAS becomes intimately involved in its pathogenesis. As such, understanding its function within the hypertensive state is of constant concern. In hypertensive human patients and multiple hypertensive animal models, Ang II is elevated, along with AT<sub>1</sub>R expression and increased AT<sub>1</sub>R cell surface localization, thereby heightening tissue sensitivity to the already elevated Ang II (Atlas 2007). These tissue responses to Ang II in hypertension are multiple. Initially, a pathological increase in Ang II can lead to sustained elevation of blood pressure through multiple avenues: direct sustained vasoconstriction; increased salt (Na<sup>+</sup>) and water retention through direct actions on the kidney tubules, indirectly via aldosterone stimulation and secretion, and/or indirectly via posterior pituitary stimulation and secretion of anti-diuretic hormone (ADH or vasopressin), increased chronic sympathetic activity, etc (Corvol and Jeunemaitre 1997; Ruiz-Ortega, Lorenzo et al. 2001). These factors, combined with additional specific responses of individually activated tissues, exacerbate the hypertensive response and lead to a general deterioration of cardiovascular function and response capabilities.

Over time, sustained elevation of Ang II can also lead to cardiovascular hypertrophy and remodeling, further deteriorating the hypertensive condition (Sasamura, Nakazato et al. 1997; Allen, Zhuo et al. 2000; Paradis, Dali-Youcef et al. 2000; Lim, Lutucuta et al. 2001; Ruiz-Ortega, Lorenzo et al. 2001). Within the heart, Ang II signals cell proliferation and differentiation and cardiomyocyte hypertrophy (Lim, Lutucuta et al. 2001). Additional signaling cascades result in cardiomyocyte contractile dysfunction, interstitial fibrosis, conductance and rhythm defects and a decompensation of cardiac function, which can be reversed by Ang II

receptor blockade (Paradis, Dali-Youcef et al. 2000). This increased remodeling, hypertrophy and heart contractile deficiencies leads to increased peripheral resistance, causes vessel damage, dysfunction of normal vascular mechanisms, and can lead to plaque buildup and atherosclerosis, a major factor for the high morbidity and mortality associated with hypertension (Atlas 2007). Simultaneously, with this increase in the activity of the ACE/Ang II/ AT<sub>1</sub>R axis comes the decrease in the protective ACE2/ Ang (1-7)/MasR axis, further reducing the possible cardioprotective and anti-hypertensive effects that this newly recognized arm of the RAS may produce (Xu, Sriramula et al. 2011). Combined, these functions of Ang II are major reasons for the need to control this peptide in hypertension and the rationale behind the use of ACE inhibitors and ARBs in hypertensive therapy (Atlas 2007).



Taken together, the RAS in hypertension is a complicated association of beneficial and deleterious components whose functional interplay is only beginning to come of light. Understanding their functions and the mechanistic pathways by which the RAS is activated and sustained in various tissues in hypertension is instrumental for the advancement of novel therapeutic options, including promoting ACE2 expression and Mas receptor agonists. However, these concepts are intensified in complexity when considering their effect on and their regulation by inflammatory mediators in hypertension.

### **INFLAMMATION, NUCLEAR FACTOR- $\kappa$ B IN HYPERTENSION**

Inflammation is associated with many CVDs, and recent evidence suggests that hypertension is a chronic low-grade inflammatory condition (Ferrario and Strawn 2006; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Pro-inflammatory cytokines (PICs) such as Tumor Necrosis Factor-*alpha* (TNF), interleukin (IL)-1 $\beta$  and IL-6, have emerged as major contributing factors in the pathogenesis of hypertension and other CVDs (Mann 2002; Ruiz-Ortega, Ruperez et al. 2002; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009). The RAS, especially the effector peptide Ang II, not only modulates the hypertensive response through the above mentioned mechanisms, but plays a key role in inducing the inflammatory response associated with hypertension (Kalra, Sivasubramanian et al. 2002). Moreover, this inflammatory response appears to upregulate both local and systemic pro-hypertensive components of the RAS while silencing those of the anti-hypertensive axis. The Ang II-mediated inflammatory response can occur through several mechanisms, including activation of monocytes and macrophages, as well as induce the production of adhesion molecules, chemokines, cytokines and ROS activators (Arenas, Xu et al. 2004; Shi, Diez-Freire et al. 2010). While still not fully known, these pathways are becoming more important to

understand, as it is increasingly clear that inflammation plays a major role in the pathophysiological changes observed in the cardiovascular system during sustained Ang II-induced AT<sub>1</sub>R activation.

One of the primary cytokines activated by Ang II is TNF. This pleiotropic peptide exists initially as a membrane bound pre-protein, which once cleaved by metalloproteinases into its soluble form, can elicit its responses through one of two similarly acting TNF receptors, TNFR1 (low affinity) or TNFR2 (high affinity) (Gearing, Beckett et al. 1994; Feldman, Combes et al. 2000; Mann 2002). Once receptor bound, TNF plays an important role in multiple pathophysiological processes, as in hypertension, such as inflammation, cell survival, growth, differentiation and apoptosis (MacEwan 2002). There is much data to support the cross-talk between the RAS and PICs, such as TNF, a conversation often shown to involve the mediation effects of the transcription factor Nuclear Factor-*kappa*B (NFκB) (Mehta and Griendling 2007; Kang, Ma et al. 2009).

NFκB is a key transcription factor regulating many inflammatory and immune responses (Bubici, Papa et al. 2006). This protein signaling cascade is highly complex, with multiple members within the “Rel” and “NFκB” related family of proteins, including RelA (p65), RelB, c-Rel, p50, p52, and additional, less widely distributed peptides, all capable of forming homo- and heterodimers *in vivo* (with the exception of RelB which can only form a homodimer) (Gilmore 2006). These subunits share a Rel-homology domain capable of binding various κB binding sites on target genes and thereby inducing transcription. NFκB is typically sequestered within the cytoplasm of cells and bound to one of several Inhibitory-κB (IκB) proteins such as IκBα, IκBβ or IκBγ, amongst others. Following a signal from any number of possible receptors (within hypertension: via AT<sub>1</sub>R, TNFRs and reactive oxygen species (ROS) signaling, etc.), IκB



becomes phosphorylated (typically in hypertension: I $\kappa$ B $\alpha$ ), leading to its subsequent ubiquitination and degradation. Once freed from I $\kappa$ B, NF $\kappa$ B (often the p50/RelA (p65) heterodimer is observed in hypertension) then translocates itself into the nucleus and binds to its target genes, including additional NF $\kappa$ B and I $\kappa$ B subunits (for negative feedback regulation/transcriptional repression) (Gilmore 2006).

Recent evidence suggests the involvement of NF $\kappa$ B in the pathogenesis of cardiac remodeling and in the failing heart (Kang, Ma et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Ang II has also been shown to activate NF $\kappa$ B and induce TNF in cardiomyocytes (Cowling, Gurantz et al. 2002). For the hypertension-associated inflammatory response, the p50/p65 dimer promotes gene expression increases for many proteins, including TNF, inducible nitric oxide synthases (iNOSs), and inflammatory adhesion molecules (Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Activation of NF $\kappa$ B via Ang II not only induces increases in PIC expression, but also leads to increases in ROS production and pro-hypertensive RAS component expression such as AT $_1$ R and ACE, and has also been shown to decrease components of the ACE2/Ang (1-7)/Mas axis. Therefore, understanding NF $\kappa$ B regulation and function within the hypertensive state in inducing the deleterious interactions of the RAS, PICs and ROS is of great interest. Furthermore, in clarifying these concepts, it provides the opportunity to develop novel therapeutic options for controlling the damaging results of hypertension.

## **REACTIVE OXYGEN SPECIES IN HYPERTENSION**

A growing body of evidence indicates that production of ROS and activation of oxidation-reduction dependent signaling cascades leads to oxidative stress and is centrally and critically involved cardiovascular events (Griendling, Sorescu et al. 2000; Touyz 2000; Harrison

and Gongora 2009). ROS and oxidative stress play an important role in diabetes mellitus, atherosclerosis, hyperlipidemia, heart failure, ischemic heart disease and hypertension. Oxidative stress is defined as the imbalanced redox state where pro-oxidants overwhelm intrinsic anti-oxidant systems, resulting in an increased production of ROS. During normal physiological conditions, ROS are produced in a controlled manner at low concentrations and function as signaling molecules or normal by-products of cellular reactions and cellular respiration. Conversely, under pathological conditions, increased ROS production contributes to cell dysfunction, cell growth, monocyte invasion, lipid peroxidation, inflammation, and increased deposition of extracellular matrix proteins, which are all important factors in vascular, renal and cardiac damage during the pathogenesis of hypertension (Sawyer, Siwik et al. 2002; Murdoch, Zhang et al. 2006; Papaharalambus and Griendling 2007).

In mammalian cells, aerobic respiration allows the reduction of molecular oxygen to water. During this process, ROS are generated, including molecular free radical, protein and lipid species. These species are short-lived, and after completing their roles in routine cellular function/maintenance, they are scavenged by a series of antioxidant enzymes (Chabrashvili, Tojo et al. 2002; Majid and Kopkan 2007; Paravicini and Touyz 2008); these highly reactive species however, at elevated and/or uncontrolled concentrations, can interact with and cause damage to proteins, lipids and DNA (Droge 2002; Vaziri 2008). Normally, the *in vivo* anti-oxidant defense is sufficient to metabolize these ROS. However, in conditions of persistent inflammation and oxidative stress, such as hypertension, anti-oxidant molecules and enzymes can be depleted and/or inactivated, thereby impairing the overall anti-oxidant defense system (Droge 2002). Although excessive production of ROS is the most common cause of oxidative stress in hypertension, oxidative stress can also be caused by the primary impairment of antioxidant

systems (Wei and Lee 2002; Ahamed and Siddiqui 2007). Under physiological conditions, ROS produced in the course of normal metabolism are fully reduced by an elaborate cellular and extracellular anti-oxidant defense system. However, in certain pathological conditions like hypertension, increased generation of ROS and/or depletion of anti-oxidant capacity leads to enhanced ROS activity and oxidative stress (Yu 1994; Vaziri, Wang et al. 2000). In fact, several recent studies have demonstrated significant impairment of anti-oxidant enzymes and increased oxidative stress in various models of hypertension, including spontaneously hypertensive (SHR) rats (Carneado, Alvarez de Sotomayor et al. 2002; Elks, Mariappan et al. 2009) and rats with chronic kidney failure (Galle 2001), diabetes (Mariappan, Elks et al. 2010), and Dahl-salt sensitive rats (Wang, Chen et al. 2006; Tian, Moore et al. 2007).

Excessive ROS production causes oxidative damage and is associated with hypertension and other disease conditions (Piotrkowski, Fraga et al. 2007; Puddu, Puddu et al. 2007). Growing evidence from animal and clinical studies suggests that inflammation-induced oxidative stress in the heart and kidney could be a key factor in the development and persistence of hypertension (Cachofeiro, Goicochea et al. ; Vanegas, Ferrebuz et al. 2005; Van Gaal, Mertens et al. 2006). Hypertension itself is a multi-factorial disorder that results from the combined effects of inflammation, ROS, reactive nitrogen species generation, and lipid metabolism. Recent work suggests that cytokines can modulate major ROS molecules, such as superoxide ( $\cdot\text{O}_2^-$ ) and nitric oxide (NO), and contribute to hypertensive response (Elks, Mariappan et al. 2008; Sriramula, Haque et al. 2008) and end organ damage (Elks, Mariappan et al. 2008; Mariappan, Elks et al. 2009). Under conditions of excessive ROS production, NO is also depleted, which is often from either a direct decrease in NO (inhibition/depletion of nitric oxide synthase [NOS – converts L-arginine into NO]) or because of a decreased bioavailability of NO due to its rapid interaction

with superoxide to form peroxynitrite (Wilcox 2002; Palm 2006; Pechánová, Zicha et al. 2006). At high concentrations, peroxynitrite is also highly toxic to tissues and could be an important signaling molecule and contributor to end organ damage in hypertension.

NO also has many known roles both peripherally and centrally in regulating blood pressure responses. It acts as a vasodilator and neurotransmitter, and it is generally accepted that the level of NO in the brain is inversely proportional to sympathetic outflow (i.e. decreased NO is sympathoexcitatory) (Zucker and Liu 2000; Ramchandra, Barrett et al. 2005). While Ang II, NO, and sympathetic regulation are known to interact, the mechanism is somewhat unclear (Zucker and Liu 2000; Ramchandra, Barrett et al. 2005). Multiple experiments have shown that Ang II infusion both in the periphery and via intracerebroventricular (ICV) cannulation downregulates neuronal NOS (nNOS) in multiple cardio-regulatory regions in the brain, including the paraventricular nucleus (PVN), coinciding with increased sympathetic outflow, and that by scavenging ROS, these changes are reversed (Campese, Shaohua et al. 2005; Tai, Wang et al. 2005). Additionally, in the presence of superoxide, NO is oxidized into peroxynitrite, which further decreases the bioavailability of NO produced by an already diminishing presence of nNOS (Zanzinger 2002). NOS overexpression studies also decreased the hypertensive state in Ang II (Tai, Wang et al. 2005) and SHRSP (Kishi, Hirooka et al. 2003) animal models, highlighting the role that NO plays in sympathetic regulation and blood pressure response. Adding complexity to this system is inducible/inflammatory NOS (iNOS). Activated by Ang II and NFkB (possibly through a redox sensitive mechanism), iNOS overexpression in the rostral ventrolateral medulla (RVLM) causes an increase in sympathetic outflow and mean arterial blood pressure (Kimura, Hirooka et al. 2005). The rationale for this phenomenon lies in the over-efficiency displayed by iNOS compared to the other homologues. By rapidly converting all

available L-arginine to NO, iNOS then begins to produce superoxide and further exasperate the already fragile oxidant state. Thus, this evidence indicates that the increase in sympathoexcitation and continuation of the hypertensive state is, in part, the result of a decreased NO bioavailability in the brain, ultimately due to an increase in oxidative stress.

Although there is evidence that inflammation plays a key role in the pathophysiology of hypertension, it is not clear whether inflammation induces oxidative stress to lead to hypertension or that hypertension induces inflammation and oxidative stress. Regardless the order, or if a combination of both, recent evidence shows that inflammation-induced oxidative stress in hypertension can ultimately lead to heart and kidney failure, as well as an adverse response in the brain and further contributing to the hypertensive response. The imbalance of redox homeostasis is integral to the progression of the hypertensive state.

**Sources of ROS.** ROS are produced by numerous enzymes in many cell types, including endothelial, vascular smooth muscle, adventitial, neuronal, microglial and various renal cells. The major ROS produced are the superoxide anion ( $\cdot\text{O}_2^-$ ), hydroxyl moiety ( $\cdot\text{OH}$ ), hypochlorite ( $\cdot\text{ClO}^-$ ), hydrogen peroxide ( $\text{H}_2\text{O}_2$ ), and hydroxyl radical ( $\cdot\text{OH}^\cdot$ ). The superoxide anion can further combine with NO, forming the reactive compound peroxynitrite ( $\text{ONOO}^\cdot$ ) and generating a nitroso-redox imbalance (Hare and Stamler 2005). Additionally, peroxynitrite oxidizes tetrahydrobiopterin ( $\text{BH}_4$ ), thereby leading to endothelial NOS (eNOS) uncoupling and diminished NO production (Lin, Moran et al. 2005). These ROS are generated as intermediate products in oxidative phosphorylation reactions and play a role in normal redox control of physiological signaling pathways. They also act as important second messengers and intracellular signaling molecules in cell growth, survival and apoptosis. However, excessive ROS generation leads to oxidative stress, triggers cell dysfunction, lipid peroxidation, and DNA

mutagenesis, among multiple additional tissue and cellular mechanistic altering functions (Murdoch, Zhang et al. 2006).

The major source of ROS generation in the cardiovascular system is NADPH oxidase. NADPH oxidase is composed of multiple subunits, including two membrane-bound subunits, p22*phox* and gp91*phox* (also known as Nox2, or the homologues Nox1 and Nox4), and the cytosolic subunits p47*phox*, p40*phox*, p67*phox* and Rac1 (a small G-protein) (Lassegue and Clempus 2003; Lambeth 2004). Upon stimulation, the cytosolic subunits migrate towards the plasma membrane bound subunits and become enzymatically active upon their unification, ultimately yielding superoxide by the 1 electron reduction of oxygen using NADPH as the electron donor:  $2\text{O}_2 + \text{NADPH} \rightarrow 2\text{O}_2^- + \text{NADP}^+$  (Lambeth 2004). Other enzymatic sources of ROS involved are xanthine oxidases, uncoupling of the mitochondrial respiratory chain, cytochrome p450, and uncoupling of eNOS. ROS are physiologically produced, but during diseased states, these sources become the main culprits of sustained cellular and tissue damage, especially during the hypertensive state (Griendling, Sorescu et al. 2000; Harrison and Gongora 2009).

Within the cardiovascular system and during the pathogenesis of hypertension, the balance between the oxidant and anti-oxidant systems tips in favor of the more deleterious oxidative side. If left uncontrolled, it can elicit many changes in the various organ systems required for cardiovascular homeostasis, including the heart, kidney and brain. It is here that over a prolonged period of time, the oxidative unbalance leads to sustained oxidative stress, an exasperated hypertensive response, and eventually, end-organ damage and death.

**Redox Balance and Inflammation in Hypertension.** The importance of redox signaling mechanisms in the heart, kidneys and brain, and their contribution to end organ damage in hypertension is a relatively new concept. It is of note that activated immune cells release large

quantities of ROS, promoting regional oxidative stress. Oxidative stress may also contribute to hypertensive risk by upregulating production of PICs such as TNF, IL-1 $\beta$ , IL-6, etc. and acute phase proteins such as C-reactive protein (CRP), through activation of the transcription factor NF $\kappa$ B (Barnes and Karin 1997; Himmelfarb 2004), all of which are involved in the hypertensive response. Increased levels of circulating PICs lead to an increase in cytosolic ROS production from sources such as NADPH oxidase. This increase in ROS can signal the mitochondria to increase their ROS production, and can also trigger the phosphorylation of I $\kappa$ B $\alpha$ , which is responsible for maintaining NF $\kappa$ B in its inactive form. Once the I $\kappa$ B $\alpha$  is phosphorylated, NF $\kappa$ B is “activated” and translocates into the nucleus to facilitate the transcription of several PIC genes, including TNF. This gene transcription will lead to further increases in circulating PICs, thereby creating a vicious positive feed-forward cycle.

Not only does ROS activate NF $\kappa$ B, but several lines of *in vitro* experimental evidence indicate that NF $\kappa$ B activation can also lead to ROS generation (Flohe, Brigelius-Flohe et al. 1997; Crack and Taylor 2005). NF $\kappa$ B activation can be triggered by the addition of H<sub>2</sub>O<sub>2</sub> to some cell types in the absence of a physiological stimulus, and NF $\kappa$ B activation is inhibited by a broad range of antioxidants (Gloire, Legrand-Poels et al. 2006). Overexpression of copper/zinc superoxide dismutase (CuZn-SOD) enhances NF $\kappa$ B activation by TNF, while overexpression of catalase or of glutathione peroxidase attenuates NF $\kappa$ B activation by TNF (Sakon, Xue et al. 2003; Pham, Bubici et al. 2004; Gloire, Legrand-Poels et al. 2006). There is a bidirectional interaction between oxidative stress and inflammation. H<sub>2</sub>O<sub>2</sub> produced from the mitochondria leads to NF $\kappa$ B activation in the cytosol and consequently to the production of PICs. Although the response to oxidative stimuli is short-lived under normal conditions, it can lead to chronic inflammatory responses when the oxidative stimuli are poorly controlled (Chung, Cesari et al.

2009). Furthermore, induction of TNF can increase cellular ROS production, mainly via activation of NADPH oxidase. Due to a positive feed-forward loop, this results in further activation of NF $\kappa$ B and production of TNF (Mariappan, Soorappan et al. 2007; Csiszar, Wang et al. 2008; Mariappan, Elks et al. 2009; Mariappan, Elks et al. 2010). The interaction between oxidative stress and inflammation appears to play an important role in vascular, heart, kidney and brain tissue inflammation and in the development of hypertension. Together, these data indicate that NF $\kappa$ B is also a redox-responsive transcription factor. Thus, the role of inflammation in hypertension cannot be overstated and must be accounted for when addressing the issue of ROS in the pathogenesis of hypertension. Therefore, it is important to understand the PIC and RAS mechanisms contributing to the generation of oxidative stress in hypertension, the effects of this oxidative stress on hypertension, as well as possible therapeutic approaches towards alleviating the oxidant component of the hypertensive state through PIC and RAS modulation.

## **THE BRAIN IN HYPERTENSION**

Hypertension is a multifaceted disorder involving not only peripheral factors and organ systems, but complex signaling mechanisms into and throughout the central nervous system (CNS) (de Wardener 2001; Guyenet 2006; Peterson, Sharma et al. 2006; Harrison and Gongora 2009; Shi, Raizada et al. 2010). Over the past decade, multiple studies have confirmed the role that central neurogenic mechanisms play in the maintenance and management of blood pressure and volume homeostasis through modulation of the vasculature, heart and kidneys (Guyenet 2006). This includes, but is not limited to, modulation of sympathetic tone, water and salt balance, and system wide regulation of circulatory hormonal release (de Wardener 2001). These nuclei are situated throughout the forebrain, midbrain, and hindbrain regions, each with specific and overlapping roles in cardiovascular homeostasis and response. These nuclei receive inputs



from afferent signals via baro-, chemo-, and osmoreceptors located throughout the body, as well as neural inputs from the circumventricular organs (CVOs), a specialized region of the brain that lacks a fully developed blood brain barrier (BBB) and enables the brain to detect blood-borne signaling hormones and blood osmolality levels through receptors protruding from this area (Guyenet 2006; Peterson, Sharma et al. 2006). These CVOs, along with other cardio-regulatory regions of the brain, are implicated in the maintenance of many experimentally observed forms of hypertension (Harrison and Gongora 2009).


Mounting evidence indicates that the brain plays a major role in the pathogenesis of hypertension and that neurogenic mechanisms are dominant in over 40% of essential hypertensive patients (Esler and Kaye 2003; Hirooka 2008), and more specifically, that the sympathetic nervous system (SNS) plays a major role in the pathogenesis of hypertension (Guyenet 2006; Hirooka 2008). When acutely and chronically activated, the SNS can become involved in 24-hour blood pressure patterns and the sustained progression of hypertension, ultimately resulting in metabolic abnormalities, end-organ damage, and even death (Kishi, Hirooka et al. 2001; Harrison and Gongora 2009). During the past several years, new evidence has also emerged that clearly demonstrates the involvement of PICs, NF $\kappa$ B and ROS in the brain in blood pressure regulation by serving as signaling/modulatory molecules within neurons of cardiovascular regulatory centers and in the regulation of the SNS (Paravicini and Touyz 2006; Peterson, Sharma et al. 2006). These components are linked to sympathetic modulation both during physiological and pathophysiological functions.

**The RAS and the Brain.** The brain is capable of expressing all the genes that comprise the components of the RAS, including renin, angiotensinogen, Ang I Ang II, Ang (1-7), ACE, ACE2, AT<sub>1</sub>R, AT<sub>2</sub>R and the Mas receptor (Davisson 2003; Veerasingham and Raizada 2003;

Xu, Sriramula et al. 2011). Recent data indicate that central AT<sub>1</sub>R up-regulation plays a critical role in activating pre-sympathetic neurons residing in various cardio-regulatory centers in the brain (Guyenet 2006). The enhancement of neuronal AT<sub>1</sub>R transcription appears to be a critical mechanism of this central AT<sub>1</sub>R up-regulation. Several factors, including PICs, ROS and RAS signaling affect AT<sub>1</sub>R expression and activity, which, in turn, modulates neuronal activity. The pre-sympathetic actions of AT<sub>1</sub>R in CVD ultimately lead to enhanced sympathoexcitation and controls many cardio-regulatory functions (Ganong 2000). AT<sub>1</sub>Rs are located directly on the neurons, and when excited, drive post-sympathetic norepinephrine release to elicit cardiovascular alterations (i.e. increased vasoconstriction, heart rate, renin release, etc.) (Davisson 2003).

**The PVN and Hypertension.** Within the brain, studies have demonstrated the location of AT<sub>1</sub>R<sub>s</sub> on many regions associated with systemic and cardiovascular homeostasis. It should also be noted that several regions show a more pronounced effect of receptor activation in regulating short- and long-term sympathetic regulation, including, but not limited to, the CVOs, the hypothalamic PVN and the ventrolateral medulla (VLM) (Davisson 2003; Coote 2005). The CVOs directly detect the presence of Ang II through AT<sub>1</sub>R activation, thus serving as a major entry point for the Ang II signal into the brain. The PVN appears to be the main integrative site of the many cardiovascular inputs to the CNS; it also has a large number of AT<sub>1</sub>R<sub>s</sub> located throughout its region (Dampney 1994; Francis, Weiss et al. 2001; Coote 2005; Kang, Ma et al. 2009). This site has direct projections to the pituitary gland and can increase ADH secretion, as well as neurons that project to the adrenal glands and elicit aldosterone synthesis and secretion (Coote 2005). Finally, the VLM is the main exit point of sympathetic neurons from the brain to the spinal column and into the periphery, also receiving signals from the PVN (Dampney 1994). Taken together, activation of AT<sub>1</sub>R<sub>s</sub> can induce systemic pressor effects via the sympathetic

nervous system, can blunt baroreceptor actions and signals, induce ADH synthesis and release, as well as control salt and water appetite.



**Figure 1.3. Schematic depicting the Ang II signaling pattern between the brain and the periphery.** Increased Ang II signals to the brain via the blood brain barrier, whereupon it signals to various cardio-regulatory centers, such as the PVN. Local Ang II signaling subsequently causes an imbalance in PICs, ROS and the RAS thereby perpetuating the hypertensive state.

The proposed intracellular signaling mechanism whereby  $AT_1R$  activation causes a sympathetic response is unclear, but many studies have pointed to the role that PICs and ROS

play in this pathway (Peterson, Sharma et al. 2006; Harrison and Gongora 2009). For example, AT<sub>1</sub>R activation activates membrane NADPH oxidases to produce ROS such as superoxide and hydrogen peroxide, and inhibits SODs. It is suspected that this NADPH oxidase activation goes through a phospholipase D/protein kinase C phosphorylating pathway (Seshiah, Weber et al. 2002). However, other investigations outline a p38 MAPK and ERK1/2 pathway, or through PIC activation of NFκB that increases ROS production (Chan, Hsu et al. 2005). Regardless, it is abundantly apparent that the combination of PIC, RAS and ROS cross-talk and responses within the brain drive the neurogenic portion of the hypertensive state.

Multiple regions within the brain have modulatory roles in the hypertensive response such as the VLM, subfornical organ (SFO), supraoptic nucleus (SON), nucleus tractus solitarius (NTS), area postrema (AP) and organum vasculosum lamina terminalis (OVLT), but central within these signaling sites is the hypothalamic PVN (Dampney 1994; Coote 2005; Kang, Ma et al. 2009). Though much is known regarding autonomic regulation, the signaling pattern between these sites is complex and still not clearly understood (Coote 2005; Guyenet 2006). In brief, baroreceptor afferents and the vagus nerve signal the NTS of the medulla oblongata during pressure changes. NTS axons project to the magnocellular neurons of the PVN (involved in neuroendocrine control of ADH and fluid balance), while projections from the AP, OVLT and SFO (CVO regions that sense blood-borne neuropeptides such as Ang II and PICs) synapse on the parvocellular neurons of the PVN and the SON (Ericsson, Liu et al. 1995; Coote 2005). These parvocellular neurons project into the VLM where the signal travels down the medial column to regulate systemic sympathetic responses (Dampney 1994). These neuronal tracts denote the central role that the PVN has in sympathetic regulation, body fluid homeostasis via water and salt modulation, and the overall control of hypertensive responses. For instance,

studies microinjecting Ang II into the PVN of rats raise mean arterial blood pressure, which is attenuated following AT<sub>1</sub>R antagonism (Zhu, Patel et al. 2002; Zhu, Gao et al. 2004). Also, chronic peripheral infusion of Ang II results in increased PIC, NFκB and ROS component expression in the PVN (Kang, Ma et al. 2009). The combination of these results points to a potential role that PICs, RAS and ROS in the PVN can play in contributing to the pathogenesis of hypertension. Better understanding these central mechanisms may also outline new pharmacological targets with which to dampen the debilitating effects of hypertension, making its study paramount.

### **STATEMENT OF THE PROBLEM AND SPECIFIC AIMS**

The role of inflammation in hypertension is evident. Increased concentrations of PICs, ROS and RAS components are predominant during the pathogenesis of hypertension. Systemically, these factors contribute to cardiovascular changes, including cardiac hypertrophy, fibrosis and contractile dysfunction. Centrally, these same factors exacerbate those systemic changes through neuronal modulation of sympathetic activity, especially within the PVN, thereby altering pressure volume homeostasis during hypertension. Current therapeutic regimes typically target components of volume regulation, peripheral adrenergic receptor activity, or of the RAS. However, these options often fall short of controlling hypertension or the CVDs associated with hypertension. Therefore, a deeper understanding of altering mechanisms of hypertension is of pressing importance.

Recent evidence highlights the role that inflammation, specifically TNF, plays in hypertension and regulating the RAS, but the understanding as to how inflammation as a whole is regulated following Ang II or TNF activation, as well as the resultant consequences, is unclear. Based upon the literature and work from our lab, we hypothesized that inflammatory regulation

at the cytosolic and transcriptional level alters the systemic hypertensive response through regulation of the transcription factor NFκB and the dysregulation of components of the RAS. We tested this hypothesis *in vivo* through several sets of experiments. First, we needed to identify how TNF infusion alone would modulate the RAS in the heart and contribute to the hypertensive response. Second, we investigated the effect of chronic inhibition of histone modifications and the resultant effects on heart inflammation and NFκB, and its effect on the hypertensive response. Next, we hypothesized that central regulation of inflammation within the PVN, through TNF and NFκB, alters local PIC, RAS and ROS responses in propagating the systemic effects of the hypertensive state. Here we conducted a series of studies in which we centrally inhibited TNF or NFκB to determine the functional role of brain or PVN inflammation in the regulation of the RAS and in the perpetuation of the hypertensive response.

In order to explore these hypotheses, we performed a series of *in vivo* experiments integrated with cardiovascular surgical, physiological and molecular techniques to elucidate our specific study aims:

**Aim 1:** Determine the role that systemic TNF infusion has on systemic cardiovascular, RAS and ROS responses in adult rat heart tissues and in blood pressure regulation.

**Aim 2:** Determine the role that histone deacetylases have on systemic cardiovascular NFκB, RAS and ROS responses in a chronically hypertensive rat model (spontaneously hypertensive rats; SHR).

**Aim 3:** Determine the role that central TNF inhibition would have on PVN PICs and RAS and ROS components in chronically Ang II-infused rats.

**Aim 4:** Determine the role that PVN specific NFκB has on regulating the RAS and ROS responses in the Ang II-induced hypertensive response.

## REFERENCES

- (2002). The World Health Report: Reducing Risks, Promoting Healthy Life. B. Campanini. Geneva, World Health Organization.
- Ahamed, M. and M. K. J. Siddiqui (2007). "Low level lead exposure and oxidative stress: Current opinions." Clinica Chimica Acta **383**(1-2): 57-64.
- Allen, A. M., J. Zhuo, et al. (2000). "Localization and function of angiotensin AT1 receptors." Am J Hypertens **13**(1 Pt 2): 31S-38S.
- Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha." Am J Physiol Cell Physiol **286**(4): C779-84.
- Atlas, S. A. (2007). "The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition." J Manag Care Pharm **13**(8 Suppl B): 9-20.
- Barnes, P. J. and M. Karin (1997). "Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases." N Engl J Med **336**(15): 1066-71.
- Bubici, C., S. Papa, et al. (2006). "Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance." Oncogene **25**(51): 6731-48.
- Cachofeiro, V., M. Goicochea, et al. "Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease." Kidney Int **74**(S111): S4-S9.
- Campese, V. M., Y. Shaohua, et al. (2005). "Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity." Hypertension **46**(3): 533-9.
- Cardinale, J. P., S. Sriramula, et al. (2010). "HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats." Hypertension **56**(3): 437-44.
- Carneado, J., M. Alvarez de Sotomayor, et al. (2002). "Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect." Journal of Hypertension **20**(3): 429-437.
- Chabrashvili, T., A. Tojo, et al. (2002). "Expression and Cellular Localization of Classic NADPH Oxidase Subunits in the Spontaneously Hypertensive Rat Kidney." Hypertension **39**(2): 269-274.
- Chan, S. H., K. S. Hsu, et al. (2005). "NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla." Circ Res **97**(8): 772-80.

- Chung, H. Y., M. Cesari, et al. (2009). "Molecular inflammation: Underpinnings of aging and age-related diseases." Ageing Research Reviews **8**(1): 18-30.
- Coote, J. H. (2005). "A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney." Exp Physiol **90**(2): 169-73.
- Corvol, P. and X. Jeunemaitre (1997). "Molecular genetics of human hypertension: role of angiotensinogen." Endocr Rev **18**(5): 662-77.
- Cowling, R. T., D. Gurantz, et al. (2002). "Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta." J Biol Chem **277**(8): 5719-24.
- Crack, P. J. and J. M. Taylor (2005). "Reactive oxygen species and the modulation of stroke." Free Radic Biol Med **38**(11): 1433-44.
- Csiszar, A., M. Wang, et al. (2008). "Inflammation and endothelial dysfunction during aging: role of NF- $\kappa$ B." J Appl Physiol **105**(4): 1333-1341.
- Dampney, R. A. (1994). "Functional organization of central pathways regulating the cardiovascular system." Physiol Rev **74**(2): 323-64.
- Davisson, R. L. (2003). "Physiological genomic analysis of the brain renin-angiotensin system." Am J Physiol Regul Integr Comp Physiol **285**(3): R498-511.
- de Wardener, H. E. (2001). "The hypothalamus and hypertension." Physiol Rev **81**(4): 1599-658.
- Donoghue, M., F. Hsieh, et al. (2000). "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9." Circ Res **87**(5): E1-9.
- Droge, W. (2002). "Free Radicals in the Physiological Control of Cell Function." Physiol. Rev. **82**(1): 47-95.
- Elks, C. M., N. Mariappan, et al. (2009). "Chronic NF- $\kappa$ B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am J Physiol Renal Physiol **296**(2): F298-305.
- Elks, C. M., N. Mariappan, et al. (2008). "Chronic NF- $\kappa$ B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am J Physiol Renal Physiol: 90628.2008.
- Ericsson, A., C. Liu, et al. (1995). "Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation." J Comp Neurol **361**(4): 681-98.



- Esler, M. and D. Kaye (2003). "Is very high sympathetic tone in heart failure a result of keeping bad company?" Hypertension **42**(5): 870-2.
- Feldman, A. M., A. Combes, et al. (2000). "The role of tumor necrosis factor in the pathophysiology of heart failure." J Am Coll Cardiol **35**(3): 537-44.
- Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease." Am J Cardiol **98**(1): 121-8.
- Flohe, L., R. Brigelius-Flohe, et al. (1997). "Redox regulation of NF-kappa B activation." Free Radic Biol Med **22**(6): 1115-26.
- Francis, J., R. M. Weiss, et al. (2001). "Progression of heart failure after myocardial infarction in the rat." Am J Physiol Regul Integr Comp Physiol **281**(5): R1734-45.
- Galle, J. (2001). "Oxidative stress in chronic renal failure." Nephrol Dial Transplant **16**(11): 2135-7.
- Ganong, W. F. (2000). "Circumventricular organs: definition and role in the regulation of endocrine and autonomic function." Clin Exp Pharmacol Physiol **27**(5-6): 422-7.
- Gearing, A. J., P. Beckett, et al. (1994). "Processing of tumour necrosis factor-alpha precursor by metalloproteinases." Nature **370**(6490): 555-7.
- Gilmore, T. D. (2006). "Introduction to NF-kappaB: players, pathways, perspectives." Oncogene **25**(51): 6680-4.
- Gloire, G., S. Legrand-Poels, et al. (2006). "NF-kappaB activation by reactive oxygen species: fifteen years later." Biochem Pharmacol **72**(11): 1493-505.
- Griendling, K. K., D. Sorescu, et al. (2000). "NAD(P)H oxidase: role in cardiovascular biology and disease." Circ Res **86**(5): 494-501.
- Guyenet, P. G. (2006). "The sympathetic control of blood pressure." Nat Rev Neurosci **7**(5): 335-46.
- Guyton, A. C. and J. E. Hall (2006). Textbook of medical physiology. Philadelphia, Elsevier Saunders.
- Hare, J. M. and J. S. Stamler (2005). "NO/redox disequilibrium in the failing heart and cardiovascular system." J Clin Invest **115**(3): 509-17.
- Harrison, D. G. and M. C. Gongora (2009). "Oxidative stress and hypertension." Med Clin North Am **93**(3): 621-35.

- Himmelfarb, J. (2004). "POOR NUTRITIONAL STATUS AND INFLAMMATION: Linking Oxidative Stress and Inflammation in Kidney Disease: Which is the Chicken and Which is the Egg?" Seminars in Dialysis **17**(6): 449-454.
- Hirooka, Y. (2008). "Role of reactive oxygen species in brainstem in neural mechanisms of hypertension." Auton Neurosci **142**(1-2): 20-4.
- Izzo, J. L., D. A. Sica, et al. (2008). Hypertension primer : [the essentials of high blood pressure : basic science, population science, and clinical management]. Philadelphia, PA, Lippincott Williams & Wilkins.
- Kalra, D., N. Sivasubramanian, et al. (2002). "Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway." Circulation **105**(18): 2198-205.
- Kang, Y. M., Y. Ma, et al. (2008). "Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB." Cardiovasc Res **79**(4): 671-8.
- Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res **82**(3): 503-12.
- Kimura, Y., Y. Hirooka, et al. (2005). "Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress." Circ Res **96**(2): 252-60.
- Kishi, T., Y. Hirooka, et al. (2003). "Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Rostral ventrolateral medulla. Stroke-prone spontaneously hypertensive rats." Hypertension **41**(2): 255-60.
- Kishi, T., Y. Hirooka, et al. (2001). "Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release." Hypertension **38**(4): 896-901.
- Lambeth, J. D. (2004). "NOX enzymes and the biology of reactive oxygen." Nat Rev Immunol **4**(3): 181-9.
- Lassegue, B. and R. E. Clempus (2003). "Vascular NAD(P)H oxidases: specific features, expression, and regulation." Am J Physiol Regul Integr Comp Physiol **285**(2): R277-97.
- Lavoie, J. L. and C. D. Sigmund (2003). "Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system." Endocrinology **144**(6): 2179-83.
- Lim, D. S., S. Lutucuta, et al. (2001). "Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy." Circulation **103**(6): 789-91.

- Lin, F., A. Moran, et al. (2005). "Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in post ischemic kidney." J Clin Invest **115**: 1756 - 1764.
- Lloyd-Jones, D., R. J. Adams, et al. (2010). "Heart disease and stroke statistics--2010 update: a report from the American Heart Association." Circulation **121**(7): e46-e215.
- MacEwan, D. J. (2002). "TNF receptor subtype signalling: differences and cellular consequences." Cell Signal **14**(6): 477-92.
- Majid, D. S. and L. Kopkan (2007). "Nitric Oxide and Superoxide Interactions in the Kidney and their Implication in the Development of Salt-Sensitive Hypertension." Clinical and Experimental Pharmacology and Physiology **34**(9): 946-952.
- Mann, D. L. (2002). "Inflammatory mediators and the failing heart: past, present, and the foreseeable future." Circ Res **91**(11): 988-98.
- Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction." Free Radic Biol Med **46**(4): 462-70.
- Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction." Free Radical Biology and Medicine **46**(4): 462-470.
- Mariappan, N., C. M. Elks, et al. (2010). "NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes." Cardiovasc Res **85**(3): 473-83.
- Mariappan, N., R. N. Soorappan, et al. (2007). "TNF- $\alpha$ -induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol." Am J Physiol Heart Circ Physiol **293**(5): H2726-2737.
- Mehta, P. K. and K. K. Griendling (2007). "Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system." Am J Physiol Cell Physiol **292**(1): C82-97.
- Murdoch, C. E., M. Zhang, et al. (2006). "NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure." Cardiovasc Res **71**(2): 208-15.
- Palm, F. (2006). "Intrarenal Oxygen in Diabetes and a Possible Link to Diabetic Nephropathy." Clinical and Experimental Pharmacology and Physiology **33**(10): 997-1001.
- Papaharalambus, C. A. and K. K. Griendling (2007). "Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury." Trends Cardiovasc Med **17**(2): 48-54.

- Paradis, P., N. Dali-Youcef, et al. (2000). "Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling." Proc Natl Acad Sci U S A **97**(2): 931-6.
- Paravicini, T. M. and R. M. Touyz (2006). "Redox signaling in hypertension." Cardiovasc Res **71**(2): 247-58.
- Paravicini, T. M. and R. M. Touyz (2008). "NADPH Oxidases, Reactive Oxygen Species, and Hypertension." Diabetes Care **31**(Supplement 2): S170-S180.
- PechÃ¡novÃ¡, O., J. Zicha, et al. (2006). "Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension." Clin. Sci. **110**(2): 235-242.
- Peterson, J. R., R. V. Sharma, et al. (2006). "Reactive oxygen species in the neuropathogenesis of hypertension." Curr Hypertens Rep **8**(3): 232-41.
- Pham, C. G., C. Bubici, et al. (2004). "Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species." Cell **119**(4): 529-42.
- Piotrkowski, B., C. G. Fraga, et al. (2007). "Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney." Am J Physiol Regul Integr Comp Physiol **292**(4): R1494-1501.
- Puddu, P., G. M. Puddu, et al. (2007). "The Putative Role of Mitochondrial Dysfunction in Hypertension." Clinical and Experimental Hypertension **29**(7): 427 - 434.
- Ramchandra, R., C. J. Barrett, et al. (2005). "Nitric oxide and sympathetic nerve activity in the control of blood pressure." Clin Exp Pharmacol Physiol **32**(5-6): 440-6.
- Ruiz-Ortega, M., O. Lorenzo, et al. (2001). "Role of the renin-angiotensin system in vascular diseases: expanding the field." Hypertension **38**(6): 1382-7.
- Ruiz-Ortega, M., M. Ruperez, et al. (2002). "Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney." Kidney Int **62**(S82): S12-S22.
- Sakon, S., X. Xue, et al. (2003). "NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death." EMBO J **22**(15): 3898-909.
- Santos, R. A., A. C. Simoes e Silva, et al. (2003). "Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas." Proc Natl Acad Sci U S A **100**(14): 8258-63.
- Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by cytokines." Hypertension **30**(1 Pt 1): 35-41.

- Sawyer, D. B., D. A. Siwik, et al. (2002). "Role of oxidative stress in myocardial hypertrophy and failure." J Mol Cell Cardiol **34**(4): 379-88.
- Seshiah, P. N., D. S. Weber, et al. (2002). "Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators." Circ Res **91**(5): 406-13.
- Shi, P., C. Diez-Freire, et al. (2010). "Brain microglial cytokines in neurogenic hypertension." Hypertension **56**(2): 297-303.
- Shi, P., M. K. Raizada, et al. (2010). "Brain cytokines as neuromodulators in cardiovascular control." Clin Exp Pharmacol Physiol **37**(2): e52-7.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-51.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of Tumor Necrosis Factor- $\alpha$  in Angiotensin II-Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy." Hypertension **51**(5): 1345-1351.
- Tai, M. H., L. L. Wang, et al. (2005). "Increased superoxide anion in rostral ventrolateral medulla contributes to hypertension in spontaneously hypertensive rats via interactions with nitric oxide." Free Radic Biol Med **38**(4): 450-62.
- Tian, N., R. S. Moore, et al. (2007). "Interactions between oxidative stress and inflammation in salt-sensitive hypertension." Am J Physiol Heart Circ Physiol **293**(6): H3388-3395.
- Tipnis, S. R., N. M. Hooper, et al. (2000). "A Human Homolog of Angiotensin-converting Enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase." Journal of Biological Chemistry **275**(43): 33238-33243.
- Touyz, R. M. (2000). "Oxidative stress and vascular damage in hypertension." Curr Hypertens Rep **2**(1): 98-105.
- Van Gaal, L. F., I. L. Mertens, et al. (2006). "Mechanisms linking obesity with cardiovascular disease." Nature **444**(7121): 875-880.
- Vanegas, V., A. Ferrebuz, et al. (2005). "Hypertension in Page (cellophane-wrapped) kidney is due to interstitial nephritis." Kidney Int **68**(3): 1161-1170.
- Vaziri, N. D. (2008). "Causal Link Between Oxidative Stress, Inflammation, and Hypertension." Iranian Journal of Kidney Diseases **2**(1): 1-10.
- Vaziri, N. D., X. Q. Wang, et al. (2000). "Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats." Hypertension **36**(1): 142-146.

- Veerasingham, S. J. and M. K. Raizada (2003). "Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives." Br J Pharmacol **139**(2): 191-202.
- Vickers, C., P. Hales, et al. (2002). "Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase." J Biol Chem **277**(17): 14838-43.
- Wang, Y., A. F. Chen, et al. (2006). "Enhanced oxidative stress in kidneys of salt-sensitive hypertension: role of sensory nerves." Am J Physiol Heart Circ Physiol **291**(6): H3136-3143.
- Wei, Y.-H. and H.-C. Lee (2002). "Oxidative Stress, Mitochondrial DNA Mutation, and Impairment of Antioxidant Enzymes in Aging." Exp. Biol. Med. **227**(9): 671-682.
- Wilcox, C. (2002). "Reactive oxygen species: Roles in blood pressure and kidney function." Current Hypertension Reports **4**(2): 160-166.
- Xu, P., S. Sriramula, et al. (2011). "ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good." Am J Physiol Regul Integr Comp Physiol **300**(4): R804-17.
- Yu, B. P. (1994). "Cellular defenses against damage from reactive oxygen species." Physiol. Rev. **74**(1): 139-162.
- Zanzinger, J. (2002). "Mechanisms of action of nitric oxide in the brain stem: role of oxidative stress." Auton Neurosci **98**(1-2): 24-7.
- Zhu, G. Q., L. Gao, et al. (2004). "ANG II in the paraventricular nucleus potentiates the cardiac sympathetic afferent reflex in rats with heart failure." J Appl Physiol **97**(5): 1746-54.
- Zhu, G. Q., K. P. Patel, et al. (2002). "Microinjection of ANG II into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats." Am J Physiol Heart Circ Physiol **282**(6): H2039-45.
- Zucker, I. H. and J. L. Liu (2000). "Angiotensin II--nitric oxide interactions in the control of sympathetic outflow in heart failure." Heart Fail Rev **5**(1): 27-43.

## **CHAPTER 2**

### **TUMOR NECROSIS FACTOR – INDUCED OXIDATIVE STRESS REGULATES COMPONENTS OF THE RENIN-ANGIOTENSIN SYSTEM**

## INTRODUCTION

Cardiovascular diseases are commonly associated with increased expression of pro-inflammatory cytokines (PICs), including hypertension (Phillips and Kagiya 2002; Ferrario and Strawn 2006). The renin-angiotensin system (RAS), the primary controlling mechanism in blood pressure regulation, also plays a major role in modulating the hypertensive response. Furthermore, studies from our lab and others have shown that in hypertension, PICs can lead to an increase in reactive oxygen species (ROS) and further increases in PIC, ROS and RAS transcription (Sriramula, Haque et al. 2008; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). Along with RAS components, PICs also activate hypertrophic mediators, which can result in cardiac hypertrophy and altered cardiac remodeling and function, potentially via a ROS-mediated mechanism (Tokuda, Kai et al. 2004; Kudo, Kai et al. 2009). Angiotensin II (Ang II), the effector peptide of the RAS, has been shown to incite the synthesis and release of PICs such as tumor necrosis factor- $\alpha$  (TNF), Interleukin (IL)-6 and chemokines (Funakoshi, Ichiki et al. 1999; Kalra, Sivasubramanian et al. 2002; Ruiz-Ortega, Ruperez et al. 2002), and both Ang II and PICs can increase ROS, which individually and combined can contribute to cardiac maladaptations, dysfunction and blood pressure response.

The actions of Ang II are typically understood through its classical pathway of angiotensin converting enzyme (ACE) and Ang II-Type 1 receptors (AT<sub>1</sub>Rs), the pro-hypertensive/vasoconstrictive and deleterious ACE/Ang II/AT<sub>1</sub>R pathway. However, a recent alternative axis of the RAS has been discovered that counteracts the actions of the pro-hypertensive RAS arm. This protective, anti-hypertensive/vasodilatory axis consists of ACE2, Ang (1-7) and the Mas receptor, amongst others (Donoghue, Hsieh et al. 2000; Tipnis, Hooper et al. 2000; Xu, Sriramula et al. 2011). Data suggests that the ACE2/Ang (1-7)/Mas arm may be



downregulated by an increase in Ang II (Xu, Sriramula et al. 2011), but the manner in which this dysregulation occurs, if through TNF, is unknown.

The PIC most central to the Ang II-driven hypertensive inflammatory responses is TNF, a multifarious cytokine that plays an important and diverse role in physiological and pathophysiological responses, including, but not limited to, inflammation, cell survival, growth, differentiation and apoptosis (Mann 2002). It is well established that there is an existent cross-talk in hypertension between the RAS, especially Ang II, and TNF (Brasier, Li et al. 1996; Sasamura, Nakazato et al. 1997; Kalra, Sivasubramanian et al. 2002; Arenas, Xu et al. 2004). We have recently demonstrated, along with others, the integral manner that Ang II-induced TNF functions to modulate blood pressure response and cardiac hypertrophy in Ang II-induced hypertension, but if and how TNF alone can modulate these RAS arms is uncertain (Muller, Shagdarsuren et al. 2002; Elmarakby, Quigley et al. 2006; Sriramula, Haque et al. 2008).

Early studies showed that the major source of vascular ROS is primarily NADPH oxidase derived superoxide (Griendling, Minieri et al. 1994; Mohazzab, Kaminski et al. 1994), which can be regulated by multiple mediators, including cytokines (Paravicini and Touyz 2008; Harrison and Gongora 2009). Moreover, an increased expression of NADPH oxidase was noted in cardiac tissue in Ang II-induced hypertensive animal models (Li, Gall et al. 2002; Paravicini and Touyz 2008). The NADPH oxidase subunit gp91*phox* (Nox2) is central to Ang II-induced cardiac hypertrophy (Bendall, Cave et al. 2002; Li, Gall et al. 2002). In Ang II-infused animal models and SHR rats, NADPH activity is increased and ROS generation is enhanced and these processes are mediated through AT<sub>1</sub>Rs and are associated with the overexpression of vascular and cardiac NADPH oxidase subunits (Cifuentes, Rey et al. 2000; Heymes, Bendall et al. 2003; Kakishita, Nakamura et al. 2003). These studies support a role for NADPH oxidase-derived superoxide and

increased oxidative stress in the pathogenesis of Ang II-induced hypertension. Within the heart, ROS signaling elicits numerous responses, including cardiac hypertrophy and fibrosis, which can be triggered by TNF and can be inhibited through the use of anti-oxidants (Seddon, Looi et al. 2007; Paravicini and Touyz 2008). Furthermore, sub-pressor doses of Ang II can also induce cardiac hypertrophy and interstitial fibrosis in mice, which can also be blunted in hearts lacking *gp91phox* (Bendall, Cave et al. 2002). Interstitial cardiac fibrosis and remodeling was also inhibited in Nox2 knockout mice subjected to aortic banding, Ang II or aldosterone infusion, or in animals treated with apocynin or diphenylene iodonium (NADPH oxidase inhibitors) (Bendall, Cave et al. 2002; Park, Park et al. 2004; Touyz, Mercure et al. 2005; Grieve, Byrne et al. 2006; Johar, Cave et al. 2006; Paravicini and Touyz 2008).

The signaling pattern from Ang II to TNF is evident, but how TNF alone can act, if at all, on components of the RAS and on blood pressure response is uncertain. With these considerations, we hypothesized that daily TNF injections would contribute to cardiac tissue RAS modulation and blood pressure response, possibly through a ROS mechanism. In order to conduct this study, we injected TNF for 5 consecutive days, during which time we recorded blood pressure via radio-telemetry probes and conducted echocardiographic assessment of cardiac function. At the conclusion of the study, left ventricle (LV) tissue was collected for assessment of RAS and ROS component expression. For determination of the role of ROS as a signaling mediator between TNF and RAS component expression, along with TNF treatment, we simultaneously administered either Tempol, a superoxide dismutase (SOD) mimetic, or etanercept, a soluble TNF receptor mimetic. While neither TNF nor the treatments had any effect on blood pressure regulation, alterations were observed in cardiac function and RAS component expression, ultimately demonstrating that the TNF can increase cardiac dysfunction (via its

function as a negative inotrope) and pro-hypertensive/vasoconstrictive RAS components, and decrease anti-hypertensive RAS component expression, which was reversed following Tempol or etanercept treatment. This study also demonstrates that ROS are a signaling mediator between TNF and the RAS and cardiac changes. More importantly, it shows that TNF can differentially regulate the damaging and protective arms of the RAS, potentially via a ROS mechanism, which may be a tipping point in the hypertensive response.

## **MATERIALS AND METHODS**

**Animals.** Adult male Sprague-Dawley rats (250-350 grams) were used in this study. Animals were housed in a temperature-controlled room ( $25 \pm 1^\circ\text{C}$ ) and maintained on a 12:12 hour light:dark cycle with free access to water and food. All animal and experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Louisiana State University in compliance with NIH guidelines.

**Experimental Protocol.** The rats were implanted with radio-telemetry transmitters to measure blood pressure, and injected daily with TNF (40 $\mu\text{g}/\text{kg}$ , i.p.) dissolved in saline or saline alone for 5 consecutive days. This TNF dose was based on unpublished dose-response studies as well as previous publications from our laboratory and others (Michie, Sherman et al. 1989; Bozkurt, Kribbs et al. 1998; Mariappan, Soorappan et al. 2007; Mariappan, Elks et al. 2009).

Simultaneously, a subset of TNF and saline-treated rats received either Tempol (Temp; 300 $\mu\text{mol}/\text{kg}$ , p.o.), a SOD mimetic, or Etanercept (ETN; 1mg/kg/day, s.c.), a soluble TNF receptor mimetic. Saline-treated rats receiving Temp or ETN were unchanged from saline-treated controls and as such were combined together for the final analysis. The study consisted of four experimental groups: 1) Controls (saline alone, saline+Tempol and saline+etanercept); 2) TNF; 3) TNF+Temp; and 4) TNF+ETN. Echocardiographic assessment was carried out at baseline and

at the conclusion of the study. After five days, the rats were euthanized and the hearts were removed for further analysis.

**Blood Pressure Measurement.** Blood pressure was measured continuously in conscious rats implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International, St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral surface of the left leg, the femoral artery and vein were exposed and bluntly dissected apart. The femoral artery was ligated distally, and another was used to temporarily interrupt the blood flow. The catheter tip was introduced through a small hole in the femoral artery, advanced ~6 cm into the abdominal aorta such that the tip was distal to the origin of the renal arteries, and secured into place. The probe body was placed into the abdominal cavity and secured to the abdominal wall. The abdominal musculature was sutured and the skin layer closed following implantation. Rats received benzathine penicillin (30000 U, i.m.) and buprenorphine (0.1 mg/kg, s.c.) immediately following surgery and 12hr postoperatively and allowed to recover for seven days.

**Echocardiographic Assessment of LV Hypertrophy.** Echocardiography was obtained at baseline, and repeated at the end of the treatment period. Echocardiogram was performed as described previously (Mariappan, Elks et al. 2009). Briefly, transthoracic echocardiography was performed under isoflurane anesthesia, using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin, California) fitted with a PST 65A sector scanner (8 MHz probe) which generates two-dimensional images at a frame rate ranging from 300-500 frames per second. Left ventricle wall and chamber parameters, fractional shortening (%FS) and Tei index were measured and calculated to assess cardiac hypertrophy and cardiac function.

**Detection of Total ROS and Superoxide ( $O_2^{\cdot-}$ ) in LV Heart Tissue.** One of the most sensitive and definitive methods of superoxide production is electron spin resonance (EPR). In this study, we utilized an established technique for total ROS detection in tissue using EPR and spin traps (Mariappan, Elks et al. 2009). Different spin probes were used for the EPR studies. 1-hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) was used to measure the  $O_2^{\cdot-}$  levels. All ESR measurements were performed using an EMX EPR eScan BenchTop spectrometer and super-high quality factor (Q) microwave cavity (Bruker Company, Germany). **Sample Preparation for EPR Studies:** The dissected LV tissue from each animal was placed into a 24-well plate containing Krebs's HEPES buffer (KHB) (20mM, pH 7.4). Tissue pieces were then washed twice with the same buffer to remove any trace contamination. Samples were then incubated at 37°C with specific spin probes for 30 minutes. **Total tissue ROS production:** Total ROS was determined as previously described (Mariappan, Elks et al. 2009). Tissue pieces were incubated at 37°C with CMH (200  $\mu$ M) for 30 minutes. Aliquots of the incubated probe media were then taken in 50  $\mu$ l glass capillary tubes (Noxygen Science Transfer and Diagnostics, Elzach, Germany) for determination of total ROS production, under the following EPR settings: field sweep 50 G; microwave frequency 9.78 GHz; microwave power 20 mW; modulation amplitude 2 G; conversion time 327 ms; time constant 655 ms; receiver gain  $1 \times 10^5$ . For superoxide production, samples were pre-incubated at 37°C with PEG-SOD (50 U/ml) for 30 minutes, then CMH (200 $\mu$ M) for an additional 30 minutes. Aliquots of the incubated probe media were taken in 50  $\mu$ l glass capillary tubes for determination of total superoxide production. Addition of PEG-SOD to CMH allowed competitive inhibition of the  $O_2^{\cdot-}$ -CMH oxidation reaction by the quenching of  $O_2^{\cdot-}$  radicals. Since it is cell permeable, PEG-SOD can competitively inhibit the CMH- $O_2^{\cdot-}$  interaction both intra-cellularly and extra-cellularly, thus

allowing accurate measurement of total tissue  $O_2^{\cdot-}$  production. To determine actual total tissue superoxide production, the values obtained from incubation with PEG-SOD and CMH were subtracted from the values obtained from incubation with CMH only.

**RNA Isolation and Real-Time RT-PCR.** Total RNA was extracted from the LV using TRI reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA expression levels of *gp91phox*, angiotensinogen, renin, angiotensin converting enzyme (ACE), ACE2, AT<sub>1</sub>R and the Mas receptor were determined using previously published specific custom made primers (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008; Agarwal, Haque et al. 2009; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). GAPDH was used as the housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384 well PCR plates using Bio-Rad PCR Master Mix (The iTaq SYBR™ Green Supermix with ROX) and the ABI Prism 7900 sequence detection system (Applied Biosystems). The PCR cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C). A dissociation step (15 s at 95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the melting temperature of the specific PCR product.

**Western Blot.** Protein was extracted from LV samples in ice-cold buffer (10mM Tris-HCl, pH 7.4, 1mM EDTA, 1% Nonidet P-40, 0.1% sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail (Roche). The protein content in the supernatant was determined using a detergent-compatible protein assay (Bio-Rad). Protein samples (25µg) were resolved in 10% SDS-polyacrylamide gel. The protein expression of *gp91phox* and AT<sub>1</sub>R in the heart was analyzed by western blot as previously described (Sriramula, Haque et al. 2008) with the use of anti-*gp91phox*, anti-AT<sub>1</sub>R (Abcam) and the Mas receptor (Santa Cruz) antibody (1:200 dilution).

Bands were normalized to  $\alpha$ -Actinin or GAPDH (Santa Cruz). Bands were analyzed for graphical and statistical densitometric representation using ImageJ.


**Measurement of Plasma TNF.** At the end of the study, blood was collected in chilled EDTA tubes, plasma was separated and stored at  $-80^{\circ}\text{C}$  until assayed. Circulating levels of TNF were quantified in the plasma using a commercially available rat TNF ELISA kit (Biosource, Camarillo, CA) according to manufacturer's instructions.

**Measurement of Plasma Catecholamines.** At the end of the study, blood was collected in chilled EDTA tubes, plasma was separated and stored at  $-80^{\circ}\text{C}$  until assayed. Circulating levels of norepinephrine (NE) and epinephrine (EPI) were measured using high performance liquid chromatography (HPLC). Plasma samples were prepared by adding activated alumina, Tris buffer, EDTA and internal standard DHBA, along with 0.5 ml of rat plasma. The samples were centrifuged and the supernatant was separated and rinsed 2x in ultra pure water and filtered through a Millipore filter (Ultrafree MC UFC30GV00, Millipore Corp.). Prepared samples were then filtered and injected into an Eicom HTEC-500 system fitted with an HPLC-ECD, as previously described (Guggilam, Haque et al. 2007).

**Localization of Ang II by Immunofluorescence.** Heart tissues were prepared as previously described (Guggilam, Haque et al. 2007). The sections were treated with primary antibody against Ang II (1:500 dilution, anti-goat) (Santa Cruz). Negative control sections were incubated with secondary antibody alone.

**Statistical Analysis of Data.** All results are expressed as mean $\pm$ SEM. For statistical analysis of the data, student's *t* test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni's *post hoc* test was performed using GraphPad Prism version 5.0 for Windows

(GraphPad Software, San Diego California, USA) to determine differences among groups. A value of  $p < 0.05$  was considered statistically significant.



## RESULTS

**Daily TNF Injections have no Effect on Blood Pressure but alters Cardiac Function in Treated Rats.** The effect of daily TNF injections was examined at the conclusion of the 5-day



study period to determine TNF plasma concentrations (Figure 2.1A). Using a TNF ELISA kit, plasma concentrations were, as expected, much higher in TNF-treated as compared to controls ( $7.61 \pm 0.53$  v  $0.65 \pm 0.22$  pg/ml, respectively;  $p < 0.05$ ). These circulating levels of TNF were reduced following Tempol ( $2.58 \pm 0.36$  pg/ml;  $p < 0.05$ ) or etanercept ( $4.3 \pm 0.48$  pg/ml;  $p < 0.05$ ) co-administration with TNF. This demonstrates that the TNF injections induced increases in endogenous TNF. The endogenously produced TNF was also reduced following ROS/superoxide reduction, thereby linking the TNF-induced TNF signal propagation to ROS intermediaries.

**Table 2.1. Effects of TNF on cardiac function as assessed by echocardiography.**

<b>Table 2.1</b>	<b>Control</b>	<b>TNF</b>	<b>TNF+Temp</b>	<b>TNF+ETN</b>
n	9	10	10	10
IVSTd (mm)	$1.36 \pm 0.02$	$1.59 \pm 0.05^{\#}$	$1.37 \pm 0.05^*$	$1.41 \pm 0.03^*$
IVSTs (mm)	$2.26 \pm 0.03$	$2.48 \pm 0.12$	$2.50 \pm 0.06$	$2.25 \pm 0.03$
LVIDd (mm)	$6.57 \pm 0.08$	$7.10 \pm 0.21$	$7.31 \pm 0.13$	$7.28 \pm 0.13$
LVIDs (mm)	$5.27 \pm 0.10$	$5.69 \pm 0.18^{\#}$	$5.06 \pm 0.13^*$	$4.78 \pm 0.15^*$
LVPWTd (mm)	$1.37 \pm 0.11$	$1.57 \pm 0.07$	$1.38 \pm 0.03$	$1.38 \pm 0.03$
LVPWTs (mm)	$2.25 \pm 0.13$	$2.15 \pm 0.06$	$2.25 \pm 0.16$	$2.15 \pm 0.11$
%FS	$55.2 \pm 1.92$	$39.7 \pm 0.95^{\#}$	$50.2 \pm 1.12^*$	$43.8 \pm 0.77$
Tei	$0.29 \pm 0.03$	$0.38 \pm 0.11^{\#}$	$0.30 \pm 0.02^*$	$0.32 \pm 0.01$
HR	$327 \pm 7.46$	$366 \pm 10.1^{\#}$	$329 \pm 3.78^*$	$337 \pm 4.68^*$


IVSTd/s, interventricular septal thickness at end-diastole and end-systole, respectively; LVIDd/s, left ventricular internal diameter at end-diastole and end-systole, respectively; LVPWTd/s, left ventricular posterior wall thickness at end-diastole and end-systole, respectively; %FS, fractional shortening; HR, heart rate; n=9-10 in each group,  $\#p < 0.05$  vs Control,  $*p < 0.05$  vs TNF.

To assess the effect of 5-day TNF injections on mean arterial pressure (MAP), blood pressure was measured using a radio-telemetry system. There was no change in MAP from baseline over the 5-day TNF injection period (Figure 2.1B). Moreover, TNF+Temp and TNF+ETN had no effect on MAP versus the saline-treated controls, with all rat groups maintaining a MAP between 105-112 mmHg during the course of the study. Interestingly,


though there were no appreciable differences in the MAP, the heart weight/body weight (HW/BW) ratio was increased in TNF-treated rats versus controls ( $3.2\pm 0.07$  v  $2.9\pm 0.05$  g/kg, respectively;  $p<0.05$ ), which was reversed following Tempol ( $2.85\pm 0.05$  g/kg;  $p<0.05$ ) and Etanercept ( $2.94\pm 0.04$  g/kg;  $p<0.05$ ) treatments (Figure 2.1C). Furthermore, interventricular septal thickness at end-diastole (IVSTd) was significantly increased, while IVST in end-systole (IVSTs) followed a similar trend (Table 2.1), confirming the HW/BW data and indicating TNF-induced cardiac hypertrophy. Also noted was that TNF treatments, possibly via its function as a negative inotrope, reduced %FS and raised HR and the Tei index, signaling cardiac dysfunction.

**TNF Increases Total ROS and gp91phox in the LV of TNF-Treated Rats.** As TNF is often

associated with increases in ROS, both total ROS and superoxide as assessed by EPR (Figure 2.2) and the expression of gp91phox (Figure 2.3) were examined in the LV. TNF-treated rats experienced a significant increase in total ROS and superoxide when compared to saline-infused control rats (total ROS:  $0.35\pm 0.006$  v  $0.11\pm 0.006$  mM/mg protein/min, respectively;  $p<0.05$ ; and superoxide:  $0.122\pm 0.007$  v  $0.021\pm 0.006$  mM/mg protein/min, respectively;  $p<0.05$ ). TNF+Temp and TNF+ETN normalized these ROS




increases (total ROS reduced to:  $0.19 \pm 0.003$  and  $0.16 \pm 0.015$  mM/mg protein/min, respectively;  $p < 0.05$ ; and superoxide reduced to:  $0.024 \pm 0.005$  and  $0.035 \pm 0.005$  mM/mg protein/min, respectively;  $p < 0.05$ ). Furthermore, the mRNA expression of *gp91phox*, the major catalytic subunit of NADPH oxidase and a major ROS contributor, was increased in TNF-treated rats versus the controls (Figure 2.3A). This was reduced in TNF+Temp and TNF+ETN rats. The reduction in protein expression was further confirmed by western blot of the LV tissue (Figure 2.3B). These results indicate that treatment with Tempol and Etanercept had beneficial effects in reducing TNF-induced oxidative stress in the LV heart tissue in TNF-infused rats.




**Components of the RAS Are Altered in the LV Following TNF Injections.** In an attempt to understand the link between the RAS and inflammation, several components of the RAS were

measured. The mRNA expression of the pro-hypertensive/vasoconstrictive RAS components angiotensinogen, renin, ACE and AT<sub>1</sub>R (Figure 2.4) are increased following 5 days of TNF treatment when compared to controls, while the anti-hypertensive/vasodilatory components ACE2 and the Mas receptor were decreased (Figure 2.6A). These trends



were reversed following treatment with Tempol or etanercept. Moreover, the protein levels of AT<sub>1</sub>R and the Mas receptor as measured via western blot followed similar patterns to their respective mRNA expressions, (Figure 2.5A, 2.6B). The levels of Ang II were further assessed within the LV tissues using immunofluorescence. Ang II was similarly increased in TNF-treated rats, but decreased in TNF+Tempol and TNF+ETN rats (Figure 2.5B). This indicates that TNF differentially alters injurious and protective RAS component expression within cardiac tissue, which can be reversed following TNF or superoxide inhibition.

**Circulating Catecholamines Increase in TNF-Infused Rats.** To assess the effect of daily TNF injections on catecholamine release, circulating plasma NE and EPI were determined by HPLC (Figure 2.7). TNF injections increased NE and EPI versus the control rats ( $1341 \pm 53.9$  v  $704.1 \pm 85.3$  pg/ml and  $459 \pm 40.7$  v  $185.7 \pm 12.4$  pg/ml, respectively;  $p < 0.05$ ). These elevated levels were decreased in TNF+Temp and TNF+ETN groups, signifying that TNF plays a role, possibly through a RAS and ROS-mediated mechanisms, in elevating circulating catecholamines and contributing to increased sympathetic activity, cardiac dysfunction and remodeling.




**Figure 2.5. Effects of TNF on AT<sub>1</sub>R protein expression and Ang II in left ventricular tissues.** Western blot and densitometric analysis reveals that similar to the mRNA expression of AT<sub>1</sub>R, TNF increases its abundance when compared to controls (A). Likewise, Tempol or etanercept attenuated these changes. Immunofluorescence (Original magnification x20) staining of Ang II in cardiac tissue sections shows an increase in Ang II in the TNF-treated rats (B). Co-administration with Tempol or etanercept eliminated this increase in Ang II within the heart. n=6-8 in each group for AT<sub>1</sub>R protein, n=3-4 for immunofluorescence images, <sup>#</sup> $p < 0.05$  vs Control, <sup>\*</sup> $p < 0.05$  vs TNF.

## DISCUSSION


The major findings in this study are as follows: 1) TNF injections for 5 days had no effect on mean arterial blood pressure, but TNF did increase cardiac hypertrophy and negatively altered cardiac function as seen with a reduction in fractional shortening and an increase in the Tei index; 2) TNF injections increased total ROS and superoxide in the LV of treated rats; 3) TNF-

infused rats showed an elevation in pro-hypertensive/vasoconstrictive RAS component expression and a decrease in anti-hypertensive/vasodilatory RAS component expression, as well as an increase in the circulating catecholamines NE and EPI; and 4) TNF-infused rats treated with Tempol or Etanercept prevented these changes observed following TNF injection alone. These findings suggest that TNF can act on the opposing components of the RAS within the LV, possibly through a ROS-driven



mechanism, and negatively affect cardiac function and cardiac mass while not effecting pressure responses in treated rats.

Hypertension is increasingly accepted as involving an inflammatory component (Ferrario and Strawn 2006; Sriramula, Haque et al. 2008; Cardinale, Sriramula et al. 2010). Furthermore, the RAS plays a key role in the development and maintenance of hypertension (Brunner 2001;



Ruiz-Ortega, Lorenzo et al. 2001), and

Ang II, the effector peptide of the RAS,

has been shown to stimulate the

production and release of PICs such as

TNF, IL-6 and chemokines (Funakoshi,

Ichiki et al. 1999; Kalra,

Sivasubramanian et al. 2002; Ruiz-

Ortega, Ruperez et al. 2002).

Components of the ACE2/Ang (1-

7)/Mas RAS axis are also downregulated

during hypertensive disease progression

(Xu, Sriramula et al. 2011). Recently,

work from our lab demonstrated the involvement of Ang II-induced TNF in the Ang II-mediated

effects on the hypertensive response (Sriramula, Haque et al. 2008). Changes observed included

an increase in salt appetite and water retention, therefore unbalancing systemic volume

homeostasis, as well as increased cardiac hypertrophy and the overall perpetuation of the

hypertensive state. Others have also observed the existence of a potential cross-talk between the

RAS and TNF. *In vitro* studies showed the production of TNF following cardiomyocyte and

fibroblast cell culture treatments with Ang II, and that neonatal rat cardiac fibroblast culture treatments with TNF caused an increase in AT<sub>1</sub>R expression (Gurantz, Cowling et al. 1999; Yokoyama, Sekiguchi et al. 1999; Kalra, Sivasubramanian et al. 2002). *In vivo* studies have also linked PICs and the RAS, including demonstrating that chronic AT<sub>1</sub>R inhibition in hypertensive and heart failure patients decreased circulating TNF and that TNF blockade prevented renal damage and lowered blood pressure in a genetic model of hypertensive rats (Cottone, Vadala et al. 1998; Tsutamoto, Wada et al. 2000; Muller, Shagdarsuren et al. 2002; Elmarakby, Quigley et al. 2006). Combined, these changes suggest an intimate connection between the RAS and PICs, especially TNF, in the hypertensive response, in that Ang II activates TNF, which is speculated to further increase pro-hypertensive RAS expression. In this study, we looked at the possible reverse signaling pattern of the afore mentioned mechanism. Though not altering blood pressure, we show that five days of continuous TNF injections can differentially regulating RAS components such as Ang II, ACE2, AT<sub>1</sub> and the Mas receptors by decreasing the vasodilatory components and increasing the vasoconstrictive components of the RAS. In time, these RAS component dysregulations, especially the increase in Ang II, could lead to arterial pressure increases, but the current study was not carried out to that point.

The role of ROS in the pathogenesis of hypertension is well established in many experimental hypertensive models (Harrison and Gongora 2009). Activation of NADPH oxidase is regulated by many vasoactive hormones, cytokines, growth factors (platelet-derived growth factor, transforming growth factors, etc.) and mechanical stimuli such as shear stress and stretch (Paravicini and Touyz 2008; Harrison and Gongora 2009). Compared to their normotensive controls, SHR and DOCA salt-sensitive rats show an increase in the production of superoxide in cardiac, renal and vascular tissues, primarily through NADPH oxidase activity (Zalba, Beaumont



et al. 2000; Zhang, Griendling et al. 2005). As seen in the current study, increased ROS production, with an increased expression of NADPH oxidase, was noted in cardiac tissue in both a pressure overload model of cardiac hypertrophy and in Ang II hypertensive animal models (Li, Gall et al. 2002; Paravicini and Touyz 2008). The role of the gp91*phox* subunit (Nox2) of NADPH oxidase in Ang II-induced cardiac hypertrophy is pivotal. Studies conducted on mice lacking gp91*phox* showed that myocardial NADPH oxidase and superoxide levels were not as elevated in these animals as compared to their wild-type controls (Bendall, Cave et al. 2002), supporting the fact that NADPH oxidase is the major source of ROS in cardiomyocytes in hypertrophy due to a chronically increased blood pressure, which can progress to heart failure (Li, Gall et al. 2002). In Ang II-infused animal models and SHR rats, NADPH activity is increased and ROS generation is enhanced; these processes are mediated through AT<sub>1</sub>Rs and associated with overexpression of vascular and cardiac NADPH oxidase subunits (Cifuentes, Rey et al. 2000; Heymes, Bendall et al. 2003; Kakishita, Nakamura et al. 2003). An *in vitro* study using cardiomyocyte cell cultures, Ang II stimulation increases both mRNA and protein expression of gp91*phox* (Griendling, Sorescu et al. 2000). These studies, combined with the current data depicting an elevation in gp91*phox* expression and total ROS and superoxide, supports a role for NADPH oxidase-derived ROS and increased oxidative stress in the pathogenesis of Ang II-induced hypertension through a TNF-driven mechanism, but the role of ROS on the protective ACE2/Ang (1-7)/Mas RAS axis is vague.

Within the heart, ROS signaling elicits numerous responses, including cardiac hypertrophy (Seddon, Looi et al. 2007; Paravicini and Touyz 2008), though its effects by and through the separate arms of the RAS are only now coming under scrutiny. Oxidative stress is also a well known profibrotic mediator in many tissue systems, including the heart. Moreover,

excessive interstitial fibrosis is an injurious aspect of cardiac hypertrophy. These changes, in turn, cause the slow progression of cardiac maladaptive remodeling and dysfunction, as observed here following TNF injection and a subsequent decrease in fractional shortening and an increase in the Tei index. In cardiomyocyte cultures, Ang II, endothelin 1, NE, TNF and mechanical stretch can all induce cellular hypertrophy, including an increase in ROS production (Cave, Grieve et al. 2005), which can be inhibited through the use of antioxidants. Ang II-treated primary rat cardiomyocytes also demonstrated increased Rac1 (a small signaling G protein) activation, superoxide production, and cell hypertrophy. These changes were blocked by adenoviral introduction of dominant negative Rac1, CuZn-SOD and by small interfering RNA (siRNA) directed to the gp91*phox* subunit of NADPH oxidase, suggesting that Ang II-activation of gp91*phox* contributes to cardiac hypertrophy (Hingtgen, Tian et al. 2006). However, subpressor doses of Ang II also induce cardiac hypertrophy and interstitial fibrosis in mice, which can also be blunted in hearts lacking gp91*phox* (Bendall, Cave et al. 2002). Interstitial cardiac fibrosis and remodeling was also inhibited in Nox2 knockout mice subjected to aortic banding, Ang II or aldosterone infusion, or in animals treated with apocynin or diphenylene iodonium (NADPH oxidase inhibitors) (Bendall, Cave et al. 2002; Park, Park et al. 2004; Touyz, Mercure et al. 2005; Grieve, Byrne et al. 2006; Johar, Cave et al. 2006; Paravicini and Touyz 2008). Similarly, TNF alone caused cardiac alterations such as cardiac hypertrophy, decreased fractional shortening and an increased Tei index, but following treatment with Tempol and etanercept, these changes were reversed. Furthermore, NE and EPI, molecules that can participate in altered cardiac function and remodeling (Badenhorst, Veliotis et al. 2003; Cave, Grieve et al. 2005), as well as in the generalized sympathetic drive associated with hypertension, was increased in TNF-infused rats, but decreased following Tempol or etanercept treatment. This

data reinforces the role that ROS plays in the TNF-induced signaling pattern for increased cardiac dysfunction and maladaptive alterations, possibly through the dysregulation of RAS component expression.

It is well understood that the RAS and Ang II can increase the production of PICs and contribute to the hypertensive state, and that blocking the PIC TNF can prevent some of the deleterious changes associated with hypertension and the ACE/Ang II/AT<sub>1</sub>R RAS axis (Funakoshi, Ichiki et al. 1999; Kalra, Sivasubramanian et al. 2002; Muller, Shagdarsuren et al. 2002; Ruiz-Ortega, Ruperez et al. 2002; Elmarakby, Quigley et al. 2006). The suggested mechanism potentially involves a positive feed-forward system whereby Ang II increases TNF and ROS, which in turn further increases injurious ACE/Ang II/AT<sub>1</sub>R RAS axis components, and decreases protective ACE2/Ang (1-7)/Mas RAS components. Therefore, we aimed to determine if administration of TNF alone could regulate components of the RAS and if so, was this mechanism achieved through modulation of ROS. As detailed above, TNF injection increased components of the deleterious axis of the RAS including angiotensinogen, ACE, Ang II and the AT<sub>1</sub>R. TNF injection also increased *gp91phox*, total ROS and superoxide, and decreased the protective RAS components ACE2 and the Mas receptor. These changes were reversed following administration of the TNF receptor mimetic etanercept, indicating that the TNF-driven pathway required the additional production of endogenous TNF, and the use of the SOD mimetic Tempol demonstrates that the TNF-induced TNF-driven pathway also requires ROS, especially superoxide, to contribute to the dysregulation of the individual RAS arms and the propagation of mediators that can contribute to the hypertensive state. In conjunction with the understanding that Ang II can cause an increase in TNF and the studies detailing that use of PIC and ROS inhibitors can reduce the hypertensive response, we demonstrate here that the ROS

involved appears to evolve through a TNF mechanism, therefore highlighting the Ang II/TNF/ROS pathway rather than an Ang II/ROS/TNF pathway, and that this in turn reduces the protective RAS axis (ACE2/Ang (1-7)/Mas) while upregulating the more injurious aspects of the pro-hypertensive/vasorestrictive RAS arm (ACE/Ang II/AT<sub>1</sub>R). This study underscores the role that TNF plays in the ROS-induced dysregulation of the RAS and the ROS driven mechanism behind TNF-induced cardiac dysfunction, spotlighting the role that PICs, such as TNF, may play in the differential RAS regulation in the pathogenesis of the hypertensive response.

## REFERENCES

- Agarwal, D., M. Haque, et al. (2009). "Role of Proinflammatory Cytokines and Redox Homeostasis in Exercise-Induced Delayed Progression of Hypertension in Spontaneously Hypertensive Rats." Hypertension **54**: 1393-400.
- Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha." Am J Physiol Cell Physiol **286**(4): C779-84.
- Badenhorst, D., D. Veliotis, et al. (2003). "Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy." Hypertension **41**(3): 499-504.
- Bendall, J. K., A. C. Cave, et al. (2002). "Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice." Circulation **105**(3): 293-6.
- Bozkurt, B., S. B. Kribbs, et al. (1998). "Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats." Circulation **97**(14): 1382-91.
- Brasier, A. R., J. Li, et al. (1996). "Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator." Hypertension **27**(4): 1009-17.
- Brunner, H. R. (2001). "Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease." Am J Cardiol **87**(8A): 3C-9C.
- Cardinale, J. P., S. Sriramula, et al. (2010). "HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats." Hypertension **56**(3): 437-44.
- Cave, A., D. Grieve, et al. (2005). "NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology." Philos Trans R Soc Lond B Biol Sci **360**(1464): 2327-34.

- Cifuentes, M. E., F. E. Rey, et al. (2000). "Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice." Am J Physiol Heart Circ Physiol **279**(5): H2234-40.
- Cottone, S., A. Vadala, et al. (1998). "Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension." Am J Hypertens **11**(5): 548-53.
- Donoghue, M., F. Hsieh, et al. (2000). "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9." Circ Res **87**(5): E1-9.
- Elks, C. M., N. Mariappan, et al. (2009). "Chronic NF- $\kappa$ B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am J Physiol Renal Physiol **296**(2): F298-305.
- Elmarakby, A. A., J. E. Quigley, et al. (2006). "Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension." Hypertension **47**(3): 557-62.
- Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease." Am J Cardiol **98**(1): 121-8.
- Funakoshi, Y., T. Ichiki, et al. (1999). "Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells." Hypertension **34**(1): 118-25.
- Griendling, K. K., C. A. Minieri, et al. (1994). "Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells." Circ Res **74**(6): 1141-8.
- Griendling, K. K., D. Sorescu, et al. (2000). "Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology." Arterioscler Thromb Vasc Biol **20**(10): 2175-83.
- Grieve, D. J., J. A. Byrne, et al. (2006). "Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload." J Am Coll Cardiol **47**(4): 817-26.
- Guggilam, A., M. Haque, et al. (2007). "TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats." Am J Physiol Heart Circ Physiol **293**(1): H599-609.
- Gurantz, D., R. T. Cowling, et al. (1999). "Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts." Circ Res **85**(3): 272-9.
- Harrison, D. G. and M. C. Gongora (2009). "Oxidative stress and hypertension." Med Clin North Am **93**(3): 621-35.

- Heymes, C., J. K. Bendall, et al. (2003). "Increased myocardial NADPH oxidase activity in human heart failure." J Am Coll Cardiol **41**(12): 2164-71.
- Hingtgen, S. D., X. Tian, et al. (2006). "Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy." Physiol Genomics **26**(3): 180-91.
- Johar, S., A. C. Cave, et al. (2006). "Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase." FASEB J **20**(9): 1546-8.
- Kakishita, M., K. Nakamura, et al. (2003). "Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor." J Cardiovasc Pharmacol **42 Suppl 1**: S67-70.
- Kalra, D., N. Sivasubramanian, et al. (2002). "Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway." Circulation **105**(18): 2198-205.
- Kudo, H., H. Kai, et al. (2009). "Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation." Hypertension **54**(4): 832-8.
- Li, J. M., N. P. Gall, et al. (2002). "Activation of NADPH oxidase during progression of cardiac hypertrophy to failure." Hypertension **40**(4): 477-84.
- Mann, D. L. (2002). "Inflammatory mediators and the failing heart: past, present, and the foreseeable future." Circ Res **91**(11): 988-98.
- Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction." Free Radic Biol Med **46**(4): 462-70.
- Mariappan, N., R. N. Soorappan, et al. (2007). "TNF- $\alpha$ -induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol." Am J Physiol Heart Circ Physiol **293**(5): H2726-2737.
- Michie, H. R., M. L. Sherman, et al. (1989). "Chronic TNF infusion causes anorexia but not accelerated nitrogen loss." Ann Surg **209**(1): 19-24.
- Mohazzab, K. M., P. M. Kaminski, et al. (1994). "NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium." Am J Physiol **266**(6 Pt 2): H2568-72.
- Muller, D. N., E. Shagdarsuren, et al. (2002). "Immunosuppressive treatment protects against angiotensin II-induced renal damage." Am J Pathol **161**(5): 1679-93.

- Paravicini, T. M. and R. M. Touyz (2008). "NADPH Oxidases, Reactive Oxygen Species, and Hypertension: Clinical implications and therapeutic possibilities." Diabetes Care **31**(Supplement\_2): S170-S180.
- Park, Y. M., M. Y. Park, et al. (2004). "NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats." Biochem Biophys Res Commun **313**(3): 812-7.
- Phillips, M. I. and S. Kagiya (2002). "Angiotensin II as a pro-inflammatory mediator." Curr Opin Investig Drugs **3**(4): 569-77.
- Ruiz-Ortega, M., O. Lorenzo, et al. (2001). "Role of the renin-angiotensin system in vascular diseases: expanding the field." Hypertension **38**(6): 1382-7.
- Ruiz-Ortega, M., M. Ruperez, et al. (2002). "Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney." Kidney Int **62**(S82): S12-S22.
- Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by cytokines." Hypertension **30**(1 Pt 1): 35-41.
- Seddon, M., Y. H. Looi, et al. (2007). "Oxidative stress and redox signalling in cardiac hypertrophy and heart failure." Heart **93**(8): 903-7.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-51.
- Tipnis, S. R., N. M. Hooper, et al. (2000). "A Human Homolog of Angiotensin-converting Enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase." Journal of Biological Chemistry **275**(43): 33238-33243.
- Tokuda, K., H. Kai, et al. (2004). "Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis." Hypertension **43**(2): 499-503.
- Touyz, R. M., C. Mercure, et al. (2005). "Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase." Hypertension **45**(4): 530-7.
- Tsutamoto, T., A. Wada, et al. (2000). "Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure." J Am Coll Cardiol **35**(3): 714-21.
- Xu, P., S. Sriramula, et al. (2011). "ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good." Am J Physiol Regul Integr Comp Physiol **300**(4): R804-17.

Yokoyama, T., K. Sekiguchi, et al. (1999). "Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts." Am J Physiol **276**(6 Pt 2): H1968-76.

Zalba, G., F. J. Beaumont, et al. (2000). "Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats." Hypertension **35**(5): 1055-61.

Zhang, Y., K. K. Griendling, et al. (2005). "Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H<sub>2</sub>O<sub>2</sub>." Hypertension **46**(4): 732-7.



## **CHAPTER 3**

### **HDAC INHIBITION ATTENUATES INFLAMMATORY, HYPERTROPHIC AND HYPERTENSIVE RESPONSES IN SPONTANEOUSLY HYPERTENSIVE RATS\***

**\*Reprinted with the kind permission of “Hypertension”**

## INTRODUCTION

Essential hypertension is a condition associated with increased expression of pro-inflammatory cytokines (PICs) (Phillips and Kagiyama 2002; Ferrario and Strawn 2006). Studies from our lab and others have shown that PICs lead to an increase in reactive oxygen species (ROS), which up-regulates Nuclear Factor-*kappa*B (NFκB) activity, thus further increasing PIC and ROS transcription and amplifying their subsequent actions (Sriramula, Haque et al. 2008; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). Along with renin-angiotensin system (RAS) components, PICs also activate hypertrophic mediators, which can result in cardiac hypertrophy and altered cardiac remodeling and function (Tokuda, Kai et al. 2004; Kudo, Kai et al. 2009).

There are many triggers of hypertensive-induced inflammation resulting in both hypertrophic and hypertensive responses, many of which are through transcription factor NFκB activation, ultimately resulting in alterations of gene transcription and perpetuation of the hypertensive state (Gupta, Young et al. 2005; Sriramula, Haque et al. 2008). In order for transcription factors such as NFκB to activate their target genes, DNA and chromatin remodeling must occur. Post-translational modifications of histone cores through a tightly regulated addition/removal of an acetyl tag on their N-terminal tails plays a major role in gene expression modulation (de Ruijter, van Gennip et al. 2003). These additions/removals are accomplished by several members of the histone acetyltransferase (HAT) and histone deacetylase (HDAC) families, which either open or close DNA strands to the actions of transcription factors (Forsberg and Bresnick 2001).

Normally, this balance is tightly controlled, but during conditions of stress and inflammation, activation of PICs can result in increased HDAC activation and histone

acetylation, correlating with an increase in NF $\kappa$ B activity and further increases in PIC expression, including tumor necrosis factor- $\alpha$  (TNF) and the interleukins (ILs) (Keslacy, Tliba et al. 2007; Kim, Rowe et al. 2007). Though HDACs would appear to repress inflammatory responses through reduced gene expression, this view is too simplistic in regards to their non-histone protein acetylation/deacetylation abilities, often times having quite opposite effects in regards to the inflammatory response (Chen, Fischle et al. 2001; Chen, Weng et al. 2005; Kong, Tannous et al. 2006; Bush and McKinsey 2009).

Recent evidence indicates that the various HDAC classes respond differently towards inducing cardiac hypertrophy in non-hypertensive animal models (Zhang, McKinsey et al. 2002; Kong, Tannous et al. 2006; Lee, Lin et al. 2007) and that global HDAC inhibition (HDACi) can prevent these hypertrophic changes (Davis, Pillai et al. 2005). However, it is not known whether HDACi protects against cardiac hypertrophy and hypertensive response by modulating PICs and oxidative stress in spontaneously hypertensive (SHR) rats. A previous study used valproate, a derivative of valproic acid (VPA), to study hypertension in SHR rats. Though they showed a reduction in systolic blood pressure (Sasaki, Nakata et al. 1990), the treatment was only carried out to 9 weeks of age, which is still 3 weeks too young to display the full systemic changes associated with hypertension in this animal model, including cardiac hypertrophy and inflammation. This study was established to assess the role of HDAC blockade on the inflammatory response and its effect on the pathogenesis of hypertension. Therefore, we hypothesize that chronic HDACi will attenuate the inflammatory and hypertensive responses associated with the hypertensive state. To test this, we administered VPA, a fairly novel HDAC inhibitor (Gottlicher, Minucci et al. 2001), especially Class I HDACs, as a long-term treatment in

SHR rats, for assessment of inflammatory, hypertrophic and hypertensive changes associated with essential hypertension.

## **MATERIALS AND METHODS**

All the procedures in this study were approved by the Louisiana State University Institutional Animal Care and Use Committee and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**Animals.** Adult male SHR or WKY rats were used for this study. They were housed in temperature- ( $23 \pm 2^\circ\text{C}$ ) and light-controlled (lights on between 7 AM and 7 PM) animal quarters and were provided with chow *ad libitum*. Vehicle (water) or valproic acid [VPA, 0.71% wt/vol (Kook, Lepore et al. 2003), Sigma] dissolved in water were prepared and provided daily.

Another subset of animals (WKY and SHR; n=5 each) were administered hydralazine [HYD, 25mg/kg/day in drinking water (Gupta, Young et al. 2005), Sigma], a direct smooth muscle relaxant and vasodilator, to determine the pressure-independent effect of VPA on cardiac hypertrophy. The experimental procedures were approved by the Louisiana State University Institutional Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

**Experimental Protocol.** SHR (n=20) and WKY (n=20) rats underwent echocardiographic assessment at the start and end of the treatment period. Rats received drug or vehicle treatment for 20 weeks starting at 7 weeks of age. Rats were euthanized at 27 weeks of age. Wet heart and lung weights were measured and analyzed against body weight. Blood and left ventricular tissue (LV) was collected for molecular analysis.

**Blood Pressure Measurement.** A tail-cuff plethysmograph (CODA 6 Blood Pressure System, Kent Scientific System, Torrington, CT) was used for blood pressure measurement at baseline,

and weekly thereafter. Blood pressure was measured for four consecutive days for determination of weekly average measures. The daily measurements were blindly analyzed for the most closely associated five consecutive runs for use as that day's average value.

**Echocardiographic Assessment of LV Hypertrophy.** Echocardiography was obtained at baseline, and repeated at the end of the treatment period. Echocardiogram was performed as described previously (Mariappan, Elks et al. 2009). Briefly, transthoracic echocardiography was performed under isoflurane anesthesia, using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin, California) fitted with a PST 65A sector scanner (8 MHz probe) which generates two-dimensional images at a frame rate ranging from 300-500 frames per second. Left ventricular posterior wall thickness at end-systole and end-diastole (LVPWTs and LVPWTd, respectively) was measured digitally on M-mode recordings and averaged from at least three cardiac cycles.

**Assessment of LV Hypertrophy Through Fibrosis Staining.** Paraffin sections (10 $\mu$ m) were obtained from heart specimens as previously described (Sriramula, Haque et al. 2008) and stained with picrosirius red for the detection of collagen. The percent area of fibrosis was calculated using ImageJ software (NIH).

**Detection of Total ROS and Superoxide ( $O_2^{\cdot-}$ ) in LV Heart Tissue.** One of the most sensitive and definitive methods of superoxide production is electron spin resonance (ESR). In this study, we utilized an established technique for total ROS detection in tissue using ESR and spin traps (Mariappan, Elks et al. 2009). Different spin probes were used for the ESR studies. 1-hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) was used to measure the  $O_2^{\cdot-}$  levels. All ESR measurements were performed using an EMX ESR eScan BenchTop spectrometer and super-high quality factor (Q) microwave cavity (Bruker Company, Germany). **Sample**

**Preparation for ESR studies:** The dissected LV tissue from each animal was placed into a 24-

well plate containing Kreb's HEPES buffer (KHB) (20mM, pH 7.4). Tissue pieces were then washed twice with the same buffer to remove any trace contamination. Samples were then incubated at 37°C with specific spin probes for 30 minutes. **Total tissue ROS production:** Total ROS was determined as previously described (Mariappan, Elks et al. 2009). Tissue pieces were incubated at 37°C with CMH (200 µM) for 30 minutes. Aliquots of the incubated probe media were then taken in 50 µl glass capillary tubes (Noxygen Science Transfer and Diagnostics, Elzach, Germany) for determination of total ROS production, under the following ESR settings: field sweep 50 G; microwave frequency 9.78 GHz; microwave power 20 mW; modulation amplitude 2 G; conversion time 327 ms; time constant 655 ms; receiver gain  $1 \times 10^5$ . For superoxide production, samples were pre-incubated at 37°C with PEG-SOD (50 U/ml) for 30 minutes, then CMH (200µM) for an additional 30 minutes. Aliquots of the incubated probe media were taken in 50 µl glass capillary tubes for determination of total superoxide production. Addition of PEG-SOD to CMH allowed competitive inhibition of the  $O_2^{\bullet-}$ -CMH oxidation reaction by the quenching of  $O_2^{\bullet-}$  radicals. Since it is cell permeable, PEG-SOD can competitively inhibit the CMH- $O_2^{\bullet-}$  interaction both intracellularly and extracellularly, thus allowing accurate measurement of total tissue  $O_2^{\bullet-}$  production. To determine actual total tissue superoxide production, the values obtained from incubation with PEG-SOD and CMH were subtracted from the values obtained from incubation with CMH only.

**RNA Isolation and Real-Time RT-PCR.** Total RNA was extracted from the LV using TRI reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA expression levels of ANP, Collagen IV, TNF, IL-1 $\beta$ , IL-6, the p50 subunit of NF- $\kappa$ B, gp91*phox* and angiotensin II-Type 1 receptor (AT<sub>1</sub>R) were determined using previously published specific

custom made primers (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008; Agarwal, Haque et al. 2009; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). GAPDH was used as the housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384 well PCR plates using Bio-Rad PCR Master Mix (The iTaq SYBR™ Green Supermix with ROX) and the ABI Prism 7900 sequence detection system (Applied Biosystems). The PCR cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C). A dissociation step (15 s at 95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the melting temperature of the specific PCR product.

**HDAC Activity Analysis by Colorimetric Assay.** Nuclear extracts of LV tissue were obtained with a Nuclear Extraction Kit (BioVision). Nuclear extract was then analyzed for HDAC activity with a Colorimetric HDAC Activity Assay Kit (BioVision), both according to manufacturer's instructions. The plate was read by a Multiskan Spectrum system and values were determined as O.D./µg protein in samples.

**AT<sub>1</sub>R Protein Analysis by Western Blot.** Protein was extracted from LV samples in ice-cold buffer (10mM Tris-HCl, pH 7.4, 1mM EDTA, 1% Nonidet P-40, 0.1% sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail (Roche). The protein content in the supernatant was determined using a detergent-compatible protein assay (Bio-Rad). Protein samples (25µg) were resolved in 10% SDS-polyacrylamide gel. The protein expression of AT<sub>1</sub>R in the heart was analyzed by Western blot as previously described (Sriramula, Haque et al. 2008) with the use of anti-AT<sub>1</sub>R antibody (Santa Cruz). Bands were normalized to GAPDH.

**Localization of TNF and IL-1β by Immunohistochemistry.** Heart tissues were prepared as previously described (Guggilam, Haque et al. 2007). The sections were treated with respective

primary antibodies TNF (1:100 dilution, anti-goat) and IL-1 $\beta$  (1:50 dilution, anti-rabbit) (Santa Cruz). Negative control sections were incubated with secondary antibody alone.

**Localization of gp91 $\alpha$  by Immunofluorescence.** For detection of gp91 $\alpha$  in LV heart tissue, slides were incubated overnight at 4°C with a 1:100 dilution of goat polyclonal anti-gp91 $\alpha$  (Santa Cruz) as previously described (Khaleduzzaman, Francis et al. 2007).

**Electrophoretic Mobility Shift Assay (EMSA) for Assessment of NF- $\kappa$ B Activity.** EMSA was used to assess the activity of NF- $\kappa$ B (p65) in the left ventricle as previously described (Agarwal, Haque et al. 2009).


**Statistical Analysis of Data.** All results are expressed as mean  $\pm$  SEM. For statistical analysis of the data, student's *t* test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni's *post hoc* test was performed using GraphPad Prism version 5.0 for Windows, GraphPad Software, San Diego California, USA, to determine differences among groups. Cardiac fibrosis measurements were compared by using nonparametric Kruskal-Wallis ANOVA followed by Mann-Whitney U *post hoc*. A value of  $p < 0.05$  was considered significant.

## RESULTS

**VPA Treatment Attenuates the Blood Pressure Changes in SHR Rats.** Blood pressure recordings show that SHR+VPA maintained a lower blood pressure level from the pre-hypertensive to the more advanced hypertensive phases as compared to SHR controls (Figure 3.1). Following 10 weeks of treatment (started at 7 weeks of age), SHR control MAP continued to rise while SHR+VPA rats plateaued at a lower pressure (163.1 $\pm$ 2.32 vs. 127.5 $\pm$ 2.35mmHg, respectively,  $p < 0.05$ ). The MAP of SHR+VPA rose slightly throughout the course of the study, becoming significantly elevated above WKY controls towards the end of the treatment period (141.2 $\pm$ 4.5 vs. 114.8 $\pm$ 3.41, respectively,  $p < 0.05$ ), but still significantly lower than the MAP of




SHR controls ( $141.2 \pm 4.5$  vs.  $173.2 \pm 3.47$ , respectively,  $p < 0.05$ ). Mean diastolic and systolic pressures followed the same pattern as the MAP (data not shown), indicating that VPA attenuated all phases of blood pressure in SHR rats. Furthermore, VPA did not have any adverse effects on the health of the animals used in this study.



Another set of animals ( $n=5$  for each SHR and WKY) were treated with HYD, a direct smooth muscle relaxant and vasodilator, to compare their effects against treatment with VPA (Figure 3.1). SHR+HYD saw a decrease similar to SHR+VPA in MAP as compared to SHR ( $142.57 \pm 4.906$  vs.  $173.2 \pm 3.47$ ). WKY+HYD had no change in MAP. Mean diastolic and systolic followed the same pattern as the MAP in HYD treated rats (data not shown), indicating that HYD similarly attenuated all phases of increased blood pressure seen in SHR rats.


**VPA Attenuates Cardiac Hypertrophy in SHR Rats.** Echocardiographic assessment showed that SHR controls had significantly more concentric hypertrophy of the left ventricular posterior wall (LVPWT) during diastole and systole (Figure 3.2A) ( $2.48 \pm 0.11$  and  $3.43 \pm 0.2$ mm,

respectively) when compared to WKY controls ( $1.73 \pm 0.02$  and  $2.32 \pm 0.06$ , respectively). However, SHR+VPA ( $1.85 \pm 0.03$ ,  $2.52 \pm 0.04$  mm) rats displayed no change in ventricular thickness as compared to WKY and WKY+VPA ( $1.75 \pm 0.06$ ,  $2.28 \pm 0.07$  mm) rats, indicating that VPA had a beneficial effect on preventing the increased LVPWTd/s that is typically observed in SHR rats.



**Figure 3.2. Effects of VPA treatment on cardiac hypertrophy.** VPA attenuated ventricular wall thickness as assessed by echocardiography (A) during both diastole and systole. VPA also attenuated the HW/BW (indicating reduction in cardiac hypertrophy) and LW/BW (indicating reduction in lung edema due to reduced cardiac function) ratio in SHR rats (B). SHR rats had increased levels of ANP and Collagen IV mRNA expression which were reduced with VPA treatment (C). Graphs expressed as fold change versus WKY rats. VPA reduced cardiac fibrosis versus SHR rats as indicated by picrosirius red staining collagen versus total area (D). Stained slides are representative of typical results for each group (n=3/group). n=7-8 in each group, \* $p < 0.05$  vs WKY, # $p < 0.05$  vs SHR.


Heart weight (HW)/body weight (BW) and lung weight (LW)/BW ratios are often used to show phenotypic changes due to hypertension such as increased heart mass due to hypertrophy (HW/BW) and increased edema of the lungs (LW/BW) due to cardiac dysfunction and increased systemic circulatory resistance. Treatment with VPA or HYD alone did not have any effects on BW (Figure 3.3A). SHR+VPA normalized both HW/BW and LW/BW indices versus SHR control rats (0.0032 and 0.0048 vs. 0.0039 and 0.0062, respectively,  $p < 0.05$ ) as compared to WKY (0.0029 and 0.0038), reinforcing that VPA




reduces cardiac hypertrophy and dysfunction (Figure 3.2B). However, the HW/BW ratio assessed for SHR+HYD did not improve cardiac hypertrophy (Figure 3.3B) as compared to SHR controls (0.0036 vs. 0.0039), indicating that improvements in cardiac hypertrophy due to VPA treatment were not pressure dependent.

**VPA Reduces Hypertrophic Response Elements in the LV Tissue of SHR Rats.** To further demonstrate the effects of VPA on hypertrophy, RT-PCR analysis was undertaken on hypertrophic response genes in the LV. Compared to WKY, untreated SHR rats had elevated levels of collagen IV and atrial natriuretic peptide (ANP) - two markers of LV remodeling

associated with cardiac hypertrophy (Figure 3.2C), as well AT<sub>1</sub>R. SHR+VPA reduced these levels to that of normotensive WKY controls ( $p<0.05$ ), indicating HDACi has a positive effect on reducing molecular markers of cardiomyocyte and interstitial growth normally attributed to systemic hypertension. Furthermore, SHR+VPA had reduced % fibrosis staining (Figure 3.2D) as compared to SHR rats ( $3.395\pm 0.07$  vs  $4.713\pm 0.32$ ), signifying a reduction in total fibrosis within the heart following HDACi. The mRNA expression of AT<sub>1</sub>R was significantly increased within the LV of SHR rats versus that of normotensive WKY controls ( $2.7\pm 0.5$  fold vs WKY) (Figure 3.4B), which was fully attenuated in SHR+VPA rats ( $2.7\pm 0.5$  vs.  $0.9\pm 0.1$  fold vs WKY, respectively) and reconfirmed by western blot of the LV tissues (Figure 3.4A). HYD had no effect on the mRNA expression of either ANP or AT<sub>1</sub>R (Figure 3.5A, B), demonstrating the effect that HDACi has on controlling these locally activated hypertrophic mediators in the LV of SHR rats.



**Figure 3.4. Effect of VPA on AT<sub>1</sub>R mRNA and protein expression.** Untreated SHR rats showed higher mRNA (B) and protein expression (A) levels of the AT<sub>1</sub>R in the LV when compared to WKY controls. SHR+VPA attenuated this increase. Western blot protein expression bands were normalized to GAPDH. n=7-8 in each group, \* $p<0.05$  vs SHR.



### VPA Reduces HDAC Activity in the LV of Treated Groups.

To assess the effectiveness of VPA on HDAC activity in LV tissue, a colorimetric assay kit was used to analyze differences between the VPA treated and untreated groups (Figure 3.6A). Global HDAC activity was reduced in untreated WKY versus untreated SHR rats ( $17.87 \pm 1.06$  vs.  $22.19 \pm 0.57$  O.D./mg protein sample, respectively,  $p < 0.05$ ).


Furthermore, WKY+VPA and SHR+VPA groups both exhibited a lower HDAC activity level (not significant and  $p < 0.05$ , respectively) as compared to their own

strain controls. Conversely, SHR and WKY rats treated with HYD did not have a decrease in HDAC activity when compared with their respective controls (data not shown).

### VPA Normalizes Inflammatory Response in the LV Tissue of SHR Rats.

Immunohistochemistry revealed that SHR controls had increased protein expression of TNF and IL-1 $\beta$  in the LV as compared to WKY controls. This protein expression was reduced in SHR+VPA rats (Figure 3.7A). RT-PCR similarly indicated that SHR controls had increased expression of TNF, IL-1 $\beta$ , IL-6 (Figure 3.7B) mRNA and NF $\kappa$ B p65 (Figure 3.6B, C) activity and mRNA in LV tissue when compared to WKY controls. This increase was attenuated in SHR+VPA rats, while WKY+VPA exhibited no change. Furthermore, HYD had no effect on the PIC mRNA


expression of TNF or IL-1 $\beta$  (data not shown). These combined results indicate that VPA treatment reduces and normalizes the inflammatory response observed in SHR rats.



**VPA Reduces ROS and gp91 $phox$  in the LV of SHR Rats.** As inflammation during hypertensive response is associated with an increase in oxidative stress, both total ROS as assessed by EPR (Figure 3.8A) and the expression of gp91 $phox$  (Figure 3.8B, 6C) were examined in the LV. Untreated SHR rats experienced a significant increase in ROS when compared to WKY rats ( $0.54\pm 0.05$  vs.  $0.22\pm 0.03$  mM/mg protein/min). SHR+VPA normalized this ROS increase ( $0.54\pm 0.05$  vs.  $0.21\pm 0.03$  mM/mg protein/min). Furthermore, gp91 $phox$ , the major catalytic subunit of NADPH oxidase and a ROS contributor, was increased in untreated SHR rats versus WKY controls. This was subsequently reduced in SHR+VPA (3.39 vs. 1.56 fold change/WKY), but not SHR+HYD (data not shown). The reduction in protein expression was confirmed by immunofluorescence of the LV tissue. These results indicate that treatment of SHR rats with VPA had beneficial effects in reducing oxidative stress in the LV tissue.


## **DISCUSSION**

The major findings in this study are as follows: 1) HDACs played an important role in hypertensive drive by modulating inflammatory and oxidative stress actions and contributed to hypertrophic and hypertensive responses in SHR rats, 2) HDACi attenuated MAP in SHR rats, 3) HDACi also attenuated LVPWT and HW/BW ratio in SHR rats, demonstrating that HDACi reduces cardiac hypertrophy, possibly in part through modulation of ANP, Collagen IV and AT<sub>1</sub>R expression, 4) untreated SHR rats had an increase in inflammatory markers, including TNF and NF $\kappa$ B, as well as an increase in ROS and gp91 $phox$  expression, which were decreased through long-term HDACi using VPA, and 5) HDACi reduced AT<sub>1</sub>R expression, thereby limiting the role that angiotensin II (Ang II) plays in mediating hypertension. These findings suggest that long-term treatment with VPA reduces hypertension-induced PICs, thereby attenuating hypertrophic and hypertensive responses in SHR rats.



**Figure 3.7. Effects of VPA treatment on TNF and IL-1 $\beta$  protein and mRNA expression.** SHR rats had notably increased protein staining of TNF and IL-1 $\beta$  in the LV when compared to WKY rats as shown through immunohistochemical staining (A). This staining increase was markedly reduced in SHR+VPA. Images shown represent results observed in preparations from 4 to 6 rats. Untreated SHR rats had increased levels of PIC expression compared to WKY rats (B). SHR+VPA reduced this increased expression in the LV tissue. n=7-8 in each group, \* $p$ <0.05 vs SHR.





HDACs play an important role in inducing the structural remodeling of chromatin that exposes DNA to transcription factors, ultimately yielding changes in gene expression. Along with HATs, HDACs maintain a relative balance in cellular systems during normal physiology that allows typical function (de Ruijter, van Gennip et al. 2003). However, during diseased conditions, this balance is tilted in favor of HDACs, which can lead to an elevation in inflammatory and immune responses (Wade 2001; Aung, Schroder et al. 2006; Brogdon, Xu et al. 2007; Ito, Charron et al. 2007; Kim, Rowe et al. 2007; Halili, Andrews et al. 2009). In this study, we also observed an elevated HDAC activity

which was accompanied by increased PIC and oxidative stress gene expression in the hearts of SHR rats.

Cardiac hypertrophy is a well described consequence of systemic hypertension. Studies have shown the role of HDACi on controlling cardiac growth and remodeling (Antos, McKinsey et al. 2003). However, little is known about the holistic role of HDACi on hypertrophy during hypertensive response. As evidence indicates (Zhang, McKinsey et al. 2002; Antos, McKinsey et al. 2003; Davis, Pillai et al. 2005; Kee, Sohn et al. 2006; Kong, Tannous et al. 2006), pathological cardiac hypertrophy and function rely upon the balanced abundance of  $\alpha$ - and  $\beta$ -myosin heavy chain (MHC) protein throughout the heart. During the progression of cardiac hypertrophy, the adult isoform of MHC ( $\alpha$ -MHC) undergoes a stressed-trigger switch to the fetal isoform ( $\beta$ -MHC), contributing to cardiac hypertrophy. HDACi blunts MHC isoform switching, therefore preserving ventricular function (Kong, Tannous et al. 2006; Lee, Lin et al. 2007; Bush and McKinsey 2009). These results are contradictory to earlier experiments showing that class II HDACs block pro-growth genes through interaction with transcription factor myocyte enhancer factor-2 (MEF2) (McKinsey, Zhang et al. 2002). More recently though, research has indicated that the pro-hypertrophic class I HDACs, when activated, are more potent and take priority over the anti-hypertrophic class II HDACs (Antos, McKinsey et al. 2003), thus explaining how global HDACi can attenuate cardiac hypertrophy in various animal models (Kee, Sohn et al. 2006; Kong, Tannous et al. 2006). From these changes, it has been suggested that within the hypertrophied heart, hypertrophic stress signals cause the phosphorylation of HDACs bound to MEF2, causing their disassociation into the cytoplasm. Since these HDACs are not bound to the chromatin structure, their inhibition would have no overt effect on MEF2 transcription, indicating that HDACi has no direct effect on the depression of MEF2 controlled pro-hypertrophic genes and signifying that another mechanism must be in place (Kong, Tannous et al. 2006).

HDACi using Trichostatin A, an inhibitor of Class I and II HDACs, either induced (Kuwahara, Saito et al. 2001) or blunted (Antos, McKinsey et al. 2003) agonist-induced expression of ANP, a hypertrophic growth factor, in cultured neonatal myocytes. The present study also demonstrated that HDACi in SHR rats showed a significant reduction in ANP, suggesting that in SHR rats, ANP possibly plays an important role in attenuating cardiac hypertrophy, and that HDACi silences/blunts this signaling mechanism. Moreover, collagen IV, an indicator of cardiac remodeling, especially within the failing heart (Grimm, Huber et al. 2001), was increased in SHR rats, but not SHR+VPA rats. Finally, AT<sub>1</sub>R, an important component of the RAS which, when acted upon by Ang II in the LV, causes cardiac hypertrophy (Makino, Sugano et al. 1997), has been shown to be attenuated with VPA treatment (Kee, Sohn et al. 2006; Lu and Yang 2009), but the mechanism involved has not been fully investigated. The present study showed significantly reduced AT<sub>1</sub>R expression in SHR+VPA rats versus SHR controls, indicating that a possible hypertrophic mechanism intimately involves AT<sub>1</sub>R activation.

There are several well known modulators of pressure-independent cardiac hypertrophy including Ang II and sympathetic neurohormones (Kang, Ma et al. 2009). Recently, it was also shown that Ang II-induced cardiac hypertrophy can be prevented using HDACi (Kee, Sohn et al. 2006). To determine if the current study's effects on cardiac hypertrophy were pressure-independent or -dependent of HDACi, we looked at the effect of HYD on blood pressure and cardiac hypertrophy, as well as on ANP and AT<sub>1</sub>R expression. HYD reduced MAP in SHR rats similar to VPA; however, cardiac hypertrophy was unaffected, including hypertrophic mediators ANP and AT<sub>1</sub>R. This indicates a possible pressure-independent mechanism regarding VPA's effect on cardiac hypertrophy. These results are in agreement with a recent study where NFκB inhibition reduces cardiac hypertrophy in a pressure-independent manner (Gupta, Young et al.

2005). This may offer another mechanism whereby HDACi reduces cardiac hypertrophy, for results herein show a decrease in NF $\kappa$ B activity and expression following VPA treatment.

Therefore, from these results, not only was cardiac hypertrophy reduced through long-term VPA treatment, but several possible mechanisms that induce cardiac remodeling were also attenuated.

We and others have recently demonstrated that hypertensive drive is partially controlled through the over-expression of PICs, especially TNF, along with downstream alterations in NF $\kappa$ B, ROS and RAS components, as regulated through AT<sub>1</sub>R activation (Wilcox and Welch 2001; Sriramula, Haque et al. 2008; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). This study demonstrates that chronic HDACi attenuates PIC response in SHR+VPA rats. Moreover, VPA reduces the presence of ROS and AT<sub>1</sub>R, two components implicated in the inflammatory response observed in hypertension. HDACi has been increasingly identified as a possible therapeutic approach towards many inflammatory conditions, including cardiovascular diseases (Gottlicher, Minucci et al. 2001; Adcock 2007; Bush and McKinsey 2009; Halili, Andrews et al. 2009). Though this mechanism has not yet been entirely delineated, it is suggested that the use of a HDACi, such as VPA, blocks HDAC actions on protein function outside of its normal action on altering transcription (Chen, Weng et al. 2005; Bode, Schroder et al. 2007), as subsets of these families possess the ability to act on non-histone proteins, further complicating their roles in gene modulation (Walkinshaw, Tahmasebi et al. 2008). A recent study showed that HDACi can deactivate Akt, a potential mediator of cardiac hypertrophy and oxidative stress, via dephosphorylation by HDAC-protein phosphatase 1 complexes (Chen, Weng et al. 2005). However, other studies have shown that specific sets of Toll-like receptor-inducible genes are targeted by HDACi in macrophages and dendritic cells, and that one of these is through the NF $\kappa$ B pathway (Aung, Schroder et al. 2006; Brogdon, Xu et al. 2007), which

concur with the present study. It underscores the role of HDACi on PIC activation of NF $\kappa$ B, preventing a further, cyclically driven up-regulation of PICs, including TNF, IL-1 $\beta$  and IL-6.

The effect of inflammation on ROS in hypertension has been previously demonstrated (Paravicini and Touyz 2006; Elks, Mariappan et al. 2009). A number of pro-inflammatory mediators of this increased ROS have been identified, including TNF and IL-6, which, as demonstrated here, are attenuated with HDACi, confirming the roles of HDACs on inflammatory and oxidative stress responses on hypertension in SHR rats. Though the signaling pathway is not entirely clear on how HDACi attenuates ROS in SHR rats, either directly or indirectly through its blockade of PICs and the NF $\kappa$ B pathway, we postulate that by blocking PIC activation, with its subsequent down-regulation of NF $\kappa$ B activity and gp91*phox* expression, ROS is inhibited.

The interaction between the RAS, PICs and ROS has also been demonstrated by work in our lab (Sriramula, Haque et al. 2008) and others (Brasier, Li et al. 1996; Sasamura, Nakazato et al. 1997; Arenas, Xu et al. 2004). Presently we show that untreated SHR rats have increased AT<sub>1</sub>R expression, an important component of the pro-hypertensive portion of the RAS. HDACi through VPA treatment attenuated this increase concomitant with that of PICs. The pathophysiological mechanism of hypertension intimately involves the action of Ang II, including vasoconstriction, increased aldosterone secretion, increased sympathetic nerve activity, tissue remodeling and increased sodium and water intake, all of which are mediated through AT<sub>1</sub>R that are distributed throughout most organ systems, including the liver, brain, kidney, heart and blood vessels (Allen, Zhuo et al. 2000). Reports indicate that Ang II is controlled by, and controls, HDAC-induced changes in gene and protein response (Kee, Sohn et al. 2006; Lu and Yang 2009). Here we show a possible new mechanism involving the regulation of Ang II responses as directed through the AT<sub>1</sub>R. HDACi reduces AT<sub>1</sub>R gene expression and receptor

density, thereby ameliorating the actions of Ang II. This alteration in AT<sub>1</sub>R expression could be either through direct HDACi effects on the receptor's production and function, or through the effects of HDACi on inflammatory gene response during hypertension. This mechanism must be further investigated in order to determine the full effect of HDACi in attenuating hypertension.

In conclusion, the present study's results show that long-term HDACi through VPA attenuated MAP and cardiac hypertrophy, possibly through modulation of ANP, Collagen IV and AT<sub>1</sub>R. HDAC inhibition also attenuated the increased inflammatory response, including TNF and NFκB, as well as the increase in ROS and *gp91phox*. These findings suggest that HDACi with VPA reduced inflammation, ROS, and AT<sub>1</sub>R, thereby attenuating hypertension and its secondary consequences in SHR rats.

## **PERSPECTIVES**

We chose to use VPA due to its current use in clinical settings as an anti-seizure and bipolar drug, demonstrating its availability to patients. In our study, VPA was administered long-term without any adverse effects towards the treated animal groups. This outlines the importance of the continuous drug administration necessary for the successful treatment of hypertension and its consequences, including cardiac hypertrophy, systemic inflammation and end organ damage due to ROS. While we cannot rule out the effects of VPA on blood pressure from its GABAergic actions or non-histone protein interactions, we feel confident that this study provides sufficient evidence that the use of HDACi can reduce not only blood pressure, but cardiac hypertrophy and the inflammatory state associated with hypertension. The specific mechanisms involved in HDACi must be studied more closely. However, as the quest to find new therapeutic strategies in hypertensive control is ever pressing, this could present a possible new approach in future treatment options.

## REFERENCES

- Adcock, I. M. (2007). "HDAC inhibitors as anti-inflammatory agents." Br J Pharmacol **150**(7): 829-831.
- Agarwal, D., M. Haque, et al. (2009). "Role of Proinflammatory Cytokines and Redox Homeostasis in Exercise-Induced Delayed Progression of Hypertension in Spontaneously Hypertensive Rats." Hypertension **54**: 1393-1400.
- Allen, A. M., J. Zhuo, et al. (2000). "Localization and function of angiotensin AT1 receptors." Am J Hypertens **13**(1 Pt 2): 31S-38S.
- Antos, C. L., T. A. McKinsey, et al. (2003). "Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors." J Biol Chem **278**(31): 28930-28937.
- Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha." Am J Physiol Cell Physiol **286**(4): C779-784.
- Aung, H. T., K. Schroder, et al. (2006). "LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression." FASEB J **20**(9): 1315-1327.
- Bode, K. A., K. Schroder, et al. (2007). "Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment." Immunology **122**(4): 596-606.
- Brasier, A. R., J. Li, et al. (1996). "Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator." Hypertension **27**(4): 1009-1017.
- Brogdon, J. L., Y. Xu, et al. (2007). "Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function." Blood **109**(3): 1123-1130.
- Bush, E. W. and T. A. McKinsey (2009). "Targeting histone deacetylases for heart failure." Expert Opin Ther Targets **13**: 767-784.
- Chen, C. S., S. C. Weng, et al. (2005). "Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes." J Biol Chem **280**(46): 38879-38887.
- Chen, L., W. Fischle, et al. (2001). "Duration of nuclear NF-kappaB action regulated by reversible acetylation." Science **293**(5535): 1653-1657.
- Davis, F. J., J. B. Pillai, et al. (2005). "Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility." Am J Physiol Heart Circ Physiol **288**(3): H1477-1490.

- de Ruijter, A. J., A. H. van Gennip, et al. (2003). "Histone deacetylases (HDACs): characterization of the classical HDAC family." Biochem J **370**(Pt 3): 737-749.
- Elks, C. M., N. Mariappan, et al. (2009). "Chronic NF- $\kappa$ B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am J Physiol Renal Physiol **296**(2): F298-305.
- Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease." Am J Cardiol **98**(1): 121-128.
- Forsberg, E. C. and E. H. Bresnick (2001). "Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world." Bioessays **23**(9): 820-830.
- Gottlicher, M., S. Minucci, et al. (2001). "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells." EMBO J **20**(24): 6969-6978.
- Grimm, D., M. Huber, et al. (2001). "Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade." J Mol Cell Cardiol **33**(3): 487-501.
- Guggilam, A., M. Haque, et al. (2007). "TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats." Am J Physiol Heart Circ Physiol **293**(1): H599-609.
- Gupta, S., D. Young, et al. (2005). "Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats." Am J Physiol Heart Circ Physiol **289**(1): H20-29.
- Halili, M. A., M. R. Andrews, et al. (2009). "Histone deacetylase inhibitors in inflammatory disease." Curr Top Med Chem **9**(3): 309-319.
- Ito, K., C. E. Charron, et al. (2007). "Impact of protein acetylation in inflammatory lung diseases." Pharmacol Ther **116**(2): 249-265.
- Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res **82**(3): 503-512.
- Kee, H. J., I. S. Sohn, et al. (2006). "Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding." Circulation **113**(1): 51-59.
- Keslacy, S., O. Tliba, et al. (2007). "Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity." Mol Pharmacol **71**(2): 609-618.



- Khaleduzzaman, M., J. Francis, et al. (2007). "Infection of cardiomyocytes and induction of left ventricle dysfunction by neurovirulent polytropic murine retrovirus." J Virol **81**(22): 12307-12315.
- Kim, H. J., M. Rowe, et al. (2007). "Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action." J Pharmacol Exp Ther **321**(3): 892-901.
- Kong, Y., P. Tannous, et al. (2006). "Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy." Circulation **113**(22): 2579-2588.
- Kook, H., J. J. Lepore, et al. (2003). "Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop." J Clin Invest **112**(6): 863-871.
- Kudo, H., H. Kai, et al. (2009). "Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation." Hypertension **54**(4): 832-838.
- Kuwahara, K., Y. Saito, et al. (2001). "The neuron-restrictive silencer element-neuron-restrictive silencer factor system regulates basal and endothelin 1-inducible atrial natriuretic peptide gene expression in ventricular myocytes." Mol Cell Biol **21**(6): 2085-2097.
- Lee, T. M., M. S. Lin, et al. (2007). "Inhibition of histone deacetylase on ventricular remodeling in infarcted rats." Am J Physiol Heart Circ Physiol **293**(2): H968-977.
- Lu, Y. and S. Yang (2009). "Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases." Tohoku J Exp Med **219**(1): 17-23.
- Makino, N., M. Sugano, et al. (1997). "Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats." Hypertension **30**(4): 796-802.
- Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction." Free Radic Biol Med **46**(4): 462-470.
- McKinsey, T. A., C. L. Zhang, et al. (2002). "MEF2: a calcium-dependent regulator of cell division, differentiation and death." Trends Biochem Sci **27**(1): 40-47.
- Paravicini, T. M. and R. M. Touyz (2006). "Redox signaling in hypertension." Cardiovasc Res **71**(2): 247-258.
- Phillips, M. I. and S. Kagiya (2002). "Angiotensin II as a pro-inflammatory mediator." Curr Opin Investig Drugs **3**(4): 569-577.

- Sasaki, S., T. Nakata, et al. (1990). "Chronic central GABAergic stimulation attenuates hypothalamic hyperactivity and development of spontaneous hypertension in rats." J Cardiovasc Pharmacol **15**(5): 706-713.
- Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by cytokines." Hypertension **30**(1 Pt 1): 35-41.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-1351.
- Tokuda, K., H. Kai, et al. (2004). "Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis." Hypertension **43**(2): 499-503.
- Wade, P. A. (2001). "Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin." Hum Mol Genet **10**(7): 693-698.
- Walkinshaw, D. R., S. Tahmasebi, et al. (2008). "Histone deacetylases as transducers and targets of nuclear signaling." J Cell Biochem **104**(5): 1541-1552.
- Wilcox, C. S. and W. J. Welch (2001). "Oxidative stress: cause or consequence of hypertension." Exp Biol Med (Maywood) **226**(7): 619-620.
- Zhang, C. L., T. A. McKinsey, et al. (2002). "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy." Cell **110**(4): 479-488.

## **CHAPTER 4**

# **CENTRAL TUMOR NECROSIS FACTOR- $\alpha$ BLOCKADE REVERSES ANGIOTENSIN II-INDUCED ALTERATIONS IN RENIN-ANGIOTENSIN SYSTEM COMPONENTS AND ATTENUATES HYPERTENSION**

## INTRODUCTION

It is well known that the renin-angiotensin system (RAS) plays a major role in blood pressure regulation and the hypertensive condition. While the pro-hypertensive components of the RAS have been extensively investigated, the recent identification of an anti-hypertensive set of RAS components has complicated the manner by which the fully activated RAS functions in physiological and pathophysiological states. Angiotensin II (Ang II), the effector peptide of the pro-hypertensive axis of the RAS that also includes angiotensin converting enzyme (ACE) and the Ang II-Type 1 receptor (AT<sub>1</sub>R), exerts diverse physiological actions in both the peripheral and central neural systems. The anti-hypertensive counterbalance to these mediators includes ACE2, and the AT<sub>2</sub> and Mas receptors. Importantly, all these essential components of the RAS, including renin and angiotensinogen, as well as various cardiovascular-modulatory aminopeptidases, are synthesized within the brain, suggesting the existence of a comprehensive intrinsic brain RAS (Bader and Ganten 2002; Veerasingham and Raizada 2003; Sakai and Sigmund 2005; Xu, Sriramula et al. 2011). Recent evidence suggests that dysregulation of the individual brain RAS arms may play a critical role in the development and maintenance of hypertension. Ang II, acting through the AT<sub>1</sub>R, plays a prominent role in the central regulation of blood pressure by activating the sympathetic nervous system, regulating fluid and salt balance and the secretion of aldosterone, amongst other actions (Veerasingham and Raizada 2003). Furthermore, the pressor response of chronic low-dose Ang II infusion in animals has been shown, at least in part, to be sympathetically driven (Bruner and Fink 1986; Gorbea-Oppliger and Fink 1994). Previous studies suggest that systemically delivered Ang II likely acts upon the circumventricular organs, where the blood brain barrier is weak or absent, and subsequently activates hypothalamic and brain stem sites such as the paraventricular nucleus (PVN) and

ventrolateral medulla, contributing to sympathoexcitation and hypertensive response (Simpson 1981; Fink, Bruner et al. 1987; Collister and Hendel 2003).

Experimental evidence indicates that the hypothalamic PVN is an important center for integrating Ang II-induced neural outflow signals for the pressor response and sympathetic vasomotor tone (Martin, Segura et al. 1991; Zhu, Gao et al. 2004). Recent findings from our lab and others suggest that the RAS, in addition to inducing neurohumoral excitation, also increases the production of proinflammatory cytokines (PICs), such as tumor necrosis factor-alpha (TNF), in brain cardiovascular regulatory centers, and has been shown to contribute to the neurogenic component of hypertension, both through direct actions and through modulating reactive oxygen species (ROS) signaling pathways (Kang, Ma et al. 2009; Shi, Diez-Freire et al. 2010). A chronic increase in peripheral Ang II levels is proposed to initiate a cascade of signaling events involving PICs and ROS in brain cardioregulatory sites raising sympathetic activity, hypertension and end organ damage. These observations, coupled with the emerging role of PICs and the little known role of the anti-hypertensive axis of the RAS in hypertension led us to hypothesize that the central effects of Ang II are, at least in part, mediated by the activation of PICs, especially TNF. The resultant of these actions are the differentially dysregulated RAS arms within cardiovascular relevant brain regions, including the PVN, ultimately enhancing the neurogenic hypertensive response. Presently, we investigate this hypothesis by examining central TNF inhibition via intracerebroventricular (ICV) etanercept (ETN) infusion, a soluble TNF receptor fusion protein, on pro- and anti-hypertensive RAS components in the PVN in Ang II-induced hypertension.

## **MATERIALS AND METHODS**

**Animals.** Male Sprague-Dawley rats (8-10 weeks old) were used in this study. Animals were housed in a temperature-controlled room ( $25 \pm 1^{\circ}\text{C}$ ) and maintained on a 12:12 hour light:dark

cycle with free access to food and water. All animal and experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Louisiana State University in compliance with NIH guidelines.

**Experimental Protocol.** The rats were implanted with radio-telemetry transmitters to measure blood pressure, and subjected to ICV infusion of etanercept (10 $\mu$ g/kg/day) or artificial cerebrospinal fluid (aCSF) (Alzet, model 1004; 0.11 $\mu$ l/hr), with and without subcutaneous infusion of Ang II (200 ng/kg/min) for 4 weeks. Osmotic minipumps (Alzet, model 2004; 0.25 $\mu$ l/hr) were filled with Ang II dissolved in 0.9% saline or saline alone, and were implanted subcutaneously in the retroscapular area. The rats were divided into 4 groups: 1) Control group - saline minipumps + ICV aCSF, 2) ETN group - saline minipumps + ICV ETN, 3) Ang II group - Ang II minipump + ICV aCSF, and 4) Ang II+ETN group - Ang II minipump + ICV etanercept. At the end of the study, rats were euthanized the brain was removed for further analysis.

**Blood Pressure Measurement.** Blood pressure was measured continuously in conscious rats implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International, St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart. The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the blood flow. The catheter tip was introduced through a small incision in the femoral artery, advanced ~6 cm into the abdominal aorta such that the tip was distal to the origin of the renal arteries, and secured into place. The body of the transmitter was placed into the abdominal cavity and secured to the abdominal wall. The abdominal musculature was sutured and the skin layer was closed following implantation. Rats received benzathine penicillin (30000 U, i.m.) and

buprenorphine (0.1 mg/kg, s.c.) immediately following surgery and 12 h postoperatively and allowed to recover for seven days.

**ICV Cannula Implantation.** Following the transmitter recovery period, the rats were implanted with ICV cannula for infusion of ETN or aCSF (Francis, Weiss et al. 2003). The rats were anaesthetized and the head was positioned in a Kopf stereotaxic apparatus. An ICV cannula was implanted into the right lateral cerebroventricle (1.3 mm caudal to bregma, 1.5 mm lateral to the midline, and 3.5 mm ventral to the dura) according to Paxinos and Watson, and fixed to the cranium using small screws and dental cement. A 4-week osmotic minipump was implanted subcutaneously and connected to the infusion cannula via the catheter tube to deliver ETN or aCSF into the brain.

**Real Time RT-PCR.** PVN punches were made from frozen brain sections using a Stoelting brain punch (Stoelting). Total RNA was isolated from PVN tissue using RNeasy plus micro kit (Qiagen) and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). Real Time PCR amplification reactions were performed with iQ SYBR Green Super mix with ROX (Bio-Rad) using the ABI Prism 7900 Real time PCR machine (Applied Biosystems). List of primers used was provided in Table 4.1. Data were normalized to GAPDH expression by the  $\Delta\Delta C_T$  comparative method.

**Immunohistochemical Analysis.** Rats (n=5 in each group) were transcardially perfused with 200 ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4% paraformaldehyde in PBS. The brains were removed, post-fixed in 4% paraformaldehyde solution for 2 hours, and transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and stored overnight. For immunostaining, 10  $\mu$ m coronal sections from paraffin embedded brains were collected on slides. First the sections were incubated with 0.3% H<sub>2</sub>O<sub>2</sub> in methanol for 10

minutes. For antigen retrieval, citrate buffer with microwave heating technique is used. Then the sections were incubated with 1.5% goat or rabbit serum in PBS containing 0.3% Triton X100 for 30 minutes. The sections were incubated with primary antibodies overnight at 4°C followed by incubation with biotinylated goat-anti rabbit or rabbit-anti goat secondary antibodies for 60 minutes, and stained with Vectastain ABC kit (Vector Laboratories) according to the manufacturer's instructions. Each step was followed by washing the sections with PBS containing 0.3% Triton X100. Sections incubated without primary antibody were used as negative controls.

**Statistical Analysis.** All results are expressed as mean±SEM. For statistical analysis of the data, student's *t* test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni's *post hoc* test was performed using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego California, USA) to determine differences among groups. A value of  $p < 0.05$  was considered statistically.


## **RESULTS**

**Effect of Ang II Infusion on the Mean Arterial Pressure.** To assess the effect of central TNF blockade on the Ang II-induced hypertensive pressure response, mean arterial pressure (MAP) was measured using a radio-telemetry system (Figure 4.1A). After 28 days, chronic Ang II infusion significantly increased the MAP in rats when compared with control rats ( $164.9 \pm 5.03$  mmHg vs  $107.7 \pm 8.03$  mmHg, respectively;  $p < 0.05$ ). In contrast, ICV treatment with etanercept attenuated the Ang II-induced increase in MAP ( $126.4 \pm 21.2$  mmHg vs  $164.9 \pm 5.03$  mmHg, respectively;  $p < 0.05$ ), while ETN treatment alone had no effect on MAP ( $103.6 \pm 3.47$  mmHg).


To evaluate Ang II-induced changes on cardiac hypertrophy in these rats, the hearts were harvested and weighed at the end of experimental period. The ratio of heart/body weight




(HW/BW) was calculated as an indicator of cardiac growth. Chronic Ang II infusion lead to increased cardiac mass when compared to controls ( $4.04 \pm 0.2$  vs  $3.16 \pm 0.1$  mg/g, respectively;  $p < 0.05$ ), as indicated by the increased HW/BW ratio (Figure 4.1B). ICV treatment with ETN inhibited Ang II-mediated cardiac growth (reduced to  $3.15 \pm 0.1$  mg/g;  $p < 0.05$ ). This data suggests a role for TNF in the brain on Ang II-induced blood pressure regulation and cardiac hypertrophy in the hypertension state.



**Effect of Ang II Infusion on the Expression of PICs in the PVN.** To determine the effect of Ang II on the production of PICs and chemokines, the mRNA expression of TNF, IL-6, IL-1 $\beta$ , and the chemokine MCP-1 were measured in the PVN by real time RT-PCR (Figure 4.2). Ang II infusion induced an increase in the gene expression of the PICs TNF, IL-6 and IL-1 $\beta$ , and the chemokine MCP-1, in the PVN, when compared to saline and saline+ETN control rats. These PICs were attenuated in the PVN of Ang II-infused rats treated ICV with ETN, demonstrating that chronic Ang II infusion increases the pro-inflammatory response within the PVN through TNF in Ang II-induced hypertension.





**Effect of Ang II Infusion on the Expression of RAS Components in the PVN.** Both Ang II and TNF have been shown to modulate RAS component expression. To determine the manner by which Ang II infusion alters the expression of the pro- and anti-hypertensive components of the RAS in the PVN, we examined the mRNA expression levels of ACE, ACE2, AT<sub>1</sub>R, AT<sub>2</sub>R, and the Mas receptor by real time RT-PCR, and the protein expression of the AT<sub>1</sub>R using immunohistochemistry. The gene expression of the pro-hypertensive RAS components (AT<sub>1</sub>R and ACE) in the PVN were significantly increased in Ang II-infused rats when compared with

control rats; whereas in Ang II-infused rats treated ICV with ETN, these components were reduced (Figure 4.3A). Immunohistochemistry against AT<sub>1</sub>R protein expression in the PVN

showed a similar pattern of increase in Ang II-infused rats, but a

reduction in ICV ETN-administered rats (Figure 4.3B). Conversely, the

anti-hypertensive components of the RAS (ACE2, AT<sub>2</sub>R and the Mas

receptor) showed a decreased gene expression in Ang II-treated rats.

These levels were increased in the Ang II+ETN group (Figure 4.4).

This data suggests that in Ang II-induced hypertension, the pro- and


anti-hypertensive components of the RAS are differentially regulated

within the PVN in a deleterious manner. Additionally, ACE2 can

increase during the normal RAS response. Here, in blocking TNF,

which decreases ACE2 as well as the other anti-hypertensive RAS

components, it possibly allows for




not only the recovery, but the overshoot observed in the ACE2 response by also not inhibiting the machinery (possibly including a ROS mechanism) responsible for modulating ACE2. This dysregulation is possibly through a PIC/TNF-mediated mechanism, and thereby perpetuating the Ang II-driven hypertensive response.

**Effect of Ang II Infusion on the Expression of gp91 $phox$  and nNOS.** Both Ang II and TNF have been shown to act through oxidative stress mediated pathways, especially within the PVN, in inducing elevated sympathetic outflow and a progressive hypertensive response. Therefore, we analyzed the PVN mRNA expression of gp91 $phox$ , the catalytic subunit of NADPH, and neuronal Nitric Oxide Synthase (nNOS; an indirect indicator of sympathoexcitation). Ang II infusion significantly increased the gp91 $phox$  subunit, and decreased nNOS mRNA expression, in Ang II infused rats; these changes were reversed in Ang II-infused rats treated with ETN (Figure 4.5). This data suggests that in Ang II-induced hypertension, oxidative stress (indicated by increased gp91 $phox$ ) and sympathoexcitation (indicated by a decreased nNOS) increase, and that this is potentially through a TNF-driven mechanism.

## **DISCUSSION**

The major findings in this study are as follows: 1) Chronic Ang II infusion increased mean arterial blood pressure and cardiac hypertrophy; 2) within the PVN, chronic Ang II infusion increased PICs such as TNF and IL-1 $\beta$ , as well as gp91 $phox$  and decreased nNOS; 3) Ang II infusion also led to an elevation in pro-hypertensive RAS component expression (ACE and AT $_1$ R) and a decrease in anti-hypertensive RAS component expression (ACE2, AT $_2$ R and Mas) within the PVN; 4) Ang II-infused rats treated ICV with etanercept, a soluble TNF receptor mimetic, prevented these changes, including attenuating MAP and PICs, and reversing the expression alterations observed between the pro- and anti-hypertensive RAS arms. These

findings demonstrate that the changes observed in Ang II-induced hypertension are regulated, at least in part, through the central actions of TNF and potentially via the dysregulation of components of the RAS within the hypothalamic PVN.



**Figure 4.5. Effects of central TNF blockade on oxidative stress marker *gp91phox* and nNOS expression in the PVN.** Ang II-infused rats demonstrated an increase in the mRNA expression of the NADPH oxidase catalytic subunit, *gp91phox*, while that of nNOS was decreased in the PVN (5A). These alterations were reversed in etanercept-treated rats. Similarly, immunofluorescence against *gp91phox* showed an increased neuronal expression in Ang II-infused rats, which was decreased in Ang II+ETN rats (5B). n=9-10 per group, \* $p < 0.05$  vs Control, # $p < 0.05$  vs Ang II.

Recent evidence suggests that hypertension is an inflammatory condition where various PICs such as TNF, IL-6 and IL-1 $\beta$ , both centrally and peripherally, have been shown to play an important role in the pathogenesis of hypertension (Chae, Lee et al. 2001; Veerasingham and

Raizada 2003; Sun, Li et al. 2004; Sriramula, Haque et al. 2008; Lu, Chen et al. 2009; Shi, Diez-Freire et al. 2010). A recent study from our lab demonstrated that chronic peripheral Ang II infusion results in increased production of PICs within the PVN (Kang, Ma et al. 2009). Blockade of TNF by etanercept has been shown to prevent renal damage in a genetic hypertensive rat model, as well as lower blood pressure in rats with Ang II- and salt-induced hypertension, suggesting a role for TNF in blood pressure regulation and renal injury (Muller, Shagdarsuren et al. 2002; Elmarakby, Quigley et al. 2006). Another study also showed that mice treated with etanercept had an attenuated hypertension and a blunted increase in superoxide production in response to Ang II (Guzik, Hoch et al. 2007). Etanercept is a soluble recombinant fusion protein that inhibits TNF by posing as a TNF receptor decoy and acting through competitive inhibition of TNF and an overall reduction in free TNF to act on endogenous receptors (Goffe and Cather 2003). Our present observations complement these findings and show that ICV administration of etanercept into the brain protects rats against Ang II-dependent cardiac hypertrophy and hypertension.

Ang II can act as a potent proinflammatory agent and stimulate the production of chemokines such as MCP-1, and PICs, such as TNF, IL-6 and IL-1 $\beta$  in the brain (Shi, Diez-Freire et al. 2010). TNF is commonly considered as one of the initiators of the pro-inflammatory cascade, which can induce production of other cytokines and chemokines (Zhang, Hein et al. 2006; Zhang, Xu et al. 2006). A recent study demonstrated that Ang II-induced hypertension involves activation of microglia and increased expression of PICs within the PVN (Shi, Diez-Freire et al. 2010). In our study, TNF blockade with etanercept decreased the expression not only of TNF, but of other cytokines such as IL-6, IL-1 $\beta$ , and chemokine MCP-1 within the PVN, supporting the hypothesis that PIC are involved in the Ang II-induced hypertensive response.

Excessive ROS production in brain cardio-regulatory centers such as the PVN can contribute to the neurogenic component of the hypertensive response by enhancing sympathetic activity and outflow (Paravicini and Touyz 2006). It has been shown that NADPH oxidase is the primary source of Ang II-induced ROS in neurons (Paravicini and Touyz 2006) and that treatment with the cell permeable superoxide dismutase (SOD) mimetic Tempol inhibits Ang II-mediated superoxide production and hypertension (Nishiyama, Fukui et al. 2001). Furthermore, TNF can induce activation of NADPH oxidase leading to enhanced oxidative stress and decreasing the bioavailability of NO (Zhang, Xu et al. 2006). Moreover, in the present study, nNOS was decreased in the PVN of Ang II-treated rats, but restored following ICV etanercept administration. Neuronal NOS is an inverse indirect indicator of sympathoexcitation, in that a decrease in nNOS correlates with an increase in sympathetic outflow. Therefore, a reduction in beneficial NO not only decreases with the reduction in nNOS expression and activity, but along with the rapid interconversion of NO to peroxynitrite ( $\text{ONOO}^-$ ) with the ever increasing production of NADPH oxidase-derived superoxide. These factors combined can lead to an increased PIC response, sympathoexcitation and a continued propagation of neurogenic hypertension. The present study provides further support for these observations by showing that central TNF blockade with etanercept reduced the expression of gp91 $\text{phox}$  (the catalytic subunit of NADPH oxidase), restored nNOS, and ultimately decreased the changes associated with the hypertensive state.

In many animal models of hypertension, the expression of the  $\text{AT}_1\text{R}$  is upregulated in central cardiovascular regulatory centers, including the hypothalamic PVN (Veerasingham and Raizada 2003). In the brain, the  $\text{AT}_1\text{R}$  mediates the central effects of Ang II, including vasopressin release, water and salt intake and balance, and increased sympathetic drive, all of



which contribute to the development of hypertension (Paul, Poyan Mehr et al. 2006; von Bohlen und Halbach and Albrecht 2006). Both *in vitro* and *in vivo* studies have demonstrated the existence of a cross-talk between Ang II and TNF (Sasamura, Nakazato et al. 1997; Arenas, Xu et al. 2004), and we have also shown that attenuation of Ang II-induced hypertension in TNF knockout mice involves a decreased expression of AT<sub>1</sub>R (Sriramula, Haque et al. 2008). Presently, we show that chronic Ang II infusion results in an increase in PVN ACE and AT<sub>1</sub>R, both which were reduced following ICV etanercept infusion. Recently, the discovery of an alternate set of components of the RAS which may act as a counterbalance to the actions of the ACE/Ang II/AT<sub>1</sub>R pathway added complexity to the understanding of RAS regulation, especially within the brain (Xu, Sriramula et al. 2011). These components, termed anti-hypertensive due to their cardio-protective effects, along with all the components of the pro-hypertensive RAS axis, are known to be expressed throughout the various central cardio-regulatory regions, including the PVN. In various experimental hypertensive models, these components (ACE2, AT<sub>2</sub>R, Ang (1-7) and the Mas receptor) are shown to be downregulated, while the pro-hypertensive components are increased. This dysregulation may be the lynch pin trigger towards developing hypertension, but its management is poorly understood. In the present study, ICV treatment with etanercept resulted in reduction of Ang II-induced pro-hypertensive RAS component expression, including ACE and AT<sub>1</sub>R upregulation in the PVN, as well as the restoration of the anti-hypertensive RAS components ACE2, AT<sub>2</sub>R and the Mas receptor. As mentioned previously, ACE2 can increase during the normal RAS response, but following the eventual increase in TNF, it decreases ACE2 as well as the other anti-hypertensive RAS components. Thus, the TNF blockade possibly allows for not only the recovery, but the overshoot observed in the ACE2 response by not inhibiting the machinery responsible for

moderating and modulating ACE2. However, these same signaling mechanisms seem to have little to no effect on the AT<sub>2</sub>R and Mas receptor gene expression increases. This/these mechanism(s) must be studied closely to delineate these observed differences. These results suggest that this RAS dysregulation and perpetuation of the hypertensive state may be the result of a pro-inflammatory response through the actions of TNF, but further studies are necessary to completely understand this mechanism.

In summary, chronic Ang II infusion resulted in cardiac hypertrophy and hypertension, and within the PVN, an increased PIC and gp91*phox* expression, and decreased expression of nNOS. Perhaps more importantly, Ang II-infused rats had an increased expression of the injurious pro-hypertensive RAS components ACE and AT<sub>1</sub>R, and a decreased expression of the protective anti-hypertensive RAS components ACE2, AT<sub>2</sub>R and the Mas receptor. Central blockade of TNF with etanercept resulted in attenuation of hypertension, cardiac hypertrophy and PIC expression, decreased oxidative stress, as well as a restored the balance between the protective and deleterious arms of the RAS, within the hypothalamic PVN. The beneficial effects of central TNF blockade in Ang II-induced hypertensive responses appears to be mediated by the returned balance of the central RAS components, especially within the PVN. It is important to note, however, that due to the administration of etanercept ICV, the TNF inhibitory effects may have impacted additional cardio-regulatory regions in the brain and elicited a similar response as in the PVN, but in light of its central integrative function versus the other regions, the PVN was of utmost concern. These other regions should also be investigated in future studies, as well as a closer look at the specific pathway between Ang II, TNF and the differential regulation of the RAS arms in the Ang II hypertension-induced animal model. Our findings provide further evidence and insight for the involvement of the RAS within the PVN and its interaction and

mediation through TNF in the neurogenic component of hypertension. Further exploration of these system interactions within the brain may be beneficial towards the development of novel hypertensive therapeutics.

## REFERENCES

- Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha." Am J Physiol Cell Physiol **286**(4): C779-784.
- Bader, M. and D. Ganten (2002). "It's renin in the brain: transgenic animals elucidate the brain renin angiotensin system." Circ Res **90**(1): 8-10.
- Bruner, C. A. and G. D. Fink (1986). "Neurohumoral contributions to chronic angiotensin-induced hypertension." Am J Physiol **250**(1 Pt 2): H52-61.
- Chae, C. U., R. T. Lee, et al. (2001). "Blood pressure and inflammation in apparently healthy men." Hypertension **38**(3): 399-403.
- Collister, J. P. and M. D. Hendel (2003). "Subfornical organ lesion attenuates chronic hypotensive effects of losartan in salt-replete rats." J Renin Angiotensin Aldosterone Syst **4**(4): 207-212.
- Elmarakby, A. A., J. E. Quigley, et al. (2006). "Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension." Hypertension **47**(3): 557-562.
- Fink, G. D., C. A. Bruner, et al. (1987). "Area postrema is critical for angiotensin-induced hypertension in rats." Hypertension **9**(4): 355-361.
- Francis, J., R. M. Weiss, et al. (2003). "Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats." Am J Physiol Regul Integr Comp Physiol **284**(2): R328-335.
- Goffe, B. and J. C. Cather (2003). "Etanercept: An overview." J Am Acad Dermatol **49**(2 Suppl): S105-111.
- Gorbea-Oppliger, V. J. and G. D. Fink (1994). "Clonidine reverses the slowly developing hypertension produced by low doses of angiotensin II." Hypertension **23**(6 Pt 2): 844-847.
- Guzik, T. J., N. E. Hoch, et al. (2007). "Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction." J Exp Med **204**(10): 2449-2460.

- Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res **82**(3): 503-512.
- Lu, Y., J. Chen, et al. (2009). "Angiotensin II receptor 1 involved in the central pressor response induced by interleukin-1 beta in the paraventricular nucleus." Neurol Res **31**(4): 420-424.
- Martin, D. S., T. Segura, et al. (1991). "Cardiovascular responses to bicuculline in the paraventricular nucleus of the rat." Hypertension **18**(1): 48-55.
- Muller, D. N., E. Shagdarsuren, et al. (2002). "Immunosuppressive treatment protects against angiotensin II-induced renal damage." Am J Pathol **161**(5): 1679-1693.
- Nishiyama, A., T. Fukui, et al. (2001). "Systemic and Regional Hemodynamic Responses to Tempol in Angiotensin II-Infused Hypertensive Rats." Hypertension **37**(1): 77-83.
- Paravicini, T. M. and R. M. Touyz (2006). "Redox signaling in hypertension." Cardiovasc Res **71**(2): 247-258.
- Paul, M., A. Poyan Mehr, et al. (2006). "Physiology of local renin-angiotensin systems." Physiol Rev **86**(3): 747-803.
- Sakai, K. and C. D. Sigmund (2005). "Molecular evidence of tissue renin-angiotensin systems: a focus on the brain." Curr Hypertens Rep **7**(2): 135-140.
- Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by cytokines." Hypertension **30**(1 Pt 1): 35-41.
- Shi, P., C. Diez-Freire, et al. (2010). "Brain Microglial Cytokines in Neurogenic Hypertension." Hypertension.
- Simpson, J. B. (1981). "The circumventricular organs and the central actions of angiotensin." Neuroendocrinology **32**(4): 248-256.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-1351.
- Sun, C., H. Li, et al. (2004). "Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity." J Neurosci **24**(44): 9944-9952.
- Veerasingham, S. J. and M. K. Raizada (2003). "Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives." Br J Pharmacol **139**(2): 191-202.
- von Bohlen und Halbach, O. and D. Albrecht (2006). "The CNS renin-angiotensin system." Cell Tissue Res **326**(2): 599-616.

- Xu, P., S. Sriramula, et al. (2011). "ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good." Am J Physiol Regul Integr Comp Physiol **300**(4): R804-817.
- Zhang, C., T. W. Hein, et al. (2006). "Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles." J Mol Cell Cardiol **40**(2): 247-257.
- Zhang, C., X. Xu, et al. (2006). "TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury." Arterioscler Thromb Vasc Biol **26**(3): 475-480.
- Zhu, G. Q., L. Gao, et al. (2004). "ANG II in the paraventricular nucleus potentiates the cardiac sympathetic afferent reflex in rats with heart failure." J Appl Physiol **97**(5): 1746-1754.

## CHAPTER 5

# NUCLEAR FACTOR-*kappa*B BLOCKADE IN THE PARAVENTRICULAR NUCLEUS MODULATES RENIN-ANGIOTENSIN SYSTEM COMPONENTS AND ATTENUATES HYPERTENSION

## INTRODUCTION

Hypertension is a condition closely associated with the renin-angiotensin system (RAS) and increased expression of proinflammatory cytokines (PICs) and reactive oxygen species, in both systemic and local hypertensive responses (Chae, Lee et al. 2001; Zimmerman, Lazartigues et al. 2002; Davisson 2003; Gao, Wang et al. 2005; Ferrario and Strawn 2006; Granger 2006; Kang, Ma et al. 2009). Studies from our laboratory and others have shown that in hypertension, angiotensin II (AngII), PICs and ROS can increase the activity of the transcription factor Nuclear Factor- $\kappa$ B (NF $\kappa$ B), which in turn, can further increase PIC and ROS expression in a positive feed-forward manner (Allen, Zhuo et al. 2000; van den Berg, Haenen et al. 2001; Zhang, Wei et al. 2003; Bubici, Papa et al. 2006; Tian, Moore et al. 2007; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010).

Within the brain, multiple cardio-regulatory regions exhibit a local RAS, including the hypothalamic paraventricular nucleus (PVN), which can synthesize and release both pro- and anti-hypertensive RAS component peptides (Davisson 2003; Xia and Lazartigues 2008). The PVN is recognized as a central integration site for the coordination of autonomic and neuroendocrine responses that regulate thirst, salt appetite and sympathetic outflow (Davisson, Oliverio et al. 2000; de Wardener 2001; Sriramula, Haque et al. 2008). AngII is a large peptide that cannot cross the blood-brain barrier (BBB). Therefore, it exerts its roles by acting on the circumventricular organs (CVOs), an area where the BBB is either weak or absent (Simpson 1981; Ganong 2000). Signals from these CVOs subsequently activate neurons within the various cardio-regulatory centers of the brainstem and hypothalamus, including the PVN (Ganong 2000), which can respond by locally producing components of the RAS and via sympathetic signals to the periphery (Kang, Ma et al. 2009).

Recent findings from our laboratory and others have shown that, with hypertension, PICs are increased in discrete brain sites, such as the PVN, and that signals from both the systemic and local RASs increase PICs and oxidative stress (Kang, Ma et al. 2009; Shi, Raizada et al.). Within the PVN, the RAS, PICs and ROS have been linked to increased sympathoexcitation and perpetuation of the hypertensive state (Sun, Li et al. 2004; Lu, Chen et al. 2009). Based upon the preceding evidence, we hypothesized that bilateral PVN blockade of NF $\kappa$ B would attenuate these observed regional changes which propagate the AngII-induced hypertensive response, including increases in PICs and ROS. To test this hypothesis, we blocked NF $\kappa$ B within the PVN using two different approaches: bilateral PVN NF $\kappa$ B decoy oligodeoxynucleotide infusion, or bilateral PVN microinjection of an Adenoviral vector containing a serine mutated Inhibitor- $\kappa$ B (IkB) (AdIkB). These inhibition techniques block two separate locations in the NF $\kappa$ B transcription activation pathway, prior to entering the nucleus (AdIkB) and following nuclear translocation (NF $\kappa$ B decoy). Our results demonstrate that NF $\kappa$ B is integral to perpetuating the hypertensive state through transcriptional activation of the local RAS, PIC and ROS actions within the PVN, as well as acting as a tipping point modulator in the balance between the pro-hypertensive and the anti-hypertensive arms of the RAS. This data shows the important role that PVN specific NF $\kappa$ B plays in the neurogenic control of hypertension through RAS modulation.

## **MATERIALS AND METHODS**

**Animals.** Male Sprague-Dawley rats (12 weeks old, 250-350grams, n=153) were used in this study. Animals were housed in a temperature- ( $25 \pm 1^{\circ}\text{C}$ ) and light-controlled (12:12 hour light:dark cycle) room with free access to water and normal rat chow (0.4% salt). All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Louisiana State University in accordance with NIH guidelines.



**Experimental Protocol.** Rats were anaesthetized and implanted with radio-telemetry transmitters. Following a 7-day recovery, bilateral cannulae were placed into the PVN. Fourteen-day osmotic minipumps (Alzet, model 2002) with an infusion rate of 0.5µl/h were filled with AngII (Bachem, 200ng/kg/min) dissolved in 0.9% saline, or saline alone, and implanted subcutaneously in the retroscapular area. Simultaneously, osmotic minipumps (infusion rate of 0.11µl/h; Alzet, model 1004) were filled with NFκB decoy or control scrambled decoy oligodeoxynucleotide (2ng/kg/min; Sigma), dissolved in aCSF, implanted subcutaneously in the retroscapular area and connected to the cannula. The NFκB decoy concentration was determined from a previous pilot study in rats using three different doses, 200pg/kg/min, 2ng/kg/min and 200ng/kg/min. The 2ng/kg/min dose was found to be optimal, while the highest dose caused increased mortality and the lowest dose did not produce complete NFκB inhibition as measured using an NFκB (p65) activity assay. Rats were divided into 4 groups: 1) No treatment (Controls; n=11); 2) Saline minipump + bilateral PVN NFκB decoy (Saline+NFκB decoy; n=8); 3) AngII minipump + bilateral PVN scrambled decoy (AngII+Scramble decoy; n=8); and 4) AngII minipump + bilateral PVN NFκB decoy (AngII+NFκB decoy; n=20). Another group of rats were also implanted with radio-telemetry transmitters and allowed a 7-day recovery. These rats were injected ( $2 \times 10^{10}$  pfu/ml, 100nL) bilaterally intra-PVN with an Adenoviral vector (Ad) containing IκB serine mutated at the S23A/S36A positions (AdIκB), or a control Ad with an empty cassette region (AdEmpty; both adenoviruses obtained from Gene Transfer Vector Core, University of Iowa, Carver College of Medicine) using a 1µl Hamilton syringe, as previously described (Feng, Yue et al. 2008). Also in this group of rats, 14-day osmotic minipumps (Alzet, model 2002; 0.5µl/h) were filled with AngII dissolved in 0.9% saline or saline alone and implanted subcutaneously into the retroscapular area. These rats were also divided into 4 groups: 1) No

treatment (Controls; n=10); 2) Saline minipump + bilateral PVN AdIkB (Saline+AdIkB; n=9); 3) AngII minipump + bilateral PVN AdEmpty (AngII+AdEmpty; n=8); and 4) AngII minipump + bilateral PVN AdIkB (AngII+AdIkB; n=21). A final group of rats were treated with AngII alone (n=15) and used for western blot, immunohistochemical and electron paramagnetic resonance (EPR) analysis. All rats were euthanized using a high ketamine+xylazine dose after 14 days of blood pressure recordings and brain tissue was collected for mRNA and protein analysis (1.8µg mRNA and 8-12µg protein extracted/side). All rats that received treatment unilaterally into the PVN or had malfunctioning pumps (based upon post-mortem analysis) were excluded from the final analysis (success rate: bilateral cannulation ~ 78%; bilateral microinjection ~ 65%). Chow salt (Na<sup>+</sup>) content did not appear to have any effect on pressure response. A  $p < 0.05$  was considered significant.

**Blood Pressure Measurement.** Blood pressure was measured continuously in conscious rats implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International, St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart. The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the blood flow. The catheter tip was introduced through a small incision in the femoral artery, advanced ~6 cm into the abdominal aorta such that the tip was distal to the origin of the renal arteries, and secured into place. The body of the transmitter was placed in to the abdominal cavity and sutured to the abdominal wall. The abdominal musculature was sutured and the skin layer was closed. Rats received benzathine penicillin (30000 U, i.m.) and buprenorphine (0.1

mg/kg, s.c.) immediately following surgery and 12 h postoperatively. The rats were allowed 7-day surgical recovery.

**Bilateral Cannula Implantation or Intra-PVN Injections.** Rats to receive NF $\kappa$ B decoy or scrambled oligodeoxynucleotide decoy were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.). The rats were placed in a stereotaxic instrument (Kopf instruments; Tujunga, CA) and the skull was exposed through an incision on the midline of the scalp. After bregma was identified, the coordinates for the PVN were determined from the Paxinos and Watson (2007) rat atlas, at 1.8 mm posterior and 7.9 mm ventral to the zero level. Rats were implanted with custom designed bilateral cannulae (Plastics One; Roanoke, VA) and subsequently attached to osmotic minipumps via sterile vinyl tubing. For adenovirus microinjections, we followed the same surgical procedure except that rats were injected bilaterally intra-PVN with AdI $\kappa$ B or AdEmpty virus using a 1 $\mu$ l Hamilton syringe with a custom made needle/tip and injector plunger that advances flush with the needle tip (Hamilton Company USA) at  $\pm$ 0.4 mm lateral to the bregma. ICV cannulated rats were examined for cannula placement during cryostat slicing with crystal violet staining prior to PVN punching and immunohistochemical slicing (bilateral cannulation ~ 78%; n=22). Microinjection locations were also determined via crystal violet staining prior to PVN punching and immunohistochemical slicing (bilateral microinjection ~ 65%; n=24). At this point, animals identified as receiving unilateral or no treatments were removed from the final analysis. Animals not able to be examined via staining methods were assessed based on pressure recordings, as the unilaterally-treated rats had a distinctive blood pressure range from the AngII+Scramble decoy and AngII+AdEmpty and the AngII+ NF $\kappa$ B decoy and AngII+ AdI $\kappa$ B treatment groups.

**Detection of Total ROS, Superoxide and Peroxynitrite in PVN Tissue.** One of the most

sensitive and definitive methods of total ROS, superoxide and peroxynitrite production is electron spin resonance (EPR). In this study, we utilized an established technique for ROS detection in tissue using EPR and spin traps as previously described (Cardinale, Sriramula et al. 2010; Guggilam, Cardinale et al. 2011).

**RNA Isolation and Real-Time RT-PCR .** Total RNA was extracted from the PVN using TRI reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA expression levels of TNF, IL-1 $\beta$ , IL-6, MCP-1, AT<sub>1</sub>R, ACE, ACE2, the Mas receptor and nNOS were determined using previously published specific custom made primers (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008; Agarwal, Haque et al. 2009; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). GAPDH was used as the housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384 well PCR plates using Bio-Rad PCR Master Mix (The iTaq SYBR™ Green Supermix with ROX) and the ABI Prism 7900 sequence detection system (Applied Biosystems). The PCR cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C). Finally, a dissociation step (15 s at 95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the melting temperature of the specific PCR product.

**Western Blot.** Western blot analysis was performed according to standard protocols. The PVN tissue was homogenized with RIPA lysis buffer. Equal amounts of protein (5 $\mu$ g) were SDS-PAGE separated on 10% wt/vol gels, transferred to PVDF membrane (Immobilon-P, Millipore) and blocked with 1% BSA in TBS-T at room temperature for 60 min. The membranes were subjected to immunoblot analyses with anti-AT<sub>1</sub> (Abcam), anti-MasR (Santa Cruz) and anti-GAPDH (Santa Cruz) antibodies (1:200 dilution). Immunodetection was accomplished with a


horse radish anti-rabbit or anti-goat secondary antibody (1:2000 dilution) using an enhanced chemiluminescence kit (Amersham) as previously described (Sriramula, Haque et al. 2008). The data were quantified using ImageJ software and were normalized to GAPDH expression.

**Immunohistochemical Analysis.** Rats (n=4 in each group) were transcardially perfused with 200ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4% paraformaldehyde in PBS. The brains were removed, postfixed in 4% paraformaldehyde solution for 2 hours, and transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and stored overnight. For immunostaining, 10 $\mu$ m coronal sections from paraffin embedded brains were collected on slides. First the sections were incubated with 0.3% H<sub>2</sub>O<sub>2</sub> in methanol for 10 minutes. For antigen retrieval, citrate buffer with microwave heating technique is used. Then the sections were incubated with 1.5% goat or rabbit serum in PBS containing 0.3% Triton X100 for 30 minutes. The sections were incubated with primary antibodies (TNF, 1:100 dilution, anti-goat; Santa Cruz; nNOS, 1:100 dilution, anti-goat; Santa Cruz) overnight at 4°C followed by incubation with biotinylated goat-anti rabbit or rabbit-anti goat secondary antibodies for 60 minutes, and stained with Vectastain ABC kit (Vector Laboratories) according to the manufacturer's instructions. Each step was followed by washing the sections with PBS containing 0.3% Triton X100. Sections incubated without primary antibody were used as negative controls.

**Determination of I $\kappa$ B Overexpression by Immunofluorescence.** For detection of I $\kappa$ B in PVN tissue, slides were incubated overnight at 4°C with a 1:100 dilution of goat polyclonal anti-I $\kappa$ B (Santa Cruz) as previously described (Cardinale, Sriramula et al. 2010).

**p65 Activity Assay for Assessment of NF- $\kappa$ B Binding Activity.** The NF $\kappa$ B/p65 TransAM Active ELISA kit (Active Motif) was used to measure the binding activity of free NF $\kappa$ B p65 in nuclear extracts (Active Motif). The extraction and analysis were done using a sandwich ELISA

method and in accordance to the manufacturer's instructions. Procedure yields 0.15-0.25mg of nuclear extract from PVN tissue at 3-5mg/ml. NFκB/p65 Active ELISA detection levels for nuclear extracts between 0.5-1μg/well at 450nm.



**Figure 5.1. PVN specific inhibition of NFκB.** (A) Schematic showing cannulae placement/microinjection stereotaxic location coordinates. (B) Representative immunofluorescence image for IκB is localized in the PVN following AdκB bilateral microinjection into control rat. (C) NFκB p65 activity assay showing increased activity in the PVN of the AngII-treated groups when compared to control groups. p65 activity is decreased in AngII-treated rats following bilateral PVN NFκB decoy infusion or AdκB microinjection. n=5-6 rats per group, \* $p < 0.05$  vs respective AngII-treated rats, # $p < 0.05$  vs respective control-treated rats.

**Statistical Analysis.** All results are expressed as mean±SEM. For statistical analysis of the data, student's *t* test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni's correction *post hoc* was performed (GraphPad Prism v5.0 for Windows, GraphPad Software, San Diego California, USA) to determine differences among groups. A value of  $p < 0.05$  was considered statistically significant.

## RESULTS


### NFκB Blockade in the PVN

#### Reduces p65 Subunit Binding

#### Activity.

To determine the role of NFκB inhibition in the central regulation of blood pressure, we either bilaterally infused NFκB decoy oligodeoxynucleotide into the PVN via a fixed cannula (Figure 5.1A) or bilaterally microinjected an Adenovirus encoding serine mutated IκB to overexpress IκB and inhibit NFκB within the PVN. Figure 5.1B shows the localization of IκB gene overexpression specifically within the PVN following bilateral PVN AdIκB

**A** Localization of Bilateral PVN Cannulae




**B** Localization of Bilateral PVN Ad Microinjections




**Figure 5.2. Localizaion of treatment sites within the PVN.** Bilateral cannulae placement (**A**; n=22) and microinjection (**B**; n=24) sites as determined by post-mortem analysis of the brain using crystal violet staining prior to punching the PVN and immunohistochemical slicing. Rats demonstrating unilateral treatments also demonstrated an elevated MAP from the bilaterally treated AngII+Scramble decoy, AngII+AdEmpty, AngII+NFκB decoy and AngII+ AdIκB groups.

microinjection, as indicated by enhanced fluorescence protein expression. Localization of injection sites of examined rats are schematically represented in Figure 5.2. To determine the efficacy of the two methods inhibiting NFκB activity, an NFκB p65 subunit activity assay was conducted following 14-day treatment in the PVN. The p65 subunit activity was dramatically increased in the PVN in the two AngII-treated groups versus their respective controls (Figure 5.1C). This increase in activity was attenuated in both AngII+NFκB decoy and Ang II+AdIκB-treated rats. This data indicates that NFκB is increased within the PVN during the AngII-induced hypertensive response and that the use of NFκB decoy or AdIκB can potentially, and site specifically, inhibit the activity of NFκB.








**Figure 5.4. Effects of NFκB inhibition on AngII-induced increases in PIC expression.** (A) mRNA expression of the PICs TNF, IL-1β, IL-6 and MCP-1 in the PVN of Ang II-infused groups are increased versus control groups. Expression is decreased following bilateral PVN NFκB decoy infusion or AdIkB microinjection. (B) Immunohistochemical staining for TNF is increased in the PVN in AngII-infused rats (AngII alone) versus Controls (no treatment). Staining was decreased in rats treated bilaterally into the PVN via NFκB decoy infusion or AdIkB microinjection. Images shown represent results observed in preparations from 4 to 6 rats. n=6-8/group, \* $p < 0.05$  vs respective AngII-treated rats, # $p < 0.05$  vs respective control-treated rats.

**NFκB Blockade in the PVN Attenuates the AngII-Induced Blood Pressure Response.** To assess the effect of NFκB inhibition in the PVN on AngII-induced hypertensive response, mean arterial pressure (MAP) was measured using a radio-telemetry system (Figure 5.3). Chronic 14-day AngII infusion significantly increased the MAP in rats that received scramble decoy or AdEmpty treatment versus their respective saline-infused controls (Saline+NFκB decoy and Saline+AdIkB). In contrast, the MAP in AngII+NFκB decoy and AngII+AdIkB had a significantly reduced MAP, though the MAP was not decreased to control levels. Rats receiving either treatment unilaterally, though showing a reduced MAP versus the AngII control groups

was not reduced as effectively as bilateral treatments. This data indicates that NFκB within the




PVN plays a contributing role to blood pressure response in AngII-induced hypertension.

### NFκB Blockade Decreases PIC

**Expression in the PVN.** To study the effect of NFκB blockade on PIC expression in the PVN, expression levels were measured by real-time PCR. AngII infusion significantly increased the mRNA expression of TNF-α, IL-1β, IL-6, and the chemokine MCP-1 in the PVN versus control rats. However, bilateral PVN NFκB decoy infusion or bilateral microinjection of AdIkB into the PVN attenuated these changes in PIC gene expression (Figure 5.4A). Furthermore, immunohistochemistry against TNF showed an increase in staining in AngII-treated rats (AngII alone) versus Controls (no treatment) (Figure 5.4B). This

protein expression was reduced via bilateral PVN NFκB decoy infusion or bilateral AdIkB microinjection into the PVN, demonstrating that through NFκB inhibition within the PVN, PIC levels are reduced within this hypothalamic region.



**NFκB Blockade Effects RAS Component Expression in the PVN.** To study the effect of NFκB on RAS components, the expression levels of ACE and ACE2 by PCR, and AT<sub>1</sub>R and

Mas receptor (MasR) by PCR and western blot, were analyzed. AngII infusion significantly increased the mRNA expression of the AT<sub>1</sub>R and ACE in the PVN when compared with control rat groups, and decreased the ACE2 and MasR expression versus their respective control groups

(Figure 5.6A). Bilateral NFκB decoy

infusion or microinjection of AdIκB into

the PVN reversed these gene expression

changes. AngII also decreased the

Mas/AT<sub>1</sub>R ratio within the PVN, which

was reversed in AngII+NFκB decoy and

AngII+AdIκB groups (Figure 5.5A).

These results were further confirmed for

AT<sub>1</sub>R and MasR protein levels in the PVN

by western blot (Figure 5.6B) and

densitometric (Figure 5.5B and C)

analysis. These results show that NFκB

plays a modulatory role in RAS

component expression in the PVN during

the AngII-induced hypertensive response.


### NFκB Blockade Reduces ROS

**Production in the PVN.** To study the


effects of NFκB blockade on ROS

production in the PVN, ROS levels were

measured by EPR analysis (Figure 5.7).



Total ROS, superoxide and peroxynitrite levels were significantly increased in the PVN of AngII-treated rats (AngII alone) versus Controls (no treatment). These ROS levels were decreased to normal levels following chronic bilateral NFκB decoy infusion or AdIκB microinjection into the PVN, indicating the role that NFκB plays in increasing ROS during the hypertensive response.



**NFκB Blockade Increases nNOS Expression in the PVN.** Neuronal NOS (nNOS) expression is an indirect indicator of sympathoexcitation. In AngII-treated rat groups, nNOS mRNA was significantly decreased when compared to the control rat groups (Figure 5.8A). Bilateral NFκB decoy infusion or AdIκB microinjection into the PVN reversed and elevated these AngII-induced changes even beyond that of the normotensive controls. These results were further confirmed with immunohistochemistry against nNOS (Figure 5.8B), where AngII-infused rats (AngII alone) had decreased nNOS presence versus Controls (no treatment). Expression levels were elevated in AngII+NFκB decoy and AngII+AdIκB groups, indicating that through reduction of NFκB, nNOS, and potentially sympathoexcitation, were beneficially decreased in the AngII-induced hypertensive state.

## **DISCUSSION**

In the present study, we investigated the effects of site specific bilateral hypothalamic PVN blockade of NFκB on the AngII-induced hypertensive response. The salient findings of this study are as follows: 1) Peripheral AngII infusion increases MAP and bilateral PVN NFκB blockade attenuates this elevated MAP; 2) Peripheral AngII infusion, within the PVN, increases PICs, ROS and pro-hypertensive (ACE and AT<sub>1</sub>R) RAS components, while decreasing the anti-hypertensive (ACE2 and Mas) RAS components; 3) bilateral PVN specific NFκB inhibition not only decreases PVN PICs, but also modulates RAS component expression, such as decreasing ACE and AT<sub>1</sub>R expression and increasing ACE2 and MasR expression; 4) PVN blockade of NFκB leads to an increase in nNOS expression and a decrease in O<sub>2</sub><sup>•-</sup> and peroxynitrite (OONO<sup>•</sup>) levels. These results indicate that the NFκB-modulated inflammatory response acts as a double-edged sword that not only increases the deleterious pro-hypertensive arm of the RAS, but also decreases the protective anti-hypertensive arm of the RAS, possibly through a ROS mechanism.

The NF $\kappa$ B response is triggered by phosphorylation of I $\kappa$ B, which then becomes ubiquitinated, is degraded, and frees NF $\kappa$ B, allowing its nuclear translocation to act on  $\kappa$ B binding sites and commence transcription (Barnes and Karin 1997). In this study, two approaches were utilized to block NF $\kappa$ B within the PVN. AdI $\kappa$ B binds to NF $\kappa$ B similar to endogenous I $\kappa$ B, but serine mutations at the S32A/S36A positions prevent the I $\kappa$ B phosphorylation and ensuing NF $\kappa$ B release, thwarting its capability to translocate into the nucleus and transcribe target genes (Gilmore 2006). Decoy oligodeoxynucleotides act by targeting and adhering to the *cis*-element binding sites of free NF $\kappa$ B, thereby preventing its binding to  $\kappa$ B gene binding sites and also blocking subsequent gene transcription (Morishita, Sugimoto et al. 1997; Morishita, Higaki et al. 1998). These two methods block NF $\kappa$ B transcription capabilities at two separate activation pathway locations: prior to entering the nucleus (AdI $\kappa$ B), and after being freed from I $\kappa$ B (NF $\kappa$ B decoy). This redundancy of blockade effectively demonstrates the role of PVN NF $\kappa$ B in AngII-induced hypertension, potentially signifying that there are no tangential pathways activated in the interim between NF $\kappa$ B release from I $\kappa$ B and NF $\kappa$ B's nuclear translocation. Previous findings from our lab investigating the role of the PVN in AngII-induced hypertension demonstrated that NF $\kappa$ B within the PVN was differentially regulated along with PIC and oxidative stress genes and proteins (Kang, Ma et al. 2009). The study presented the involvement of brain NF $\kappa$ B in regulating the hypertensive response, a previously novel proposal. However, in the study, intracerebroventricular (ICV) infusion of PDTC, a known antioxidant (Moellering, McAndrew et al. 1999), was used to investigate NF $\kappa$ B in the PVN in hypertension, indicating that NF $\kappa$ B could have been reduced through an antioxidant mechanism rather than direct NF $\kappa$ B blockade. Also, due to ICV administration, it could not rule out the possible involvement of other affected cardio-regulatory regions for the observed reduction in the hypertensive response. Therefore, the

exact role and proposed involvement/mechanism of NFκB within the PVN was still uncertain. The current study looks specifically at NFκB blockade within the PVN in the AngII-induced hypertensive response, delineates the involvement of PVN NFκB in regulating ROS and PIC expression, and potentially shows that NFκB serves as a tipping point trigger between the pro-hypertensive and protective anti-hypertensive arms of the RAS within the PVN.

Extensive evidence has implicated the RAS in the brain in hypertension (Gorbea-Oppliger and Fink 1995; Davisson 2003; Veerasingham and Raizada 2003). Within the PVN, an important central cardio-regulatory region, AngII is increased in multiple hypertensive animal models and PVN blockade of the AT<sub>1</sub>R partially inhibits the effects of AngII-induced hypertension (Gorbea-Oppliger and Fink 1995; de Wardener 2001; Veerasingham and Raizada 2003; Silva, Santos et al. 2005; Kang, Ma et al. 2009). In the current study, following NFκB blockade within the PVN, ACE and the AT<sub>1</sub>R were decreased, thereby limiting the effect that AngII could have on perpetuating AngII-induced hypertension. Moreover, and perhaps more importantly, NFκB inhibition also increased ACE2 and MasR expression, as well as improved the Mas/AT<sub>1</sub>R ratio, indicating enhancement of the protective anti-hypertensive axis of the RAS. ACE2 is the counterpoint to ACE, in that instead of converting AngI to AngII, AngI and AngII are converted to Ang(1-7) (Xu, Sriramula et al.), which acts on the MasR to elicit actions opposing those of AngII, including vasorelaxation and decreased sympathetic activity (Diez-Freire, Vazquez et al. 2006; Ferrario 2006; Yamazato, Yamazato et al. 2007). Our results agree with other findings detailing the anti-hypertensive actions of ACE2 and the MasR (Diez-Freire, Vazquez et al. 2006; Yamazato, Yamazato et al. 2007), including their interplay with, and decreased activity following, AT<sub>1</sub>R activation within the brain (Ferrario 2006; Feng, Yue et al. 2008; Xia, Feng et al. 2009; Feng, Xia et al. 2010). Combined, these results suggest NFκB as an




important tipping point between the protective (ACE2/Ang(1-7)/Mas) and non-protective (ACE/AngII/AT<sub>1</sub>R) arms of the RAS, and that NFκB blockade promotes the more beneficial actions of ACE2 and the MasR.

The association between the RAS and elevated PICs in hypertension has often been explored, with many confirming more than a casual relationship between these two systems in the disease state (Chae, Lee et al. 2001; Sun, Li et al. 2004; Sriramula, Haque et al. 2008; Lu, Chen et al. 2009). NFκB is a key regulator of the PIC expression and inflammatory response speculated to have a role in the inflammatory component of hypertension (Cowling, Gurantz et al. 2002; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Here, we show that bilateral NFκB inhibition in the PVN reduces PIC expression, establishing not only the definitive involvement of NFκB within the PVN in regulating the AngII-induced hypertensive response, but also that PICs may play a role in RAS modulation. Recently, ROS, especially O<sub>2</sub><sup>•-</sup>, have been shown as important signaling factors within the brain for enhancement of sympathetic outflow and increased hypertensive response through both AngII and PIC mechanisms (van den Berg, Haenen et al. 2001; Zhang, Wei et al. 2003; Zimmerman, Lazartigues et al. 2004; Guggilam, Haque et al. 2007). In this study, bilateral NFκB blockade reduced the ROS response, including that of O<sub>2</sub><sup>•-</sup>, thus potentially inhibiting one of the mechanistic pathways by which sympathoexcitation is modulated. These results are further confirmed by previous experiments in our lab showing a reduction of renal sympathetic nerve activity in AngII-treated rats following ICV administration of the ROS scavenger, Tempol (Kang, Ma et al. 2009). Here we show that PVN specific NFκB blockade reduced the PIC and ROS reactions typically associated with AngII-induced hypertension, highlighting the central position that PVN NFκB plays in regulating the neurogenic component of the hypertensive response.

Sympathoexcitation is a major component of hypertension, and increased levels of AngII in the CNS can enhance sympathetic outflow through ROS and AT<sub>1</sub>R activation and a subsequent down-regulation of nNOS (Zanzinger, Czachurski et al. 1995; Liu, Murakami et al. 1998; Campese, Shaohua et al. 2005; Gao, Wang et al. 2005; Guggilam, Cardinale et al. 2011), and the PVN plays a role in modulating sympathetic outflow (Allen 2002). NO, a well known sympatho-inhibitory neurotransmitter, when blocked, results in elevated MAP and sympathoexcitation (Campese, Ye et al. 2002; Campese, Shaohua et al. 2005). The expression and presence of nNOS, an indirect indicator of downstream sympathetic activity, is inversely proportional to the level of sympathetic outflow (Wang, Liu et al. 2005; Li, Wang et al. 2006; Guggilam, Patel et al. 2008). Furthermore, increased superoxide can interact with the nNOS-produced NO, forming OONO<sup>•</sup> and further affecting the decrease in NO bioavailability, also resulting in enhanced sympathoexcitation (Zanzinger 2002; Yu, Zhang et al. 2010). Recently, Ang(1-7) and MasR activation have been shown to increase nNOS activity and NO release (Sampaio, Souza dos Santos et al. 2007). The current study shows that following AngII treatment, nNOS is decreased within the PVN, potentially indicating an increased sympathetic response. Also in the present study, OONO<sup>•</sup> was increased in the AngII-treated rats, which, following bilateral NFκB inhibitor administration, was decreased. The OONO<sup>•</sup> decrease paralleled that of O<sub>2</sub><sup>•-</sup> and was concurrent with the nNOS increase, indicating that NFκB plays potentially a deciding role in increasing NO availability and regulating sympathetic outflow. Therefore, bilateral NFκB inhibition increased nNOS and reduced O<sub>2</sub><sup>•-</sup> and OONO<sup>•</sup>, potentially through protective RAS component balance, thus increasing nNOS and the capacity for NO availability and potentially decreasing subsequent sympathetic outflow.

In conclusion, this study shows that following the activation of the pro-hypertensive arm of the RAS, PICs are increased, both of which can act to increase the activity of NFκB, leading to the transcription of additional modulators of the hypertensive state in a positive feed-forward manner. NFκB acts further to increase, along with AngII, the presence of ROS, such as  $O_2^{\bullet-}$ , which subsequently affects the present NO levels, thereby increasing sympathoexcitation. Blockade of NFκB at two separate locations in its activation pathway prevents these changes, restoring balance and promoting the anti-hypertensive arm of the RAS, including ACE2 and the MasR, as well as reducing PIC and ROS expression and elevating nNOS, all of which contributes to a reduction in MAP and an improvement in the AngII-induced hypertensive state. However, this signaling mechanism must be further studied to delineate the manner by which NFκB and  $O_2^{\bullet-}$  interact within the PVN in AngII-induced hypertension. We propose that AngII activation of NFκB increases PICs and  $O_2^{\bullet-}$ , tipping the balance of the RAS in favor of the pro-hypertensive arm and decreasing the anti-hypertensive arm, resulting in a further increase in PIC and ROS expression, in a vicious positive feed-forward mechanism (Figure 5.9). Limitations for this study include the use of the AngII-induced hypertensive model, since this does not represent all modes of hypertension. Furthermore, we only explored the PVN region in this hypertensive model. There are multiple cardio-relevant regions of the brain that can play a role in modulating the hypertensive response; however, we feel that the PVN is of importance due to its integrative functions. Moreover, as the literature suggests, Adenoviruses are well known for their lack of cell specificity and can be expressed by neurons and glia as well as participate in retrograde transport (Sinnayah, Lindley et al. 2002). For this reason, we employed NFκB decoy oligodeoxynucleotides to further verify our results. Finally, to show the minimal effects of the potential perfusion of bilateral PVN NFκB decoy infusion leakage into the third ventricle and its

subsequent effect on other regions of the brain, ICV infusion of the same dose at the same infusion rate could have been performed, but we feel, based on similar experiments, that though third ventricle leakage may have occurred, its effects would be negligible. In the current clinical environment where novel hypertensive therapeutic measures are being sought, this study provides a conceptual basis for including NFκB inhibitors that can specifically act within the brain as a possible future pharmacological approach for the treatment of hypertension.



**Figure 5.9. Schematic showing the proposed signaling mechanism in the PVN.** Ang II leads to an exasperated hypertensive response via NFκB and modulation of the balance between the pro- and anti-hypertensive arms of the renin-angiotensin system (solid lines/arrows) and how NFκB inhibition attenuates this response (green lines/arrows). Ang II activates NFκB via an AT<sub>1</sub>R/superoxide pathway. NFκB increases transcription of PICs and ROS production genes, as well as the pro-hypertensive RAS components, while decreasing the anti-hypertensive RAS components. The increased PICs and ROS positively feeds back upon NFκB (while also signaling for increased sympathetic outflow). These signals combine to propagate the hypertensive state.

## PERSPECTIVES

Increasing evidence indicates that central nervous system mechanisms play an important role in the pathogenesis of cardiovascular disease. In this study, we demonstrate that inflammatory molecules, specifically the transcription factor NF $\kappa$ B, within the PVN, can modulate the hypertensive response. Additionally, we demonstrate that inflammation is a double-edged weapon that not only up-regulates the pro-hypertensive axis of the RAS, but also down-regulates the protective anti-hypertensive axis of the RAS. Thus, inflammation-mediated modulation of the RAS system within the brain might be an important critical contributor to neurogenic hypertension. Since inflammation and RAS are potent inducers of oxidative stress and NF $\kappa$ B has been shown to respond to and induce oxidative stress, it would be advantageous to target NF $\kappa$ B to better treat neurogenic hypertension. While the current methods used within this study are impractical for current clinical administration, one can explore the use of NF $\kappa$ B small molecule inhibitors that might cross the BBB, thereby targeting the brain's source of inflammation and oxidative stress for controlling and treating this debilitating condition.

## REFERENCES

- Agarwal, D., M. Haque, et al. (2009). "Role of Proinflammatory Cytokines and Redox Homeostasis in Exercise-Induced Delayed Progression of Hypertension in Spontaneously Hypertensive Rats." Hypertension **54**: 1393-400.
- Allen, A. M. (2002). "Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone." Hypertension **39**(2): 275-80.
- Allen, A. M., J. Zhuo, et al. (2000). "Localization and function of angiotensin AT1 receptors." Am J Hypertens **13**(1 Pt 2): 31S-38S.
- Barnes, P. J. and M. Karin (1997). "Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases." N Engl J Med **336**(15): 1066-71.

- Bubici, C., S. Papa, et al. (2006). "Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance." Oncogene **25**(51): 6731-48.
- Campese, V. M., Y. Shaohua, et al. (2005). "Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity." Hypertension **46**(3): 533-9.
- Campese, V. M., S. Ye, et al. (2002). "Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity." Hypertension **39**(2 Pt 2): 519-24.
- Cardinale, J. P., S. Sriramula, et al. (2010). "HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats." Hypertension **56**(3): 437-44.
- Chae, C. U., R. T. Lee, et al. (2001). "Blood pressure and inflammation in apparently healthy men." Hypertension **38**(3): 399-403.
- Cowling, R. T., D. Gurantz, et al. (2002). "Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta." J Biol Chem **277**(8): 5719-24.
- Davisson, R. L. (2003). "Physiological genomic analysis of the brain renin-angiotensin system." Am J Physiol Regul Integr Comp Physiol **285**(3): R498-511.
- Davisson, R. L., M. I. Oliverio, et al. (2000). "Divergent functions of angiotensin II receptor isoforms in the brain." J Clin Invest **106**(1): 103-6.
- de Wardener, H. E. (2001). "The hypothalamus and hypertension." Physiol Rev **81**(4): 1599-658.
- Diez-Freire, C., J. Vazquez, et al. (2006). "ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR." Physiol Genomics **27**(1): 12-9.
- Elks, C. M., N. Mariappan, et al. (2009). "Chronic NF- $\kappa$ B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am J Physiol Renal Physiol **296**(2): F298-305.
- Feng, Y., H. Xia, et al. (2010). "Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension." Circ Res **106**(2): 373-82.
- Feng, Y., X. Yue, et al. (2008). "Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation." Circ Res **102**(6): 729-36.

- Ferrario, C. M. (2006). "Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation." Hypertension **47**(3): 515-21.
- Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease." Am J Cardiol **98**(1): 121-8.
- Ganong, W. F. (2000). "Circumventricular organs: definition and role in the regulation of endocrine and autonomic function." Clin Exp Pharmacol Physiol **27**(5-6): 422-7.
- Gao, L., W. Wang, et al. (2005). "Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM." Am J Physiol Heart Circ Physiol **288**(5): H2271-9.
- Gilmore, T. D. (2006). "Introduction to NF-kappaB: players, pathways, perspectives." Oncogene **25**(51): 6680-4.
- Gorbea-Oppliger, V. J. and G. D. Fink (1995). "Cerebroventricular injection of angiotensin II antagonist: effects on blood pressure responses to central and systemic angiotensin II." J Pharmacol Exp Ther **273**(2): 611-6.
- Granger, J. P. (2006). "An emerging role for inflammatory cytokines in hypertension." Am J Physiol Heart Circ Physiol **290**(3): H923-4.
- Guggilam, A., J. P. Cardinale, et al. (2011). "Central TNF inhibition results in attenuated neurohumoral excitation in heart failure: a role for superoxide and nitric oxide." Basic Res Cardiol **106**(2): 273-86.
- Guggilam, A., M. Haque, et al. (2007). "TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats." Am J Physiol Heart Circ Physiol **293**(1): H599-609.
- Guggilam, A., K. P. Patel, et al. (2008). "Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus." Eur J Heart Fail **10**(7): 625-34.
- Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res **82**(3): 503-12.
- Li, Y. F., W. Wang, et al. (2006). "Angiotensin-mediated increase in renal sympathetic nerve discharge within the PVN: role of nitric oxide." Am J Physiol Regul Integr Comp Physiol **290**(4): R1035-43.
- Liu, J. L., H. Murakami, et al. (1998). "Angiotensin II-nitric oxide interaction on sympathetic outflow in conscious rabbits." Circ Res **82**(4): 496-502.

- Lu, Y., J. Chen, et al. (2009). "Angiotensin II receptor 1 involved in the central pressor response induced by interleukin-1 beta in the paraventricular nucleus." Neurol Res **31**(4): 420-4.
- Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction." Free Radic Biol Med **46**(4): 462-70.
- Moellering, D., J. McAndrew, et al. (1999). "Effects of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress." Free Radic Biol Med **26**(9-10): 1138-45.
- Morishita, R., J. Higaki, et al. (1998). "Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease." Circ Res **82**(10): 1023-8.
- Morishita, R., T. Sugimoto, et al. (1997). "In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction." Nat Med **3**(8): 894-9.
- Sampaio, W. O., R. A. Souza dos Santos, et al. (2007). "Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways." Hypertension **49**(1): 185-92.
- Shi, P., M. K. Raizada, et al. (2010). "Brain cytokines as neuromodulators in cardiovascular control." Clin Exp Pharmacol Physiol **37**(2): e52-7.
- Silva, A. Q., R. A. Santos, et al. (2005). "Blockade of endogenous angiotensin-(1-7) in the hypothalamic paraventricular nucleus reduces renal sympathetic tone." Hypertension **46**(2): 341-8.
- Simpson, J. B. (1981). "The circumventricular organs and the central actions of angiotensin." Neuroendocrinology **32**(4): 248-56.
- Sinnayah, P., T. E. Lindley, et al. (2002). "Selective gene transfer to key cardiovascular regions of the brain: comparison of two viral vector systems." Hypertension **39**(2 Pt 2): 603-8.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-51.
- Sun, C., H. Li, et al. (2004). "Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity." J Neurosci **24**(44): 9944-52.
- Tian, N., R. S. Moore, et al. (2007). "Interactions between oxidative stress and inflammation in salt-sensitive hypertension." Am J Physiol Heart Circ Physiol **293**(6): H3388-95.



- van den Berg, R., G. R. Haenen, et al. (2001). "Transcription factor NF-kappaB as a potential biomarker for oxidative stress." Br J Nutr **86 Suppl 1**: S121-7.
- Veerasingham, S. J. and M. K. Raizada (2003). "Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives." Br J Pharmacol **139**(2): 191-202.
- Wang, Y., X. F. Liu, et al. (2005). "Effects of nNOS antisense in the paraventricular nucleus on blood pressure and heart rate in rats with heart failure." Am J Physiol Heart Circ Physiol **288**(1): H205-13.
- Xia, H., Y. Feng, et al. (2009). "Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice." Hypertension **53**(2): 210-6.
- Xia, H. and E. Lazartigues (2008). "Angiotensin-converting enzyme 2 in the brain: properties and future directions." J Neurochem **107**(6): 1482-94.
- Xu, P., S. Sriramula, et al. (2011). "ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good." Am J Physiol Regul Integr Comp Physiol **300**(4): R804-17.
- Yamazato, M., Y. Yamazato, et al. (2007). "Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats." Hypertension **49**(4): 926-31.
- Yu, Y., Z. H. Zhang, et al. (2010). "Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction." Hypertension **55**(3): 652-9.
- Zanzinger, J. (2002). "Mechanisms of action of nitric oxide in the brain stem: role of oxidative stress." Auton Neurosci **98**(1-2): 24-7.
- Zanzinger, J., J. Czachurski, et al. (1995). "Inhibition of basal and reflex-mediated sympathetic activity in the RVLM by nitric oxide." Am J Physiol **268**(4 Pt 2): R958-62.
- Zhang, Z. H., S. G. Wei, et al. (2003). "Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins." Am J Physiol Regul Integr Comp Physiol **284**(4): R916-27.
- Zimmerman, M. C., E. Lazartigues, et al. (2002). "Superoxide mediates the actions of angiotensin II in the central nervous system." Circ Res **91**(11): 1038-45.
- Zimmerman, M. C., E. Lazartigues, et al. (2004). "Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system." Circ Res **95**(2): 210-6.

**CHAPTER 6**  
**CONCLUDING REMARKS**

## OVERALL SUMMARY OF FINDINGS

Hypertension is one of the world's great public health problems, affects more than 74 million American adults, and is the leading cause of death worldwide (2002; Lloyd-Jones, Adams et al. 2010). Hypertension is not only a serious condition with its own high morbidity and mortality rates, it is also a major risk factor for multiple cardiovascular diseases (CVDs), including myocardial infarction, stroke, heart failure, atrial fibrillation and peripheral arterial disease. Moreover, with the rise in additional causes for increased blood pressure, including obesity, excessive salt intake, poor lifestyle choices and a growing population of aging individuals, the incidence of hypertension is rising (Lloyd-Jones, Adams et al. 2010). While the condition is easily detectable, it still remains poorly controlled in more than half of identified hypertensive patients. Current therapeutics for primary hypertension are multiple and varied, targeting and exploiting the many endogenous controlling mechanisms of normal pressure response as well as pathophysiological contributors towards hypertension (Izzo, Sica et al. 2008). However, many of these therapies fail to have a beneficial effect, prompting the need for novel therapeutic approaches and a greater understanding of the mechanistic pathways involved in the pathogenesis and maintenance of hypertension.

Recent evidence suggests that hypertension is a chronic low-grade inflammatory condition where pro-inflammatory cytokines (PICs), such as tumor necrosis factor-*alpha* (TNF), interleukin (IL)-1 $\beta$  and IL-6, have emerged as major contributing factors in the pathogenesis of hypertension and other CVDs (Mann 2002; Ruiz-Ortega, Ruperez et al. 2002; Ferrario and Strawn 2006; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). The renin-angiotensin system (RAS), especially the effector peptide angiotensin II (Ang II), not only modulates the hypertensive response, but also induces the inflammatory response

associated with hypertension (Kalra, Sivasubramanian et al. 2002). Moreover, this inflammatory response is capable of regulating local and systemic RAS components, including increasing the pro-hypertensive axis (Ang II, angiotensin converting enzyme (ACE) and Ang II type-1 receptor (AT<sub>1</sub>R)) while silencing those of the anti-hypertensive axis (ACE2, AT<sub>2</sub>R, Ang (1-7) and the Mas receptor). The Ang II-mediated inflammatory response appears to occur through several mechanisms, including activation of monocytes and macrophages, as well as the production of adhesion molecules, chemokines, PICs and reactive oxygen species (ROS) (Arenas, Xu et al. 2004; Shi, Diez-Freire et al. 2010). While still not fully known, the interaction of these various hypertensive regulatory pathways are becoming increasingly important to understand, especially in regards to their contribution towards the pathogenesis of hypertension. Therefore, elucidating the mechanism by which these signaling pathways interact is critical for the development of novel therapeutics in the fight to control the debilitating effects of hypertension.

Chapter 2 acknowledges evidence that the RAS and Ang II can increase the production of PICs and contribute to the hypertensive state, and that blocking the PIC TNF can prevent some of the deleterious changes associated with hypertension and the ACE/Ang II/AT<sub>1</sub>R RAS axis (Funakoshi, Ichiki et al. 1999; Kalra, Sivasubramanian et al. 2002; Muller, Shagdarsuren et al. 2002; Ruiz-Ortega, Ruperez et al. 2002; Elmarakby, Quigley et al. 2006). The suggested mechanism potentially involved a positive feed-forward system whereby Ang II increases TNF and ROS, which in turn further increases injurious ACE/Ang II/AT<sub>1</sub>R RAS axis components, and decreases protective ACE2/Ang (1-7)/Mas RAS components. Therefore, we aimed to determine if administration of TNF alone could regulate components of the RAS, and if so, was this mechanism achieved through modulation of ROS. TNF infusion for five days increased the components of the deleterious axis of the RAS, including angiotensinogen, ACE, Ang II and the

AT<sub>1</sub>R. TNF infusion also increased gp91*phox* (the NADPH oxidase catalytic subunit), total ROS and superoxide, and decreased the protective RAS components ACE2 and the Mas receptor. These changes were reversed following administration of the superoxide dismutase (SOD) mimetic, Tempol, or the TNF receptor mimetic, etanercept, indicating that the TNF-induced TNF-driven pathway required ROS, especially superoxide, for dysregulation of the individual RAS arms and propagation of the hypertensive state. In conjunction with the understanding that Ang II increases TNF and that use of PIC and ROS inhibitors can reduce the hypertensive response, we demonstrate here that the ROS appears to evolve through a TNF-activated mechanism, therefore highlighting the Ang II/TNF/ROS pathway. This pathway in turn reduces the protective RAS axis (ACE2/Ang (1-7)/Mas) while up-regulating the more injurious aspects of the pro-hypertensive RAS arm (ACE/Ang II/AT<sub>1</sub>R). This study underscores the role that TNF plays in the ROS-induced dysregulation of the RAS and the ROS-driven mechanism behind TNF-induced cardiac dysfunction, further spotlighting the role that PICs such as TNF may play in the differential RAS regulation in the pathogenesis of the hypertension.

Chapter 3 discusses the interaction between the RAS, PICs and ROS demonstrated by work in our laboratory and others (Brasier, Li et al. 1996; Sasamura, Nakazato et al. 1997; Arenas, Xu et al. 2004; Sriramula, Haque et al. 2008). Here we showed that untreated spontaneously hypertensive (SHR) rats have increased AT<sub>1</sub>R expression, an important component of the pro-hypertensive portion of the RAS. Histone Deacetylase inhibition (HDACi) through valproic acid (VPA) treatment attenuated this increase and the increased production of PICs. Reports previously indicated that Ang II is controlled by, and controls, HDAC-induced changes in gene and protein response (Kee, Sohn et al. 2006; Lu and Yang 2009). Here we show a possible new mechanism involving the regulation of Ang II responses as directed through the

AT<sub>1</sub>R. HDACi reduces AT<sub>1</sub>R gene expression and receptor density, thereby ameliorating the actions of Ang II. This alteration in AT<sub>1</sub>R expression could be either through direct HDACi effects on the receptor's production and function, or through the effects of HDACi on inflammatory gene response during hypertension. Thus, results of this study showed that long-term HDACi through VPA attenuated mean arterial pressure (MAP) and cardiac hypertrophy, possibly through modulation of atrial natriuretic peptide (ANP), Collagen IV and AT<sub>1</sub>R. HDAC inhibition also attenuated the increased inflammatory response, including TNF and nuclear factor-*kappa*B (NFκB), as well as the increase in ROS and gp91*phox*. These findings suggest that HDACi with VPA reduced inflammation, ROS, and AT<sub>1</sub>R, thereby attenuating hypertension and its secondary consequences in SHR rats.

In Chapter 4, we demonstrated that chronic Ang II infusion resulted in cardiac hypertrophy and hypertension, increased PIC and gp91*phox*, and decreased expression of neuronal Nitric Oxide Synthase (nNOS) within the hypothalamic paraventricular nucleus (PVN). Perhaps more importantly, Ang II-infused rats had an increased expression of the injurious pro-hypertensive RAS components ACE and AT<sub>1</sub>R, and a decreased expression of the protective anti-hypertensive RAS components ACE2, AT<sub>2</sub>R and the Mas receptor. Central blockade of TNF with etanercept resulted in attenuation of hypertension, cardiac hypertrophy and PIC expression, decreased oxidative stress, as well as a restored balance between the protective and deleterious RAS arms within the hypothalamic PVN. The beneficial effects of central TNF blockade in Ang II-induced hypertensive responses appear to be mediated by the returned balance of the central RAS, especially within the PVN. Our findings provide further evidence for the involvement of the RAS within the PVN and its interaction and mediation through TNF in the neurogenic component of hypertension.

Finally, in Chapter 5, we demonstrated that following the activation of the pro-hypertensive arm of the RAS, PICs are increased, both of which can act to increase the activity of NFκB within the PVN. This in turn leads to the transcription of additional modulators of the hypertensive state in a positive feed-forward manner that contributes to the hypertensive state. Furthermore, NFκB acted to increase, along with AngII, the presence of ROS, such as superoxide, which subsequently decreased the presence of Nitric Oxide (NO), thereby increasing sympathoexcitation. Blockade of NFκB within the PVN at two separate locations in its activation pathway, prior to entering the nucleus (via PVN transfection with an Adenoviral vector containing Inhibitory-*kappa*B), and after nuclear translocation (via PVN infusion of NFκB decoy oligodeoxynucleotide), prevented these changes. These treatments promoted the anti-hypertensive arm of the RAS, including ACE2 and the Mas receptor, as well as reducing PIC and ROS expression, and elevating nNOS, all of which contributes to a reduction in MAP and an improvement in the AngII-induced hypertensive state. Therefore, we proposed that AngII activation of NFκB within the PVN increases PICs and superoxide, tipping the balance of the RAS in favor of the pro-hypertensive arm and decreasing the anti-hypertensive arm, resulting in an even further increase in PIC and ROS expression, resulting in a vicious and positive feed-forward mechanism.

## **SIGNIFICANCE OF RESEARCH AND FUTURE DIRECTIONS**

Current treatment regimens for hypertension are only partially effective in controlling the disease state. These therapeutics act on the endogenous mechanisms that control pressure response in normal and pathological conditions. Briefly, these therapies can include lifestyle modifications and/or a multitude of pharmacological therapeutics. Lifestyle modifications can include weight reduction, sodium reduction, diet modification, increased physical activity and

moderation of alcohol and tobacco consumption, amongst others. Common pharmacological interventions can include any number of drugs alone or in combination, including, but not limited to, diuretics,  $\beta$ -blockers,  $\alpha_1$ -blockers,  $\text{Ca}^{2+}$  channel blockers, ACE inhibitors and angiotensin receptor blockers (ARBs) (Izzo, Sica et al. 2008). However, while many current therapeutics have clearly reduced the morbidity and mortality of some hypertensive patients, they still fail to have a beneficial effect on over 50% of treated individuals, prompting the need for novel therapeutic approaches and a greater understanding of the mechanistic pathways involved in the pathogenesis and maintenance of hypertension.

The complexity and somewhat unclear signaling mechanisms involved in hypertension are of intense investigational interest. Recent evidence shows that hypertension is a chronic low-grade inflammatory condition (Ferrario and Strawn 2006; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010) where PICs, such as TNF, have emerged as major contributing factors in the pathogenesis of hypertension (Mann 2002; Ruiz-Ortega, Ruperez et al. 2002; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009). Despite the overwhelming evidence linking TNF to CVDs, large clinical trials targeted against this PIC have been largely unsuccessful (RENAISSANCE, RECOVER and ATTACH) (Anker and Coats 2002; Mann, McMurray et al. 2004); it is speculated that the lack of success of these trials lies not in the use of anti-cytokine agents, but the use of system wide TNF inhibition and the consequences resultant from this type of therapy (Mann, McMurray et al. 2004). Therefore, the need for improved knowledge of the contributing pathways to hypertension, and the requirement for continued therapeutic developments remain of the utmost importance. The studies conducted herein provide significant advancements in delineating mechanistic pathways and potential therapeutic targets for the treatment of hypertension.



The studies described here underscore the role that inflammation plays in hypertension and the means by which it is regulated, providing a strong foundation for the future development of novel therapeutic options. It shows that TNF plays a major part in the ROS-induced dysregulation of the RAS and the ROS-driven mechanism behind TNF-induced cardiac dysfunction. These studies also show how central blockade of TNF with etanercept can attenuate hypertension, cardiac hypertrophy and PIC expression, decrease oxidative stress, and restore the balance between the protective and deleterious RAS arms, within the hypothalamic PVN, pointing to a role for TNF in the neurogenic component of hypertension as well. Furthermore, we proposed that AngII activation of NF $\kappa$ B within the PVN increases PICs and superoxide, tipping the balance of the RAS in favor of the pro-hypertensive arm and decreasing the anti-hypertensive arm, resulting in sustained hypertension. This study showed that specifically targeting NF $\kappa$ B within the PVN can attenuate the hypertensive state, providing a conceptual basis for including NF $\kappa$ B inhibitors that can specifically act within the brain as a possible future pharmacological approach for the treatment of hypertension. Finally, we demonstrated how the use of VPA, an anti-seizure and bipolar drug currently used in clinical settings, administered long-term without any adverse effects towards the treated animals, was successful in the treatment of hypertension and its consequences, including cardiac hypertrophy, systemic inflammation and end organ damage due to ROS. This study outlines the importance of the continuous drug administration necessary to treat hypertension and also provides sufficient evidence for the use of HDACi to reduce not only blood pressure, but cardiac hypertrophy and the inflammatory state associated with hypertension. Whereas ACEi and ARBs only target a portion of the systemically activated RAS, combined, these studies identify the involvement of several inflammatory mediators (TNF, NF $\kappa$ B and HDAC), through ROS, in activating and

dysregulating the local RAS within the heart and brain and contributing to the pathogenesis and sustainment of hypertension.

Although we believe that these studies identify novel pathways through which TNF, NF $\kappa$ B, ROS and the RAS interact in the heart and brain in hypertension, further studies are required to understand the exact mechanistic pathways involved, as well as identify additional possible therapeutic targets whose inhibition/activation would not lead to adverse responses (as observed in several clinical trials against TNF). Further identification of additional mediators of TNF and NF $\kappa$ B, determining the role of additional cardio-regulatory centers in the brain in the hypertensive response, and elucidating how peripheral modulators signal to the brain, would all greatly improve this knowledge base. Moreover, a closer look at the protective axis of the RAS provides an appealing option for the future of therapeutics. Based on these studies, a clear link between inflammatory mediators and the dysregulation of the RAS is clear, but more work must be done to develop safe and effective means by which to positively influence this mechanism. Other issues also present both challenges and avenues of exploration for future hypertensive studies. For instance, specific Sirtuins and hypoxia inducible factors (HIF) are known to interact with NF $\kappa$ B and differentially regulate its actions, but how and in what pathological states this occurs is unknown (Biala, Tauriainen et al. ; Miyazaki, Ichiki et al. 2008). Also, thus far, our labs interest has been with the role of inflammation in the PVN, but attention must be made for the rostral ventrolateral medulla (RVLM) and supraoptic nucleus (SON), amongst others, to determine the signaling patterns between these regions and to the periphery and determine how this signaling can be subjected to controlling in hypertension. Finally, speculations of the manner by which peripheral signals interact with the brain are prevalent, but identifying this with more certainty can ultimately lead to the development of better, more efficient therapeutics. All

together, the data presented here, along with the contributions of current and future studies, will go a long way in aiding in the identification of efficacious treatments in the constant pursuit to alleviate patients suffering from the debilitating effects of hypertension.

## REFERENCES

- (2002). The World Health Report: Reducing Risks, Promoting Healthy Life. B. Campanini. Geneva, World Health Organization.
- Anker, S. D. and A. J. Coats (2002). "How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH." Int J Cardiol **86**(2-3): 123-30.
- Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha." Am J Physiol Cell Physiol **286**(4): C779-84.
- Biala, A., E. Tauriainen, et al. "Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes." Blood Press **19**(3): 196-205.
- Brasier, A. R., J. Li, et al. (1996). "Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator." Hypertension **27**(4): 1009-17.
- Cardinale, J. P., S. Sriramula, et al. (2010). "HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats." Hypertension **56**(3): 437-44.
- Elmarakby, A. A., J. E. Quigley, et al. (2006). "Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension." Hypertension **47**(3): 557-62.
- Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease." Am J Cardiol **98**(1): 121-8.
- Funakoshi, Y., T. Ichiki, et al. (1999). "Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells." Hypertension **34**(1): 118-25.
- Izzo, J. L., D. A. Sica, et al. (2008). Hypertension primer : [the essentials of high blood pressure : basic science, population science, and clinical management]. Philadelphia, PA, Lippincott Williams & Wilkins.
- Kalra, D., N. Sivasubramanian, et al. (2002). "Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway." Circulation **105**(18): 2198-205.

- Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res **82**(3): 503-12.
- Kee, H. J., I. S. Sohn, et al. (2006). "Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding." Circulation **113**(1): 51-9.
- Lloyd-Jones, D., R. J. Adams, et al. (2010). "Heart disease and stroke statistics--2010 update: a report from the American Heart Association." Circulation **121**(7): e46-e215.
- Lu, Y. and S. Yang (2009). "Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases." Tohoku J Exp Med **219**(1): 17-23.
- Mann, D. L. (2002). "Inflammatory mediators and the failing heart: past, present, and the foreseeable future." Circ Res **91**(11): 988-98.
- Mann, D. L., J. J. McMurray, et al. (2004). "Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)." Circulation **109**(13): 1594-602.
- Miyazaki, R., T. Ichiki, et al. (2008). "SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells." Arterioscler Thromb Vasc Biol **28**(7): 1263-9.
- Muller, D. N., E. Shagdarsuren, et al. (2002). "Immunosuppressive treatment protects against angiotensin II-induced renal damage." Am J Pathol **161**(5): 1679-93.
- Ruiz-Ortega, M., M. Ruperez, et al. (2002). "Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney." Kidney Int **62**(S82): S12-S22.
- Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by cytokines." Hypertension **30**(1 Pt 1): 35-41.
- Shi, P., C. Diez-Freire, et al. (2010). "Brain microglial cytokines in neurogenic hypertension." Hypertension **56**(2): 297-303.
- Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy." Hypertension **51**(5): 1345-51.

**APPENDIX**

**LETTER OF PERMISSION**

**WOLTERS KLUWER HEALTH LICENSE  
TERMS AND CONDITIONS**

May 20, 2011

---

This is a License Agreement between Jeffrey P Cardinale ("You") and Wolters Kluwer Health ("Wolters Kluwer Health") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Wolters Kluwer Health, and the payment terms and conditions.

**All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.**

License Number	2657170929714
License date	Apr 27, 2011
Licensed content publisher	Wolters Kluwer Health
Licensed content publication	Hypertension
Licensed content title	HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats
Licensed content author	Jeffrey P. Cardinale
Licensed content date	Sep 1, 2010
Volume Number	56
Issue Number	3
Type of Use	Dissertation/Thesis
Requestor type	Individual
Title of your thesis / dissertation	The role of inflammatory mediators in hypertension
Expected completion date	Jun 2011
Estimated size(pages)	110
Billing Type	Invoice
Billing Address	6048 Milne Blvd  New Orleans, LA 70124  United States
Customer reference info	
Total	0.00 USD

## VITA

Jeffrey Paul Cardinale was born in Bedico, Louisiana, on October 11<sup>th</sup>, 1983, to Gerald and Yvette Cardinale. He attended Saint Paul's School in Covington, Louisiana, and graduated in the top 10% of his class in May, 2002. Following high school, he attended Louisiana State University in Baton Rouge, Louisiana, where he gained an appreciation and fostered an interest in medicine and the basic sciences while working in the clinics and labs at the Louisiana State University School of Veterinary Medicine, Department of Veterinary Clinical Sciences. Through the mentorship and guidance of Susan Eades, D.V.M., Ph.D., Diplomate ACVIMLA, and following his graduation in May, 2006 with a Bachelor of Science degree, he was introduced to the work of Associate Professor Joseph Francis, B.V.Sc. & A.H., M.V.Sc., Ph.D., in cardiovascular pathophysiology, in whose lab he began the pursuit of his doctoral degree in August, 2006. During his time, he gained a working understanding of the basic physiological and pathophysiological mechanisms of the heart and brain in cardiovascular disease. During these studies, in October, 2008, he married Lauren Elise Mesman. Following his graduation with his Doctor of Philosophy degree (Ph.D.) in August, 2011, he will continue his studies at Louisiana State University Health Sciences Center in New Orleans, Louisiana, to pursue his medical doctorate degree. His career goals are to combine his knowledge of the basic sciences with his future studies in medicine in the hopes of conducting clinical based research in cardiovascular diseases.